Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
08b596353bedf69df8977f6faddfc9852984a3e4dbad836b3d87bcce78799e84.png
simple
<table><tr><td>GO.ID</td><td>Term<sup>1</sup></td><td>Corrected p-value<sup>2</sup></td></tr><tr><td>GO:0050825</td><td>ice binding</td><td>&lt; 1E-26</td></tr><tr><td>GO:0003677</td><td>DNA binding</td><td>4.01E-15</td></tr><tr><td>GO:0003700</td><td>transcription factor activity</td><td>1.26E-13</td></tr><tr><td>GO:0043565</td><td>sequence-specific DNA binding</td><td>5.79E-13</td></tr><tr><td>GO:0005199</td><td>structural constituent of cell wall</td><td>1.00E-08</td></tr><tr><td>GO:0004879</td><td>ligand-dependent nuclear receptor activity</td><td>3.15E-07</td></tr><tr><td>GO:0003682</td><td>chromatin binding</td><td>2.54E-06</td></tr><tr><td>GO:0003723</td><td>RNA binding</td><td>7.63E-05</td></tr><tr><td>GO:0008270</td><td>zinc ion binding</td><td>0.000303826</td></tr><tr><td>GO:0004969</td><td>histamine receptor activity</td><td>0.0008013</td></tr><tr><td>GO:0045735</td><td>nutrient reservoir activity</td><td>0.0008013</td></tr><tr><td>GO:0003702</td><td>RNA polymerase II transcription factor activity</td><td>0.001116964</td></tr><tr><td>GO:0003676</td><td>nucleic acid binding</td><td>0.001580342</td></tr><tr><td>GO:0003705</td><td>RNA polymerase II transcription factor activity, enhancer binding</td><td>0.009862154</td></tr><tr><td>GO:0003735</td><td>structural constituent of ribosome</td><td>0.02671</td></tr><tr><td>GO:0005249</td><td>voltage-gated potassium channel activity</td><td>0.049858667</td></tr><tr><td>GO:0004386</td><td>helicase activity</td><td>0.065105625</td></tr><tr><td>GO:0016563</td><td>transcription activator activity</td><td>0.13355</td></tr><tr><td>GO:0003714</td><td>transcription corepressor activity</td><td>0.13355</td></tr><tr><td>GO:0005179</td><td>hormone activity</td><td>0.199622105</td></tr></table>
c7c1698e48eb9e6109b3cdc6b0c0459e7ee005ab4bece6a81c1f0c1b78c6b357.png
complex
<table><tr><td rowspan="2">Experiment</td><td rowspan="2">Mean POG</td><td rowspan="2">RSOG</td><td colspan="2">RSOG Distribution</td><td rowspan="2">PRSOG</td><td rowspan="2">Experiment</td><td rowspan="2">Mean POG</td><td rowspan="2">RSOG</td><td colspan="2">RSOG Distribution</td><td rowspan="2">PRSOG</td></tr><tr><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td></tr><tr><td>1.1</td><td>0.34</td><td>0.26</td><td>0.21</td><td>0.0070</td><td>1.11 &#215; 10<sup>&#8722;16</sup></td><td>2.1</td><td>0.38</td><td>0.23</td><td>0.24</td><td>0.0067</td><td>0.88</td></tr><tr><td>1.2</td><td>0.085</td><td>0.047</td><td>0.046</td><td>0.0009</td><td>0.19</td><td>2.2</td><td>0.060</td><td>0.030</td><td>0.033</td><td>0.0022</td><td>0.84</td></tr><tr><td>1.3</td><td>0.085</td><td>0.045</td><td>0.046</td><td>0.0005</td><td>0.94</td><td>2.3</td><td>0.065</td><td>0.031</td><td>0.034</td><td>0.0024</td><td>0.83</td></tr><tr><td>1.4</td><td>0.100</td><td>0.051</td><td>0.053</td><td>0.0004</td><td>0.99</td><td>2.4</td><td>0.040</td><td>0.019</td><td>0.019</td><td>0.0020</td><td>0.58</td></tr><tr><td>1.5</td><td>0.055</td><td>0.030</td><td>0.029</td><td>0.0027</td><td>0.47</td><td>2.5</td><td>0.120</td><td>0.053</td><td>0.063</td><td>0.0035</td><td>0.99</td></tr><tr><td>1.6</td><td>0.060</td><td>0.027</td><td>0.030</td><td>0.0031</td><td>0.81</td><td>2.6</td><td>0.040</td><td>0.015</td><td>0.019</td><td>0.0020</td><td>0.95</td></tr></table>
3d37ed1f897527c3cf2984ee0fa7eda6d70450d728293a99f24361f0fde70ce1.png
complex
<table><tr><td>Items</td><td colspan="10">Sampling time, h</td></tr><tr><td>Criterion</td><td>0</td><td>8</td><td>16</td><td>24</td><td>32</td><td>40</td><td>48</td><td>56</td><td>64</td><td>72</td></tr><tr><td>Anisidine value</td><td>0.24</td><td>0.34</td><td>0.50</td><td>1.09</td><td>1.26</td><td>1.83</td><td>2.44</td><td>3.48</td><td>4.29</td><td>5.40</td></tr><tr><td>Crude fat, %</td><td>&gt;99.75</td><td>&gt;99.75</td><td>&gt;99.75</td><td>&gt;99.75</td><td>&gt;99.75</td><td>&gt;99.75</td><td>&gt;99.75</td><td>&gt;99.75</td><td>&gt;99.75</td><td>&gt;99.75</td></tr><tr><td>DDE<sup>1</sup>, mg/mL</td><td>56.6</td><td>52.8</td><td>21.5</td><td>24.2</td><td>30.5</td><td>65.7</td><td>343.9</td><td>716.8</td><td>948.7</td><td>1276.4</td></tr><tr><td>Free fatty acids, %</td><td>1.12</td><td>1.12</td><td>0.83</td><td>1.83</td><td>0.70</td><td>0.98</td><td>1.27</td><td>1.41</td><td>1.40</td><td>1.84</td></tr><tr><td>Hexanal, &#956;g/g</td><td>1.70</td><td>1.90</td><td>2.24</td><td>3.27</td><td>3.90</td><td>4.61</td><td>5.22</td><td>5.79</td><td>6.08</td><td>6.60</td></tr><tr><td>HNE<sup>2</sup>, &#956;g/g</td><td>2.0</td><td>2.2</td><td>1.4</td><td>1.8</td><td>3.2</td><td>6.6</td><td>8.7</td><td>10.5</td><td>24.1</td><td>27.0</td></tr><tr><td>Insoluble, %</td><td>&lt;0.15</td><td>&lt;0.15</td><td>&lt;0.15</td><td>&lt;0.15</td><td>&lt;0.15</td><td>&lt;0.15</td><td>&lt;0.15</td><td>&lt;0.15</td><td>&lt;0.15</td><td>&lt;0.15</td></tr><tr><td>Moisture, %</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr><tr><td>Peroxide value, mEq/kg</td><td>2.11</td><td>2.87</td><td>6.17</td><td>7.06</td><td>8.12</td><td>13.10</td><td>13.75</td><td>13.94</td><td>13.85</td><td>13.57</td></tr><tr><td>TBARS<sup>3</sup>, mg MDA<sup>4</sup> eq/g oil</td><td>0.018</td><td>0.023</td><td>0.023</td><td>0.027</td><td>0.020</td><td>0.034</td><td>0.032</td><td>0.027</td><td>0.029</td><td>0.032</td></tr><tr><td>Unsaponafiable, %</td><td>0.78</td><td>0.73</td><td>0.76</td><td>0.82</td><td>0.78</td><td>0.70</td><td>0.68</td><td>0.67</td><td>0.77</td><td>0.83</td></tr><tr><td>Viscosity, cP @ 20C</td><td>56.6</td><td>56.3</td><td>56.6</td><td>58.5</td><td>60.4</td><td>62.8</td><td>65.7</td><td>70.9</td><td>74.9</td><td>78.8</td></tr><tr><td>OSI<sup>5</sup>, h</td><td>10.33</td><td>8.91</td><td>6.58</td><td>3.97</td><td>2.59</td><td>1.14</td><td>&lt;1.00</td><td>&lt;1.00</td><td>&lt;1.00</td><td>&lt;1.00</td></tr><tr><td>Fatty acids, % of total fat<sup>6</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Pentadecanoic acid (C15:0)</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.09</td><td>0.13</td><td>0.14</td><td>0.16</td><td>0.18</td><td>0.15</td></tr><tr><td>Palmitic (16:0)</td><td>14.36</td><td>12.26</td><td>11.50</td><td>11.63</td><td>11.88</td><td>11.81</td><td>12.20</td><td>12.26</td><td>12.55</td><td>13.02</td></tr><tr><td>Palmitoleic (9c-16:1)</td><td>0.14</td><td>0.11</td><td>0.10</td><td>0.11</td><td>0.11</td><td>0.11</td><td>0.11</td><td>0.12</td><td>0.12</td><td>0.11</td></tr><tr><td>Margaric (17:0)</td><td>0.00</td><td>0.08</td><td>0.00</td><td>0.09</td><td>0.09</td><td>0.09</td><td>0.09</td><td>0.10</td><td>0.10</td><td>0.00</td></tr><tr><td>Stearic (18:0)</td><td>1.75</td><td>1.87</td><td>1.89</td><td>1.93</td><td>2.00</td><td>1.99</td><td>2.02</td><td>2.04</td><td>2.13</td><td>2.07</td></tr><tr><td>Oleic (9c-18:1)</td><td>28.93</td><td>29.79</td><td>29.97</td><td>30.16</td><td>30.51</td><td>30.56</td><td>30.79</td><td>31.04</td><td>31.49</td><td>31.60</td></tr><tr><td>Linoleic (18:2n6)</td><td>53.06</td><td>53.66</td><td>54.21</td><td>53.69</td><td>52.63</td><td>52.67</td><td>51.91</td><td>51.40</td><td>50.40</td><td>50.32</td></tr><tr><td>Linolenic (18:3n3)</td><td>0.89</td><td>0.90</td><td>0.92</td><td>0.91</td><td>0.85</td><td>0.87</td><td>0.82</td><td>0.81</td><td>0.77</td><td>0.75</td></tr><tr><td>Arachidic (20:0)</td><td>0.28</td><td>0.37</td><td>0.40</td><td>0.41</td><td>0.43</td><td>0.44</td><td>0.41</td><td>0.42</td><td>0.46</td><td>0.40</td></tr><tr><td>Gonodic (20:1n9)</td><td>0.26</td><td>0.33</td><td>0.35</td><td>0.34</td><td>0.36</td><td>0.36</td><td>0.34</td><td>0.36</td><td>0.00</td><td>0.35</td></tr><tr><td>Behenoic (22:0)</td><td>0.12</td><td>0.17</td><td>0.16</td><td>0.21</td><td>0.20</td><td>0.21</td><td>0.20</td><td>0.20</td><td>0.22</td><td>0.19</td></tr><tr><td>Lignoceric (24:0)</td><td>0.00</td><td>0.15</td><td>0.19</td><td>0.19</td><td>0.21</td><td>0.26</td><td>0.22</td><td>0.25</td><td>0.24</td><td>0.27</td></tr></table>
83f49ef0092a935f56b949b17d25d3f7e80b59bb762076c80279ea74f3cdc3b0.png
complex
<table><tr><td colspan="5">Flexion PPIVMs</td></tr><tr><td>LSI</td><td>Sensitivity (CI)</td><td>Specificity (CI)</td><td>LR+ (CI)</td><td>LR- (CI)</td></tr><tr><td>Rotation LSI</td><td>.05 (.01, .36)</td><td>.99 (.96, .1.00)</td><td>4.12 (.21, 80.3)</td><td>.96 (.83, 1.11)</td></tr><tr><td>Translation LSI</td><td>.05 (.01, .22)</td><td>.995 (.97, 1.00)</td><td>8.73 (.57, 134.7)</td><td>.96 (.88, 1.05)</td></tr><tr><td colspan="5">Extension PPIVMs</td></tr><tr><td>LSI</td><td>Sensitivity (CI)</td><td>Specificity (CI)</td><td>LR+ (CI)</td><td>LR- (CI)</td></tr><tr><td>Rotation LSI</td><td>.22 (.06, .55)</td><td>.97 (.94, .99)</td><td>8.40 (1.88, 37.55)</td><td>.80 (.56, 1.13)</td></tr><tr><td>Translation LSI</td><td>.16 (.06, .38)</td><td>.98 (.94, .99)</td><td>7.07 (1.71, 29.2)</td><td>.86 (.71, 1.05)</td></tr></table>
32be704d551c3c50c35560cbbf4c04ae2e32cc95f4a1a5bf06e505a01c7e3e18.png
complex
<table><tr><td></td><td>Pre</td><td>Post</td><td>Fu3</td><td colspan="2">Change Pre-Post</td><td colspan="2">Change Pre-Fu3</td></tr><tr><td></td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (95% CI)</td><td>Effect size (<i>d</i>)<sup>a</sup></td><td>Mean (95% CI)</td><td>Effect size (<i>d</i>) <sup>a</sup></td></tr><tr><td>Positive Day Time Ratings</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Bibliotherapy with support (n = 44)</td><td>2.5 (0.79)</td><td>3.2 (0.70)</td><td>3.1 (0.74)</td><td>0.69 (0.46 to 0.92)</td><td>0.94</td><td>0.58 (0.34 to 0.82)</td><td>0.78</td></tr><tr><td> Bibliotherapy (n = 45)</td><td>2.6 (0.65)</td><td>3.0 (0.72)</td><td>3.0 (0.84)</td><td>0.38 (0.19 to 0.58)</td><td>0.58</td><td>0.44 (0.21 to 0.67)</td><td>0.58</td></tr><tr><td> Waiting list control (n = 43)</td><td>2.6 (0.73)</td><td>2.8 (0.75)</td><td>2.7 (0.76)</td><td>0.17 (-0.02 to 0.36)</td><td>0.27</td><td>0.13 (-0.07 to 0.32)</td><td>0.13</td></tr><tr><td>Day Time Fatigue (DTF)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Bibliotherapy with support (n = 44)</td><td>2.8 (0.98)</td><td>1.5 (1.0)</td><td>1.8 (1.1)</td><td>-1.23 (-1.54 to -0.91)</td><td>-1.31</td><td>-0.98 (-1.3 to -0.66)</td><td>-0.96</td></tr><tr><td> Bibliotherapy (n = 45)</td><td>2.7 (0.82)</td><td>2.2 (0.99)</td><td>2.1 (0.94)</td><td>-0.49 (-0.81 to -0.17)</td><td>-0.55</td><td>-0.61 (-0.92 to -0.31)</td><td>-0.68</td></tr><tr><td> Waiting list control (n = 43)</td><td>2.7 (0.82)</td><td>2.4 (0.89)</td><td>2.6 (1.0)</td><td>-0.28 (-0.50 to -0.05)</td><td>-0.35</td><td>-0.14 (-0.42 to 0.13)</td><td>-0.11</td></tr><tr><td>Perceived Stress Scale (PSS)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Bibliotherapy with support (n = 44)</td><td>17.4 (7.4)</td><td>13.1 (5.7)</td><td>13.2 (5.9)</td><td>-4.3 (-6.0 to -2.6)</td><td>-0.65</td><td>-4.2 (-6.1 to -2.3)</td><td>-0.63</td></tr><tr><td> Bibliotherapy (n = 45)</td><td>18.8 (6.2)</td><td>16.1 (7.1)</td><td>15.1 (7.4)</td><td>-2.7 (-4.2 to -1.1)</td><td>-0.41</td><td>-3.6 (-5.2 to -2.0)</td><td>-0.54</td></tr><tr><td> Waiting list control (n = 44)</td><td>19.0 (6.8)</td><td>17.2 (6.3)</td><td>17.3 (7.2)</td><td>-1.8 (-3.0 to -0.6)</td><td>-0.27</td><td>-1.7 (-3.3 to -0.2)</td><td>-0.24</td></tr><tr><td>CORE-OM</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Bibliotherapy with support (n = 44)</td><td>37.0 (17.7)</td><td>24.4 (14.0)</td><td>27.2 (17.0)</td><td>-12.5 (-17.0 to -8.0)</td><td>-0.79</td><td>-9.7 (-14.7 to -4.7)</td><td>-0.56</td></tr><tr><td> Bibliotherapy (n = 45)</td><td>36.7 (15.8)</td><td>32.5 (16.1)</td><td>29.6 (15.4)</td><td>-4.2 (-8.5 to 0.1)</td><td>-0.26</td><td>-7.1 (-11.6 to -2.7)</td><td>-0.46</td></tr><tr><td> Waiting list control (n = 44)</td><td>41.7 (15.6)</td><td>36.2 (15.3)</td><td>36.0 (18.4)</td><td>-5.5 (-8.9 to-2.0)</td><td>-0.36</td><td>-5.7 (-9.6 to -1.7)</td><td>-0.33</td></tr></table>
a26241bb2603404a99b89e18a3d17d18a6541eaa3b962fbfc14c21d917b2dbed.png
simple
<table><tr><td></td><td>Factor 1 (Cardiopulmonary)</td><td>Factor 2 (Pain-fatigue)</td><td>Factor 3 (Gastrointestinal)</td><td>Factor 4 (Dysmenorrhea)</td></tr><tr><td>PHQ11: Shortness of breath</td><td>0.799</td><td></td><td></td><td></td></tr><tr><td>PHQ10: Palpitation</td><td>0.738</td><td></td><td></td><td></td></tr><tr><td>PHQ07: Chest pain</td><td>0.709</td><td></td><td></td><td></td></tr><tr><td>PHQ09: Fainting spells</td><td>0.661</td><td></td><td></td><td></td></tr><tr><td>PHQ03: Pain in extremities</td><td></td><td>0.689</td><td></td><td></td></tr><tr><td>PHQ02: Back pain</td><td></td><td>0.662</td><td></td><td></td></tr><tr><td>PHQ06: Headache</td><td></td><td>0.638</td><td></td><td></td></tr><tr><td>PHQ08: Dizziness</td><td></td><td>0.603</td><td></td><td></td></tr><tr><td>PHQ14: Sleep disturbance</td><td></td><td>0.594</td><td></td><td></td></tr><tr><td>PHQ15: Fatigue</td><td></td><td>0.524</td><td></td><td>0.520</td></tr><tr><td>PHQ13: Nausea or indigestion</td><td></td><td></td><td>0.715</td><td></td></tr><tr><td>PHQ01: Stomach pain</td><td></td><td></td><td>0.651</td><td></td></tr><tr><td>PHQ12: Constipation or diarrhea</td><td></td><td></td><td>0.612</td><td></td></tr><tr><td>PHQ05: Sexual problems</td><td></td><td></td><td>0.428</td><td></td></tr><tr><td>PHQ04: Menstrual cramps</td><td></td><td></td><td></td><td>0.822</td></tr></table>
27c16a4d1fd0b632cffebe39ab4517b762912ec23e4c9b5c9cb0241765a0958c.png
simple
<table><tr><td>Organ ischaemia and I/R injury</td><td>Expression of TLRs</td><td>Upregulation of TLRs in ischaemia</td><td>Evidence for role of TLR in pathophysiology</td><td>Potential endogenous ligand implicated in pathogenesis</td></tr><tr><td>Cerebral</td><td>Glial cells: TLR 1&#8211;9 [32, 33]Neurons: TLR 2 and 4 [34]</td><td>TLR 2, 4 and 9 [34, 35]</td><td>TLR 2 and 4 knockout mice have reduced infarct size following ischaemia [34, 36&#8211;38]</td><td>HSP 70 [34]</td></tr><tr><td>Liver</td><td>Hepatocytes: TLR 2, 3, 4 and 5 [39]Non-parenchymal cells: TLR 2, 3, 4, 5, 7 and 9 [39]</td><td>TLR 2 [40]</td><td>TLR 4 and 9 knockout mice are protected against ischaemia-induced liver injury [41&#8211;43]</td><td>HSP 72 [44] and HMGB-1 [42, 45]</td></tr><tr><td>Renal</td><td>Parenchyma: TLRs 1&#8211;10 at varying detection levels [46&#8211;48]</td><td>TLR 2 and 4 [47, 49]</td><td>TLR 2 and 4 knockout mice are protected against renal I/R injury, and this is associated with a reduction in inflammatory cytokine levels [49&#8211;52]</td><td>HMGB-1, hyaluronan and biglycan [49, 51, 53]</td></tr><tr><td>Myocardial</td><td>Myocytes: TLR 2, 3, 4 and 6 [54]</td><td>TLR 4 [55]</td><td>TLR 2- and 4-deficient mice show reduced myocardial infarct size [56&#8211;59]. TLR 4 antagonist eritoran leads to reduced infarct size, NF-<i>&#954;</i>B nuclear translocation, and proinflammatory cytokine expression [60]</td><td>HMGB-1 [61]</td></tr><tr><td>Skeletal muscle</td><td>TLR 1&#8211;9 [62&#8211;64]</td><td>TLR 2, 4, 6 [65]</td><td>TLR 2 antagonsim reduces pro-inflammatory cytokine expression in an <i>in vitro </i>model of skeletal muscle ischaemia [65]</td><td>Under investigation</td></tr></table>
e6dc17c948e2cd76d6dd3bf8627377a24c0e3749ccc414e587c8b81b634e1361.png
complex
<table><tr><td rowspan="2">Population<sup>a</sup></td><td colspan="2">Relatively benign (<i>n</i> = 30 SNPs)</td><td colspan="2">Relatively deleterious (<i>n</i> = 29 SNPs)</td></tr><tr><td>Mean (s.d.)</td><td>Mean difference compared to EUR (95% CI); <i>P</i> value</td><td>Mean (s.d.)</td><td>Mean difference compared to EUR (95% CI); <i>P</i> value</td></tr><tr><td>AFR</td><td>29.85 (2.846)</td><td>1.98 (0.38, 3.58); 0.016</td><td>34.68 (3.109)</td><td>1.18 (&#8722;0.51, 2.87); 0.167</td></tr><tr><td>AMR</td><td>28.28 (3.449)</td><td>&#8722;0.41 (&#8722;1.35,2.17); 0.642</td><td>36.12 (3.768)</td><td>2.62 (0.76,4.48); 0.007</td></tr><tr><td>EAS</td><td>28.56 (3.127)</td><td>0.69 (&#8722;0.98,2.36); 0.412</td><td>35.66 (2.881)</td><td>2.16 (0.53, 3.79); 0.010</td></tr><tr><td>SAS</td><td>28.35 (3.332)</td><td>0.48 (&#8722;1.25,2.21); 0.579</td><td>34.10 (3.243)</td><td>0.60 (&#8722;1.12, 2.32); 0.488</td></tr><tr><td>EUR</td><td>27.87 (3.283)</td><td>ref</td><td>33.50 (3.360)</td><td>ref</td></tr></table>
a7f38818fd409c3236aa98fe9b576e8b903837ceaa5030008c3c958bcc247457.png
complex
<table><tr><td>Clinical characterization</td><td colspan="4">SOX2/TERC amplifications/polyploidy</td><td colspan="3">Odds ratio (95% confidence interval), p (two-tailed Fisher exact test)</td></tr><tr><td> </td><td>Normal</td><td>Polyploidy only</td><td>Amplification and poliploidy</td><td>Total abnormal FISH results</td><td>Normal vs. total abnormal FISH results</td><td>Normal vs. Polyploidy only</td><td>Normal vs. amplification with poliploidy</td></tr><tr><td>Controls</td><td>21</td><td>0</td><td>1</td><td>1</td><td rowspan="2">46.77 (5.91-370) 0.00</td><td rowspan="2">N/D<sup>2</sup> (N/D<sup>2</sup>) 0.00</td><td rowspan="2">21.00 (2.56-455) 0.00</td></tr><tr><td>OSCC</td><td>22</td><td>27</td><td>22</td><td>49</td></tr><tr><td>Stage: I, II, III</td><td>8</td><td>7</td><td>8</td><td>15</td><td rowspan="2">1.29 (0.39 &#8211; 4.23), 0.78</td><td rowspan="2">1.25 (0.41-6.03) 0.76</td><td rowspan="2">1.00 (0.25-4.07) 1.00</td></tr><tr><td>Stage: IV</td><td>14</td><td>20</td><td>14</td><td>34</td></tr><tr><td>Stage: I, II</td><td>4</td><td>5</td><td>7</td><td>12</td><td rowspan="2">0.69 (0.17-2.77), 0.76</td><td rowspan="2">0.98 (0.18-5,13) 1.00</td><td rowspan="2">0.48 (0.09-2.34) 0.49</td></tr><tr><td>Stage: III, IV</td><td>18</td><td>22</td><td>15</td><td>37</td></tr><tr><td>Oropharynx</td><td>6</td><td>11</td><td>10</td><td>21</td><td rowspan="2">2.00 (0.59-6.93), 0.29</td><td rowspan="2">1.83 (0.47-7.46) 0.38</td><td rowspan="2">2.22 (0.53-9.52) 0.34</td></tr><tr><td>Outside oropharynx<sup>1</sup></td><td>16</td><td>16</td><td>12</td><td>28</td></tr></table>
de3f02778879a0c28038e0afb28781408bd6ddb40eab7eb5b03a477b1ad9e8d7.png
simple
<table><tr><td></td><td>Total DW</td><td>Shoot DW</td><td>Root DW</td><td>Shoot Zn cont.</td><td>Shoot Zn conc.</td><td>Root number</td><td><i>RSA</i></td><td>% fine roots</td><td>Root: shoot ratio</td></tr><tr><td>Total DW</td><td>&#8211;</td><td>0.99</td><td>0.97</td><td>0.89</td><td>&#8211;0.01</td><td>0.72</td><td>0.81</td><td>&#8211;0.38</td><td>&#8211;0.17</td></tr><tr><td>Shoot DW</td><td>0.99</td><td>&#8211;</td><td>0.94</td><td>0.87</td><td>&#8211;0.06</td><td>0.70</td><td>0.80</td><td>&#8211;0.37</td><td>&#8211;0.24</td></tr><tr><td>Root DW</td><td>0.95</td><td>0.90</td><td>&#8211;</td><td>0.91</td><td>0.14</td><td>0.75</td><td>0.78</td><td>&#8211;0.41</td><td>0.08</td></tr><tr><td>Shoot Zn cont.</td><td>0.91</td><td>0.94</td><td>0.77</td><td>&#8211;</td><td>0.43</td><td>0.72</td><td>0.69</td><td>&#8211;0.29</td><td>0.01</td></tr><tr><td>Shoot Zn conc.</td><td>&#8211;0.47</td><td>&#8211;0.42</td><td>&#8211;0.55</td><td>&#8211;0.14</td><td>&#8211;</td><td>0.20</td><td>&#8211;0.07</td><td>0.1</td><td>0.50</td></tr><tr><td>Root number</td><td>0.90</td><td>0.89</td><td>0.85</td><td>0.82</td><td>&#8211;0.40</td><td>&#8211;</td><td>0.75</td><td>&#8211;0.34</td><td>0.05</td></tr><tr><td><i>RSA</i></td><td>0.92</td><td>0.89</td><td>0.93</td><td>0.72</td><td>&#8211;0.58</td><td>0.84</td><td>&#8211;</td><td>&#8211;0.45</td><td>&#8211;0.16</td></tr><tr><td>% fine roots</td><td>&#8211;0.63</td><td>&#8211;0.63</td><td>&#8211;0.59</td><td>&#8211;0.59</td><td>0.27</td><td>&#8211;0.37</td><td>&#8211;0.58</td><td>&#8211;</td><td>&#8211;0.06</td></tr><tr><td>Root:shoot ratio</td><td>0.27</td><td>0.16</td><td>0.52</td><td>0.01</td><td>&#8211;0.42</td><td>0.22</td><td>0.38</td><td>&#8211;0.24</td><td>&#8211;</td></tr></table>
47a892185d4e69f2c941155ee942f9c2dff28348212a411c09e3c747fb52729b.png
complex
<table><tr><td colspan="2"></td><td>Total population (<i>N</i> = 16)</td></tr><tr><td rowspan="3">Age [years]</td><td><i>N</i></td><td>16</td></tr><tr><td>Mean (SD)</td><td>62.5 (13.4)</td></tr><tr><td>Median (min, max)</td><td>67.0 (31, 76)</td></tr><tr><td rowspan="2">Gender [<i>n</i> (%)]<sup>&#8727;</sup></td><td>Male</td><td>7 (43.7%)</td></tr><tr><td>Female</td><td>9 (56.3%)</td></tr><tr><td rowspan="2">Duration of diabetes [years]</td><td>Mean (SD)</td><td>20.1 (7.6)</td></tr><tr><td>Median (min, max)</td><td>21.5 (2, 30)</td></tr><tr><td rowspan="2">Type of diabetes mellitus [<i>n</i> (%)]<sup>&#8727;</sup></td><td>Type 1</td><td>1 (6.3%)</td></tr><tr><td>Type 2</td><td>15 (93.7%)</td></tr><tr><td>Treatment of diabetes [<i>n</i> (%)]<sup>&#8727;</sup></td><td>Insulin</td><td>16 (100.0%)</td></tr><tr><td rowspan="2">Hba1c [%]</td><td>Mean (SD)</td><td>7.76 (0.7)</td></tr><tr><td>Median (min, max)</td><td>7.70 (6.3, 9)</td></tr><tr><td rowspan="2">Classification of diabetic retinopathy [<i>n</i> (%)]<sup>&#8727;</sup></td><td>Nonproliferative</td><td>14 (87.5%)</td></tr><tr><td>Proliferative</td><td>2 (12.5%)</td></tr></table>
f6d2738b3a143c74256d0c206b9200efbf442c5a6d7686ce3546f4b2a7d5bceb.png
simple
<table><tr><td> </td><td>%</td><td>Sun exposure</td><td>Localization</td><td>Clinical aspects</td><td>Colors</td><td>Histology</td></tr><tr><td>Superficial spreading melanoma</td><td>70</td><td>Intermittent</td><td>Back&#8212;Man Legs&#8212;Woman</td><td>Flat Papule Nodule</td><td>Tan, Brown, Gray, Black, Violaceous, Pink</td><td>Radial growth phase characterized by the proliferation within the epidermis of single atypical melanocytes in a pagetoid pattern</td></tr><tr><td>Nodular melanoma</td><td>5</td><td>Intermittent</td><td>Trunk Limb</td><td>Nodule Ulcerated polyp Elevated plaque</td><td>Brown Black Achromic</td><td>Radial growth phase absent</td></tr><tr><td>Lentigo maligna melanoma</td><td>4&#8211;15</td><td>Long term</td><td>Head Neck</td><td>Flat Papula</td><td>Brown Black</td><td>Radial growth phase composed of a lentiginous proliferation atypical melanocytes at the dermo-epidermal junction</td></tr><tr><td>Acral lentiginoso melanoma</td><td>5</td><td>N/A</td><td>Glabrous skin (palmoplantar, subungueal)</td><td>Flat Nodule Plaque</td><td>Irregular, poorly circumscribed pigmentation</td><td>Radial growth phase characterized by lentiginous proliferation of atypical melanocytes, marked acanthosis and elongation of the rete ridges of the epidermis</td></tr><tr><td>Desmoplastic melanoma</td><td>2</td><td>Long term</td><td>Head Neck</td><td>Papule Nodule</td><td>Erythemato us Flash colored Achromic</td><td>Vertical growth phase composed of atypical spindle cells embedded in a fibrous stroma</td></tr><tr><td>Melanoma arising from blu nevus</td><td>Rare</td><td>N/A</td><td>Head</td><td>Recent history of enlargement or change in pre-existing nevus</td><td>Blu-Black</td><td>Malignant dermal, deep seated component juxtaposed to a benign blue nevus</td></tr><tr><td>Melanoma arising in a giant</td><td>Rare</td><td>N/A</td><td>Trunk</td><td>Nodule growing in</td><td>Dark, brown</td><td>Dermal sharply delineated nodule</td></tr><tr><td>Congenital nevus</td><td> </td><td> </td><td> </td><td>A nevus</td><td>Black</td><td>Composed of atypical ephitelioid, spindle or small cells, arising in a preexisting giant congenital nevus</td></tr><tr><td>Melanoma of childhood</td><td>0,4</td><td>N/A</td><td>Trunk</td><td>SSM or NM</td><td>SSM: Tan, Brown, Gray, Black, Violaceous, Pink</td><td>Conventional epithelioid melanoma or small cells or melanoma simulating Spitz nevus</td></tr><tr><td>Nevoid melanoma</td><td>1-2</td><td>N/A</td><td>Leg, trunk</td><td>Small papule</td><td>Tan to dark, brown</td><td>Nevus-like silhouette, limited intraepidermal component, loss/lack of maturation, cytological atypia, mitoses in the dermal component</td></tr></table>
0e9659e13b51c4bf6475a6fc6f8f91ec50c71b23c395fb35aa82be264288f515.png
complex
<table><tr><td> </td><td colspan="3">PFS-rates</td></tr><tr><td> </td><td>3 years</td><td>5 years</td><td>10 years</td></tr><tr><td>Entire cohort</td><td>92.30%</td><td>87.00%</td><td>84.10%</td></tr><tr><td>Group 1 (unknown/Grade I)</td><td>96.80%</td><td>92.70%</td><td>89.60%</td></tr><tr><td>Group 2 (Grade II/III)</td><td>52.60%</td><td>19.70%</td><td>n/a</td></tr><tr><td>Unknown histology</td><td>97.40%</td><td>94.20%</td><td>90.40%</td></tr><tr><td>Grade I</td><td>93.90%</td><td>85.80%</td><td>85.80%</td></tr><tr><td>Grade II</td><td>62.70%</td><td>41.80%</td><td>n/a</td></tr><tr><td>Grade II</td><td>29.30%</td><td>n/a</td><td>n/a</td></tr><tr><td>Volume &lt; 60 ccm</td><td>95.80%</td><td>91.20%</td><td>89.30%</td></tr><tr><td>Volume &gt; 60 ccm</td><td>100%</td><td>85.70%</td><td>n/a</td></tr><tr><td>Primary RT</td><td>98.10%</td><td>98.10%</td><td>96.80%</td></tr><tr><td>Postoperative RT</td><td>87.60%</td><td>78.10%</td><td>73.40%</td></tr><tr><td>nFSRT</td><td>92.70%</td><td>88.90%</td><td>86.90%</td></tr><tr><td>hFSRT</td><td>92.40%</td><td>80.90%</td><td>n/a</td></tr><tr><td>SRS</td><td>95.80%</td><td>87.80%</td><td>n/a</td></tr></table>
33fc19a2fe0c58780c1e2f55d43736e8e24b493595ad2e6f300d82d166d21d33.png
simple
<table><tr><td></td><td>Variables</td><td>Measures used/source</td></tr><tr><td>Outcomes or responses</td><td>Musculoskeletal symptoms by body region</td><td>Modified from NIOSH symptom report items (NIOSH 2000)Hand diagram (Katz et al. 1990)</td></tr><tr><td></td><td>Signs from physical exam</td><td>Modified from SHARP physical exam protocol (Viikari-Juntura 2000)</td></tr><tr><td></td><td>MSDs</td><td>Combinations of signs and symptoms used to define working case definitions (Sluiter et al. 2001; Palmer et al. 2000 and Walker-Bone et al. 2002; Gerr et al. 2002)</td></tr><tr><td></td><td>Acute work-related injury</td><td>Self-report</td></tr><tr><td></td><td>Health-related quality of lifea</td><td>SF-12 (Ware et al. 1996)</td></tr><tr><td></td><td>Upper extremity functiona</td><td>Upper extremity function scale (Pransky et al. 1997)</td></tr><tr><td></td><td>Depressive symptomsa</td><td>CES-D (Radloff 1977)</td></tr><tr><td>Exposures</td><td>Work requirements Repetition, posture, force, temperature, tool use</td><td>Key informant interviews, project-specific self-report exposure tool</td></tr><tr><td>Modifiers</td><td>Work organization (decision latitude, control, demand, social support, job satisfaction)</td><td>Job Content Questionnaire (Karasek et al. 1998)</td></tr><tr><td></td><td>Discrimination and response</td><td>Self-reported by race or gender and usual response (Krieger and Sidney 1996)</td></tr><tr><td></td><td>Assertiveness at work</td><td>Scale measure from self-reported items; developed from key. informant interviews</td></tr><tr><td></td><td>Coping style</td><td>John Henryism Active Coping Scale (James et al. 1987)</td></tr><tr><td></td><td>Socioeconomic strain</td><td>Self-report of &#8220;Weeks you could be out of work without pay before loss of income would be a major problem.&#8221;</td></tr><tr><td></td><td>Other health conditions</td><td>Medical history (select items based on possible relationship to MSDs&#8212;pregnancy, hormonal therapies, diabetes, etc.)</td></tr></table>
9a69d4c0f69d8f6e084b6b240432d0953074a6b56514656806e8f08be4e56b01.png
simple
<table><tr><td>GM allotypes</td><td>Proportions (number of individuals)</td></tr><tr><td>5</td><td>100% (216)</td></tr><tr><td>17</td><td>100% (216)</td></tr><tr><td>1</td><td>99.5% (215)</td></tr><tr><td>14</td><td>98.6% (213)</td></tr><tr><td>13</td><td>82.4% (178)</td></tr><tr><td>6</td><td>49.5% (107)</td></tr><tr><td>3</td><td>1.9% (4)</td></tr><tr><td>21</td><td>1.4% (3)</td></tr><tr><td>23</td><td>0.5% (1)</td></tr></table>
14ad145e1a03f346e1d1ee655ff953b3b33afa8c4ae0b4678e3c1b87c67364ac.png
simple
<table><tr><td>Evaluation criteria</td><td>ML-kNN</td><td>kNN</td><td>RankSVM</td><td>BPMLL</td></tr><tr><td>Average_Precision(%)</td><td>77.4 &#177; 3.3</td><td>73.6 &#177; 3.1</td><td>71.0 &#177; 2.1</td><td>75.4 &#177; 2.7</td></tr><tr><td>Coverage</td><td>3.31 &#177; 0.31</td><td>3.44 &#177; 0.30</td><td>3.69 &#177; 0.28</td><td>3.36 &#177; 0.33</td></tr><tr><td>Ranking_Loss</td><td>0.283 &#177; 0.035</td><td>0.386 &#177; 0.037</td><td>0.419 &#177; 0.041</td><td>0.311 &#177; 0.039</td></tr></table>
7f989af19d010b448084f239c8883579bc9ff4c3d6c815b545952e3efc8efb00.png
complex
<table><tr><td>Type of intervention</td><td>Specific intervention</td><td>Votes</td><td>% of total votes</td></tr><tr><td>Other vaccines</td><td>None specified by any group</td><td>0</td><td>0</td></tr><tr><td rowspan="8">Information &amp; skills</td><td>Lifestyle education</td><td>20</td><td>10</td></tr><tr><td>Oral health education (with or without provision of toothbrush and paste)</td><td>18</td><td>9</td></tr><tr><td>Diet &amp; exercise education</td><td>17</td><td>8</td></tr><tr><td>Sexual &amp; reproductive health and rights</td><td>12</td><td>6</td></tr><tr><td>Hygiene education (with or without provision of soap)</td><td>12</td><td>6</td></tr><tr><td>Health promotion through the school health programme</td><td>12</td><td>6</td></tr><tr><td>Road safety education</td><td>10</td><td>5</td></tr><tr><td>Education on mental health</td><td>8</td><td>4</td></tr><tr><td rowspan="2">Screening</td><td>Visual acuity</td><td>31</td><td>15</td></tr><tr><td>General health checks</td><td>15</td><td>7</td></tr><tr><td rowspan="3">Commodities &amp; treatment</td><td>Deworming, including schistosomiasis and/or soil-transmitted helminth treatment</td><td>38</td><td>18</td></tr><tr><td>Youth-friendly services provision</td><td>12</td><td>6</td></tr><tr><td>Provision of school meals</td><td>3</td><td>1</td></tr><tr><td>Total</td><td></td><td>208</td><td>100</td></tr></table>
a23051826ca34c7f0e2ac1dc3ccb5825e9bb9d47f105036df797738c00f1c122.png
complex
<table><tr><td></td><td colspan="2">Spring Tides</td><td colspan="2">Neap Tides</td></tr><tr><td></td><td>PC1 (75.0%)</td><td>PC2 (17%)</td><td>PC1 (84.0%)</td><td>PC2 (8%)</td></tr><tr><td>AChla</td><td>0.40</td><td>0.88</td><td>0.24</td><td>&#8722;0.94</td></tr><tr><td>DTB</td><td>0.80</td><td>&#8722;0.35</td><td>0.83</td><td>0.24</td></tr><tr><td>DNB</td><td>&#8722;0.27</td><td>&lt;0.01</td><td>&#8722;0.37</td><td>&#8722;0.18</td></tr><tr><td>GZB</td><td>&#8722;0.32</td><td>0.29</td><td>&#8722;0.32</td><td>0.11</td></tr><tr><td>FChla</td><td>&lt;0.01</td><td>&lt;0.01</td><td>&lt;0.01</td><td>&lt;0.01</td></tr></table>
d36e1935f5f24c7a5055eb3bfcd4911266515c23d18b6f0ba319a4052d09804a.png
complex
<table><tr><td rowspan="2">Protein</td><td rowspan="2">Sequence</td><td rowspan="2">NetCTLpansupertype prediction</td><td>Antigen specific T-cell response</td></tr><tr><td>HLA alleles assessed</td></tr><tr><td rowspan="8">NP</td><td>IPVYQVNNL</td><td>B7</td><td>B7: HLA-B*07:02</td></tr><tr><td>RLEELLPAV</td><td>A2</td><td>A2: HLA-A*02:01</td></tr><tr><td>FLSFASLFL</td><td>A2</td><td>A2: HLA-A*02:01</td></tr><tr><td>HPLARTAKV</td><td>B7</td><td>B7: HLA-B*07:02, HLA-B*35:01, HLA-B*51:01</td></tr><tr><td>GLFPQLSAI</td><td>A2</td><td>A2: HLA-A*02:01</td></tr><tr><td>FPQLSAIAL</td><td>B7</td><td>A2: HLA-A*02:01B7: HLA-B*07:02</td></tr><tr><td>QTNAMVTLR</td><td>A3</td><td>A3: HLA-A*03:01, HLA-A*11:01</td></tr><tr><td>KLTEAITAA</td><td>A2</td><td>A2: HLA-A*02:01</td></tr><tr><td rowspan="2">VP40</td><td>LPQYFTFDL</td><td>B7</td><td>B7: HLA-B*07:02, HLA-B*35:01</td></tr><tr><td>FTFDLTALK</td><td>A3</td><td>A3: HLA-A*03:01, HLA-A*11:01</td></tr><tr><td rowspan="2">&#8220;Pre-295 All GP&#8221;</td><td>ILFQRTFSI</td><td>A2</td><td>A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01</td></tr><tr><td>FLLQLNETI</td><td>A2</td><td>A2: HLA-A*02:01</td></tr><tr><td rowspan="5">&#8220;Post-295 GP&#8221;</td><td>MASENSSAM</td><td>B7</td><td>A2: HLA-A*02:01B7: HLA-B*07:02</td></tr><tr><td>LITNTIAGV</td><td>A2</td><td>A2: HLA-A*02:01</td></tr><tr><td>LANETTQAL</td><td>B7</td><td>B7: HLA-B*07:02, HLA-B*35:01</td></tr><tr><td>RTFSILNRK</td><td>A3</td><td>A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01</td></tr><tr><td>KAIDFLLQR</td><td>A3</td><td>A2: HLA-A*02:01A3: HLA-A*03:01, HLA-A*11:01</td></tr><tr><td>VP24</td><td>VLSDLCNFL</td><td>A2</td><td>A2: HLA-A*02:01</td></tr><tr><td rowspan="6">L</td><td>IISDLSIFI</td><td>A2</td><td>A2: HLA-A*02:01, HLA-A*69:01</td></tr><tr><td>LLADGLAKA</td><td>A2</td><td>A2: HLA-A*02:01, HLA-A*69:01</td></tr><tr><td>HSGFIYFGK</td><td>A3</td><td>A3: HLA-A*11:01, HLA-A*31:01</td></tr><tr><td>KLINTLFHA</td><td>A2</td><td>A2: HLA-A*02:01</td></tr><tr><td>TPVMSRFAA</td><td>B7</td><td>B7: HLA-B*07:02, HLA-B*35:01</td></tr><tr><td>KPTFKHASV</td><td>B7</td><td>B7: HLA-B*07:02</td></tr></table>
556dcdb5fc6369ebe37a7790695b8b25b712b172d7546ad89db520b56943bbce.png
simple
<table><tr><td>Steel</td><td>YS (MPa)</td><td>TS (MPa)</td><td>% Elongation</td><td>&#963;<sub>ppt</sub> (MPa)</td></tr><tr><td>CMn</td><td>267</td><td>401</td><td>33</td><td>&#8211;</td></tr><tr><td>1.7 Cu</td><td>452</td><td>567</td><td>15.2</td><td>158</td></tr><tr><td>TiMo</td><td>642</td><td>770</td><td>16.6</td><td>347</td></tr><tr><td>1.7 CuTiMo</td><td>695</td><td>840</td><td>11.6</td><td>380</td></tr></table>
d36d3931920ea303a2e1770f82b7234d9c5d91583ba20825a6dac843f2e5d4a0.png
complex
<table><tr><td colspan="2">Complete blood count</td><td colspan="2">Coagulation</td></tr><tr><td>Erythrocytes</td><td>3.52 &#215; 10<sup>12</sup> cells/L</td><td>PT-INR</td><td>1</td></tr><tr><td>Hemoglobin</td><td>6.5 g/dL</td><td>aPTT</td><td>35 seconds</td></tr><tr><td>Hematocrit</td><td>27.7%</td><td>Fib</td><td>4.41 g/L</td></tr><tr><td>White blood cells</td><td>9.94 &#215; 10<sup>9</sup>/L</td><td colspan="2">Other tests</td></tr><tr><td>Platelets</td><td>11 &#215; 10<sup>9</sup>/L</td><td>AST</td><td>35 U/L</td></tr><tr><td>Reticulocyte count</td><td>1.92%</td><td>ALT</td><td>19 U/L</td></tr><tr><td></td><td></td><td>Cr</td><td>1.1 mg/dL</td></tr><tr><td></td><td></td><td>Urea</td><td>40 mg/dL</td></tr><tr><td></td><td></td><td>Na</td><td>140 mEq/L</td></tr><tr><td></td><td></td><td>K</td><td>3.9 mEq/L</td></tr><tr><td></td><td></td><td>Total bilirubin</td><td>1.0 mg/dL</td></tr><tr><td></td><td></td><td>Uric acid</td><td>7.3 mg/dL</td></tr><tr><td></td><td></td><td>Lactate dehydrogenase</td><td>183 U/L</td></tr><tr><td></td><td></td><td>Ferritin blood test</td><td>148 ng/Ml</td></tr><tr><td></td><td></td><td>Transferrin saturation</td><td>11.8%</td></tr><tr><td></td><td></td><td>Serum iron</td><td>38 &#956;g/dL</td></tr><tr><td></td><td></td><td>B12 vitamin</td><td>668.4 pg/mL</td></tr></table>
8cf5c128eb834b238844606dbf56a9b4e6105e2859b95d9aad830df5ce3860f4.png
simple
<table><tr><td>Variables</td><td>Best Cutoff Values</td><td>AUC (95% CI)</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>Accuracy (%)</td></tr><tr><td>AF duration</td><td>66.5 mhs</td><td>0.653(0.593 ~ 0.712)</td><td>39.7</td><td>89.0</td><td>55.3</td></tr><tr><td>Pre-op BNP</td><td>251 pg/ml</td><td>0.691(0.636 ~ 0.746)</td><td>60.3</td><td>71.4</td><td>67.2</td></tr><tr><td>Pre-op heart rate</td><td>82 bpm</td><td>0.842(0.802 ~ 0.882)</td><td>75.1</td><td>81.5</td><td>75.8</td></tr><tr><td>Pre-op LAD</td><td>67.9 mm</td><td>0.600(0.540 ~ 0.660)</td><td>31.8</td><td>91.4</td><td>68.7</td></tr></table>
29a947f73e3e428f28846cb843f262bc44eab1d9071e84c2618531f3e21a3702.png
complex
<table><tr><td colspan="2">Demographic characteristics</td><td>Cases</td><td>2008 population</td><td>Attack rate per 1000</td></tr><tr><td rowspan="4">Age</td><td>0&#8211;4</td><td>12</td><td>524</td><td>23</td></tr><tr><td>5&#8211;8</td><td>13</td><td>510</td><td>26</td></tr><tr><td>9&#8211;13</td><td>11</td><td>675</td><td>16</td></tr><tr><td>14+</td><td>29</td><td>3554</td><td>8</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>42</td><td>2650</td><td>16</td></tr><tr><td>Female</td><td>23</td><td>2613</td><td>9</td></tr><tr><td>Total</td><td></td><td>65</td><td>5263</td><td>12</td></tr></table>
179305576f6c9f52ce48eff19ded33c8026b7f8f1d1858b6a99ac20b3a681709.png
complex
<table><tr><td>Demographic characteristics</td><td colspan="2">N</td><td>%</td><td colspan="2"> </td></tr><tr><td><i>Female gender</i></td><td colspan="2">243</td><td>64.5</td><td colspan="2"> </td></tr><tr><td> </td><td colspan="2"><i>M</i></td><td>SD</td><td colspan="2">Range</td></tr><tr><td><i>Age at study (years)</i></td><td colspan="2">25.0</td><td>2.1</td><td colspan="2">22.5 - 30.9</td></tr><tr><td>Disease characteristics</td><td>N</td><td>%</td><td> </td><td>N</td><td>%</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>Congenital disorder</i></td><td>200</td><td>53.1</td><td><i>Daily medicine use</i></td><td>196</td><td>52.0</td></tr><tr><td><i>Perceptible disability</i></td><td>159</td><td>42.2</td><td><i>Medical aids/devices</i></td><td>184</td><td>48.8</td></tr><tr><td><i>Course of illness</i></td><td> </td><td> </td><td><i>Limitations in fingers/hand</i></td><td>148</td><td>39.3</td></tr><tr><td>Worse/variable</td><td>156</td><td>41.4</td><td><i>Limitation of sight</i></td><td>90</td><td>23.9</td></tr><tr><td>Stable/positive</td><td>221</td><td>58.6</td><td><i>Limitations of hearing</i></td><td>31</td><td>8.2</td></tr><tr><td> </td><td> </td><td> </td><td><i>Able to sit half an hour</i></td><td>350</td><td>92.8</td></tr><tr><td> </td><td> </td><td> </td><td><i>Able to stand half an hour</i></td><td>220</td><td>58.4</td></tr><tr><td>Chronic conditions</td><td colspan="3">N</td><td colspan="2"> </td></tr><tr><td><i>Visually impaired/blind</i></td><td colspan="3">51</td><td colspan="2"> </td></tr><tr><td><i>Spasm</i></td><td colspan="3">45</td><td colspan="2"> </td></tr><tr><td><i>Rheumatoid arthritis</i></td><td colspan="3">45</td><td colspan="2"> </td></tr><tr><td><i>Epilepsy</i></td><td colspan="3">31</td><td colspan="2"> </td></tr><tr><td><i>Back complaints</i></td><td colspan="3">28</td><td colspan="2"> </td></tr><tr><td><i>Hearing impaired/deaf</i></td><td colspan="3">27</td><td colspan="2"> </td></tr><tr><td><i>Intestinal complaints</i></td><td colspan="3">21</td><td colspan="2"> </td></tr><tr><td><i>CFS</i></td><td colspan="3">20</td><td colspan="2"> </td></tr><tr><td><i>Lung complaints</i></td><td colspan="3">20</td><td colspan="2"> </td></tr><tr><td><i>Accident damage</i></td><td colspan="3">19</td><td colspan="2"> </td></tr><tr><td><i>Paralysis</i></td><td colspan="3">19</td><td colspan="2"> </td></tr><tr><td><i>Cancer</i></td><td colspan="3">18</td><td colspan="2"> </td></tr><tr><td><i>Muscular dystrophy</i></td><td colspan="3">17</td><td colspan="2"> </td></tr><tr><td><i>Arthritis</i></td><td colspan="3">16</td><td colspan="2"> </td></tr><tr><td><i>Kidney diseases</i></td><td colspan="3">13</td><td colspan="2"> </td></tr><tr><td><i>Skin disease</i></td><td colspan="3">9</td><td colspan="2"> </td></tr><tr><td><i>Migraine</i></td><td colspan="3">9</td><td colspan="2"> </td></tr><tr><td><i>Heart disease</i></td><td colspan="3">7</td><td colspan="2"> </td></tr><tr><td><i>Other</i></td><td colspan="3">119</td><td colspan="2"> </td></tr></table>
4b335d1a78df464fe494d40cc0310c93f83a08a0d31174f555de4262cc468f99.png
complex
<table><tr><td>HCH- isomers</td><td>Incubation period (days)</td><td>Degradation by isolate DAB-1Y (5 &#956;g/mL) in %</td><td>Degradation by isolate. DAB-1W(5 &#956;g/mL) in %</td></tr><tr><td rowspan="2"><i>&#945;</i></td><td>8</td><td>86</td><td>93</td></tr><tr><td>28</td><td>18</td><td>10</td></tr><tr><td rowspan="2"><i>&#946;</i></td><td>8</td><td>12</td><td>14</td></tr><tr><td>28</td><td>35</td><td>32</td></tr><tr><td rowspan="2"><i>&#947;</i></td><td>8</td><td>94</td><td>98</td></tr><tr><td>28</td><td>30</td><td>28</td></tr><tr><td><i>&#948;</i></td><td>8</td><td>80</td><td>76</td></tr><tr><td></td><td>28</td><td>32</td><td>28</td></tr></table>
480b7ab2b66184fd4683a6f0caadad148b662b434b9342b4b1f89a13068e8243.png
complex
<table><tr><td rowspan="2">Variable<sup>a</sup></td><td>Odds ratio</td><td rowspan="2"><i>P</i>-value</td></tr><tr><td>(95% CI)</td></tr><tr><td colspan="3">Basal-like n = 205 (pr = 72, nr = 133)</td></tr><tr><td>B/P</td><td>1.26 (0.95-1.68)</td><td>0.12</td></tr><tr><td>T/NK</td><td>1.53 (0.93-2.51)</td><td>0.09</td></tr><tr><td>M/D</td><td>1.66 (1.15-2.39)</td><td>0.007</td></tr><tr><td colspan="3">Claudin-low n = 47 (pr = 17, nr = 30)</td></tr><tr><td>B/P</td><td>1.92 (1.10-3.34)</td><td>0.02</td></tr><tr><td>T/NK</td><td>2.08 (0.80-5.47)</td><td>0.14</td></tr><tr><td>M/D</td><td>1.11 (0.43-2.86)</td><td>0.82</td></tr><tr><td colspan="3">HER2-E n = 72 (pr = 26, nr = 46)</td></tr><tr><td>B/P</td><td>1.31 (0.84-2.04)</td><td>0.23</td></tr><tr><td>T/NK</td><td>0.83 ( 0.36-1.92)</td><td>0.67</td></tr><tr><td>M/D</td><td>1.19 (0.54-2.59)</td><td>0.67</td></tr><tr><td colspan="3">LumB n = 133 (pr = 23, nr = 110)</td></tr><tr><td>B/P</td><td>1.33 (0.93-1.89)</td><td>0.11</td></tr><tr><td>T/NK</td><td>1.44 ( 0.86-2.42)</td><td>0.16</td></tr><tr><td>M/D</td><td>1.71(1.01-2.91)</td><td>0.05</td></tr><tr><td colspan="3">LumA n = 207 (pr = 7, nr = 200)</td></tr><tr><td>B/P</td><td>1.52 (0.82-2.83)</td><td>0.19</td></tr><tr><td>T/NK</td><td>1.16 (0.52-2.60)</td><td>0.72</td></tr><tr><td>M/D</td><td>0.93 (0.43-2.02)</td><td>0.85</td></tr></table>
d0bff3e9142394073a73f2136d561e39dd7c1257f4951f09c9a4e843493da1de.png
complex
<table><tr><td rowspan="3">Genes</td><td colspan="4">Frequency of mRNA level changes, %</td><td colspan="2">Median of mRNA level changes, <i>n</i>-fold*</td></tr><tr><td colspan="2">ccRCC</td><td colspan="2">pRCC</td><td rowspan="2">ccRCC</td><td rowspan="2">pRCC</td></tr><tr><td>&#8595;</td><td>&#8593;</td><td>&#8595;</td><td>&#8593;</td></tr><tr><td><i>LRRN1 </i></td><td>53 (9/17)</td><td>0 (0/17)</td><td>11 (1/9)</td><td>33 (3/9)</td><td>3&#8595;(1&#8211;15&#8595;)</td><td>3&#8593;(2.1 &#215; 10<sup>3</sup>&#8593;&#8211;10&#8595;)</td></tr><tr><td><i>GORASP1 </i></td><td>42 (5/12)</td><td>0 (0/12)</td><td>36 (4/11)</td><td>0 (0/12)</td><td>1 (1&#8211;3&#8595;)</td><td>1 (1&#8211;7&#8595;)</td></tr><tr><td><i>IQSEC1 </i></td><td>0 (0/12)</td><td>8 (1/12)</td><td>58 (7/12)</td><td>0 (0/12)</td><td>1 (3&#8593;&#8211;1)</td><td>2&#8595; (1&#8211;53&#8595;)</td></tr><tr><td><i>FOXP1 </i></td><td>20 (2/10)</td><td>0 (0/10)</td><td>17 (2/12)</td><td>25 (3/12)</td><td>1 (1&#8211;2&#8595;)</td><td>1 (19&#8593;&#8211;14&#8595;)</td></tr><tr><td><i>GNAI2 </i></td><td>8 (1/12)</td><td>33 (4/12)</td><td>17 (2/12)</td><td>25 (3/12)</td><td>1 (4&#8593;&#8211;2&#8595;)</td><td>1 (3&#8593;&#8211;4&#8595;)</td></tr><tr><td><i>FGD5 </i></td><td>25 (3/12)</td><td>8 (1/12)</td><td>83 (10/12)</td><td>0 (0/12)</td><td>1 (3&#8593;&#8211;7&#8595;)</td><td>3&#8595;(1&#8211;59&#8595;)</td></tr><tr><td><i>PLCL2 </i></td><td>50 (6/12)</td><td>0 (0/12)</td><td>83 (10/12)</td><td>8 (1/12)</td><td>1 (1&#8211;5&#8595;)</td><td>3&#8595;(2&#8593;&#8211;8&#8595;)</td></tr><tr><td><i>ALDH1L1 </i></td><td>92 (11/12)</td><td>0 (0/12)</td><td>92 (11/12)</td><td>0 (0/12)</td><td>4&#8595;(1&#8211;1.1 &#215; 10<sup>2</sup>&#8595;)</td><td>6&#8595;(1&#8211;1.6 &#215; 10<sup>2</sup>&#8595;)</td></tr></table>
b761855920de9861fb1621f1ae97b9b331d9b7423c9f68f159de2b98ef108533.png
simple
<table><tr><td></td><td>Odd ratio (95% CI)</td></tr><tr><td>Crude: Age &lt; 50 years</td><td>1</td></tr><tr><td>&lt; 50 years</td><td>8.14 (3.49~18.98)</td></tr><tr><td> Gender - Male</td><td>1</td></tr><tr><td>- Female</td><td>2.36 (1.12~5.11)</td></tr><tr><td> p-CagA - Sparse</td><td>1</td></tr><tr><td>- Weak</td><td>4.38 (1.15~16.72)</td></tr><tr><td>- Strong</td><td>8.34 (2.21~31.55)</td></tr><tr><td>Age and gender adjusted</td><td></td></tr><tr><td> Sparse p-CagA</td><td>1</td></tr><tr><td> Weak p-CagA</td><td>3.67 (0.93~14.37)</td></tr><tr><td> Strong p-CagA</td><td>8.44 (2.08~34.12)</td></tr><tr><td>Age, gender and disease adjusted</td><td></td></tr><tr><td> Sparse p-CagA</td><td>1</td></tr><tr><td> Weak p-CagA</td><td>3.93 (0.92~16.94)</td></tr><tr><td> Strong p-CagA</td><td>10.45 (2.25~48.48)</td></tr></table>
6061e25af7fdf690970bc979f1c9d2edee844b7109fa1906a32077f4e7c9dc46.png
simple
<table><tr><td>Surgery</td><td>Pre-surgery</td><td>Post-surgery</td><td>Median change</td></tr><tr><td>Control</td><td>0&#8212;11.0 ng/mL</td><td>NA</td><td>NA</td></tr><tr><td>Lumpectomy</td><td>0.1&#8212;15.8 ng/mL</td><td>1.0&#8212;53.8 ng/mL</td><td>4.8</td></tr><tr><td>Mastectomy</td><td>0.4&#8212;7.6 ng/mL</td><td>6.4&#8212;53.8 ng/mL</td><td>14.7</td></tr></table>
15af2597443cbd9313a57b50106fdfac38205b4cd2c95d75ced0bca4f8edabb6.png
complex
<table><tr><td rowspan="3">Liver</td><td colspan="4">Estimated ELOVL6 activity</td><td colspan="4">Estimated SCD1 activity</td><td rowspan="2" colspan="2">C16:0/C18:2n-6</td><td rowspan="2" colspan="2">C16:0</td></tr><tr><td colspan="2">C18:0/C16:0</td><td colspan="2">C18:1/C16:1</td><td colspan="2">C16:1/C16:0</td><td colspan="2">C18:1/C18:0</td></tr><tr><td>Adult</td><td>Old</td><td>Adult</td><td>Old</td><td>Adult</td><td>Old</td><td>Adult</td><td>Old</td><td>Adult</td><td>Old</td><td>Adult</td><td>Old</td></tr><tr><td>C16:1n-7</td><td>&#8722;0.797<sup>**</sup></td><td>&#8722;0.718<sup>**</sup></td><td>&#8722;0.865<sup>**</sup></td><td>&#8722;0.658<sup>**</sup></td><td>0.970<sup>**</sup></td><td>0.946<sup>**</sup></td><td>0.887<sup>**</sup></td><td>0.517<sup>**</sup></td><td>0.466<sup>*</sup></td><td>&#8722;0.602<sup>**</sup></td><td>0.514<sup>*</sup></td><td>&#8722;0.485<sup>**</sup></td></tr><tr><td>C18:1n-9</td><td>&#8722;0.735<sup>**</sup></td><td>&#8722;0.096</td><td>&#8722;0.508<sup>*</sup></td><td>0.589<sup>**</sup></td><td>0.734<sup>**</sup></td><td>0.294</td><td>0.954<sup>**</sup></td><td>0.843<sup>**</sup></td><td>0.494<sup>*</sup></td><td>&#8722;0.355</td><td>0.662<sup>**</sup></td><td>&#8722;0.707<sup>**</sup></td></tr><tr><td>C20:4n-6</td><td>0.727<sup>**</sup></td><td>&#8722;0.016</td><td>0.618<sup>**</sup></td><td>&#8722;0.643<sup>**</sup></td><td>&#8722;0.475<sup>*</sup></td><td>&#8722;0.152</td><td>&#8722;0.552<sup>*</sup></td><td>&#8722;0.722<sup>**</sup></td><td>&#8722;0.291</td><td>0.245</td><td>&#8722;0.735<sup>**</sup></td><td>0.560<sup>**</sup></td></tr></table>
6613572c1c39a8525f049c36f00f936459334970055cbf5e00d918f5fa91effa.png
complex
<table><tr><td rowspan="2">RNAi</td><td colspan="3">Strain</td></tr><tr><td><i>rrf-1</i> %Mog (<i>n</i>)</td><td><i>rrf-1</i>; <i>fbf-1</i> %Mog (<i>n</i>)</td><td><i>rrf-1</i>; <i>fbf-2</i> %Mog (<i>n</i>)</td></tr><tr><td>Control day 1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>day 3</td><td>0</td><td>0</td><td>0</td></tr><tr><td><i>mtr-4</i> day 1</td><td>43% (23)</td><td>97% (33)</td><td>80% (45)</td></tr><tr><td>day 3</td><td>37% (27)</td><td>89% (35)</td><td>48% (31)</td></tr><tr><td><i>prp-17</i> day 1</td><td>62% (42)</td><td>100% (33)</td><td>98% (64)</td></tr><tr><td>day 3</td><td>47% (15)</td><td>87% (46)</td><td>93% (29)</td></tr><tr><td><i>F43G9.12</i> day 1</td><td>4% (23)</td><td>41% (34)</td><td>52% (46)</td></tr><tr><td>day 3</td><td>0% (26)</td><td>56% (34)</td><td>25% (56)</td></tr></table>
678ac447c9ef569e1c6223c65529c2df1940358b5e2fa899c3d73cb494c9280f.png
simple
<table><tr><td>Variable</td><td>non-Xp11.2 translocation group (<i>n</i> = 82)</td><td>Xp11.2 translocation group (<i>n</i> = 16)</td><td><i>P</i> value</td></tr><tr><td>Age(y)</td><td></td><td></td><td>0.296</td></tr><tr><td>Media(Range)</td><td>40 (18&#8211;45)</td><td>27 (21&#8211;40)</td><td></td></tr><tr><td>Gender(n)</td><td></td><td></td><td>0.086</td></tr><tr><td>Male</td><td>56 (68.3 %)</td><td>7 (43.8 %)</td><td></td></tr><tr><td>Female</td><td>25 (31.7 %)</td><td>9 (56.3 %)</td><td></td></tr><tr><td>Size(cm)</td><td></td><td></td><td>0.588</td></tr><tr><td>Media(Range)</td><td>4.6 (1.8&#8211;17.0)</td><td>4.5 (3.0&#8211;11.5)</td><td></td></tr><tr><td>Laterality(n)</td><td></td><td></td><td>1.000</td></tr><tr><td>Left</td><td>39 (47.6 %)</td><td>7 (43.8 %)</td><td></td></tr><tr><td>Right</td><td>43 (52.4 %)</td><td>9 (56.3 %)</td><td></td></tr><tr><td>Symptoms(n)</td><td></td><td></td><td></td></tr><tr><td>Asymptomatic</td><td>57 (69.5 %)</td><td>11 (68.8 %)</td><td></td></tr><tr><td>Symptomatic</td><td>25 (30.5 %)</td><td>5 (31.3 %)</td><td>1.000</td></tr><tr><td>Nephrectomy (n)</td><td></td><td></td><td>0.156</td></tr><tr><td>Radical</td><td>49 (59.8 %)</td><td>13 (81.3 %)</td><td></td></tr><tr><td>Partial</td><td>33 (40.2 %)</td><td>3 (18.8 %)</td><td></td></tr><tr><td>Overall stage(n)</td><td></td><td></td><td>0.026</td></tr><tr><td>I</td><td>57 (69.5 %)</td><td>10 (62.5 %)</td><td></td></tr><tr><td>II</td><td>22 (26.8 %)</td><td>2 (12.5 %)</td><td></td></tr><tr><td>III</td><td>2 (2.4 %)</td><td>3 (18.8 %)</td><td></td></tr><tr><td>IV</td><td>1 (1.2 %)</td><td>1 (6.3 %)</td><td></td></tr><tr><td>TNM(2010AJCC)</td><td></td><td></td><td></td></tr><tr><td>T(n)</td><td></td><td></td><td>0.026</td></tr><tr><td>T1</td><td>57 (69.5 %)</td><td>10 (62.5 %)</td><td></td></tr><tr><td>T2</td><td>22 (26.8 %)</td><td>2 (12.5 %)</td><td></td></tr><tr><td>T3</td><td>2 (2.4 %)</td><td>3 (18.8 %)</td><td></td></tr><tr><td>T4</td><td>1 (1.2 %)</td><td>1 (6.3 %)</td><td></td></tr><tr><td>N(n)</td><td></td><td></td><td>0.013</td></tr><tr><td>N<sub>0</sub></td><td>81 (98.8 %)</td><td>13 (81.3 %)</td><td></td></tr><tr><td>N<sub>1</sub></td><td>1 (1.2 %)</td><td>3 (18.8 %)</td><td></td></tr><tr><td>M(n)</td><td></td><td></td><td></td></tr><tr><td>M<sub>0</sub></td><td>82 (100 %)</td><td>16 (100 %)</td><td></td></tr><tr><td>M<sub>1</sub></td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Tumor grade (n)</td><td></td><td></td><td>0.011</td></tr><tr><td>Low</td><td>25 (30.5 %)</td><td>0 (0 %)</td><td></td></tr><tr><td>Medium</td><td>38 (46.3 %)</td><td>9 (56.3 %)</td><td></td></tr><tr><td>High</td><td>19 (23.2 %)</td><td>7 (43.8 %)</td><td></td></tr><tr><td>Follow-up (mo)</td><td></td><td></td><td>0.464</td></tr><tr><td>Media(Range)</td><td>33.5 (7&#8211;71)</td><td>29 (3&#8211;70)</td><td></td></tr></table>
94bdebebf084b25d6b689817ab12e10b5615f1dd4cc4c1d0260e546ccd9899c1.png
complex
<table><tr><td></td><td>Total Score</td><td>Vegetables</td><td>Fruit</td><td>Meat *</td><td>Meat Alt. *</td><td>Grains</td><td>Dairy</td></tr><tr><td>Age Groups</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total (<i>n</i> = 93,252)</td><td>34.1 &#177; 9.7</td><td>11.5 &#177; 4.3</td><td>5.5 &#177; 2.9</td><td>3.0 &#177; 1.6</td><td>2.6 &#177; 1.3</td><td>5.7 &#177; 2.3</td><td>4.0 &#177; 2.1</td></tr><tr><td>16&#8211;24 years (<i>n</i> = 37,229)</td><td>32.6 &#177; 9.7</td><td>10.6 &#177; 4.3</td><td>5.4 &#177; 2.8</td><td>2.7 &#177; 1.6</td><td>2.5 &#177; 1.4</td><td>5.6 &#177; 2.3</td><td>3.9 &#177; 2.1</td></tr><tr><td>25&#8211;34 years (<i>n</i> = 26,068)</td><td>33.1 &#177; 8.9</td><td>11.5 &#177; 4.0</td><td>4.8 &#177; 2.6</td><td>2.9 &#177; 1.6</td><td>2.6 &#177; 1.3</td><td>5.5 &#177; 2.3</td><td>3.8 &#177; 2.0</td></tr><tr><td>35&#8211;44 years (<i>n</i> = 12,322)</td><td>34.5 &#177; 9.1</td><td>12.3 &#177; 4.0</td><td>5.1 &#177; 2.8</td><td>3.2 &#177; 1.6</td><td>2.7 &#177; 1.3</td><td>5.6 &#177; 2.4</td><td>3.8 &#177; 2.0</td></tr><tr><td>45&#8211;54 years (<i>n</i> = 9214)</td><td>35.3 &#177; 8.9</td><td>12.9 &#177; 3.8</td><td>5.4 &#177; 2.8</td><td>3.4 &#177; 1.6</td><td>2.6 &#177; 1.3</td><td>5.4 &#177; 2.3</td><td>3.8 &#177; 2.0</td></tr><tr><td>55&#8211;64 years (<i>n</i> = 5840)</td><td>36.5 &#177; 8.7</td><td>13.5 &#177; 3.6</td><td>5.8 &#177; 2.7</td><td>3.5 &#177; 1.6</td><td>2.7 &#177; 1.2</td><td>5.4 &#177; 2.2</td><td>4.0 &#177; 1.9</td></tr><tr><td>65&#8211;74 years (<i>n</i> = 2111)</td><td>37.2 &#177; 8.5</td><td>13.7 &#177; 3.6</td><td>6.1 &#177; 2.6</td><td>3.6 &#177; 1.6</td><td>2.7 &#177; 1.2</td><td>5.3 &#177; 2.1</td><td>4.2 &#177; 1.9</td></tr><tr><td>75+ years (<i>n</i> = 468)</td><td>35.8 &#177; 15.3</td><td>12.1 &#177; 6.0</td><td>6.2 &#177; 3.7</td><td>3.2 &#177; 1.8</td><td>2.9 &#177; 1.8</td><td>5.7 &#177; 3.2</td><td>4.0 &#177; 2.3</td></tr><tr><td>16&#8211;44 years (<i>n</i> = 75,619)</td><td>33.1 &#177; 9.4</td><td>11.2 &#177; 4.2</td><td>5.1 &#177; 2.8</td><td>2.9 &#177; 1.6</td><td>2.6 &#177; 1.3</td><td>5.6 &#177; 2.3</td><td>3.8 &#177; 2.1</td></tr><tr><td>45&#8211;75 years+ (<i>n</i> = 17,633)</td><td>35.9 &#177; 9.0</td><td>13.2 &#177; 3.8</td><td>5.6 &#177; 2.8</td><td>3.5 &#177; 1.6</td><td>2.7 &#177; 1.3</td><td>5.4 &#177; 2.3</td><td>3.9 &#177; 2.0</td></tr><tr><td><i>p</i>-value</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td></tr><tr><td>16&#8211;44 years vs. 45&#8211;75+ years</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Females (<i>n</i> = 71,290)</td><td>34.5 &#177; 9.3</td><td>11.8 &#177; 4.2</td><td>5.7 &#177; 2.8</td><td>3.0 &#177; 1.6</td><td>2.6 &#177; 1.3</td><td>5.7 &#177; 2.3</td><td>3.9 &#177; 2.1</td></tr><tr><td>16&#8211;24 years (<i>n</i> = 27,977)</td><td>33.0 &#177; 9.4</td><td>10.9 &#177; 4.2</td><td>5.5 &#177; 2.8</td><td>2.6 &#177; 1.6</td><td>2.5 &#177; 1.4</td><td>5.6 &#177; 2.2</td><td>3.8 &#177; 2.1</td></tr><tr><td>25&#8211;34 years (<i>n</i> = 20,033)</td><td>33.8 &#177; 8.6</td><td>11.8 &#177; 3.9</td><td>5.0 &#177; 2.6</td><td>2.9 &#177; 1.6</td><td>2.7 &#177; 1.3</td><td>5.6 &#177; 2.2</td><td>3.8 &#177; 2.0</td></tr><tr><td>35&#8211;44 years (<i>n</i> = 9516)</td><td>35.1 &#177; 8.9</td><td>12.6 &#177; 3.9</td><td>5.3 &#177; 2.7</td><td>3.2 &#177; 1.6</td><td>2.7 &#177; 1.3</td><td>5.6 &#177; 2.3</td><td>3.9 &#177; 2.0</td></tr><tr><td>45&#8211;54 years (<i>n</i> = 7393)</td><td>35.8 &#177; 8.9</td><td>13.2 &#177; 3.7</td><td>5.5 &#177; 2.8</td><td>3.4 &#177; 1.6</td><td>2.7 &#177; 1.3</td><td>5.4 &#177; 2.3</td><td>3.9 &#177; 2.0</td></tr><tr><td>55&#8211;64 years (<i>n</i> = 4544)</td><td>37.0 &#177; 8.6</td><td>13.8 &#177; 3.5</td><td>5.8 &#177; 2.7</td><td>3.5 &#177; 1.6</td><td>2.7 &#177; 1.2</td><td>5.4 &#177; 2.2</td><td>4.1 &#177; 2.0</td></tr><tr><td>65&#8211;74 years (<i>n</i> = 1556)</td><td>37.9 &#177; 8.4</td><td>14.1 &#177; 3.5</td><td>6.3 &#177; 2.5</td><td>3.7 &#177; 1.6</td><td>2.7 &#177; 1.2</td><td>5.3 &#177; 2.1</td><td>4.3 &#177; 1.9</td></tr><tr><td>75+ years (<i>n</i> = 271)</td><td>35.1 &#177; 14.2</td><td>11.8 &#177; 5.8</td><td>6.1 &#177; 3.5</td><td>3.1 &#177; 1.8</td><td>2.8 &#177; 1.6</td><td>5.4 &#177; 3.2</td><td>4.1 &#177; 2.3</td></tr><tr><td>Males (<i>n</i> = 21,962)</td><td>33.1 &#177; 10.6</td><td>10.7 &#177; 4.5</td><td>5.2 &#177; 3.1</td><td>3.2 &#177; 1.6</td><td>2.5 &#177; 1.4</td><td>5.7 &#177; 2.5</td><td>4.0 &#177; 2.1</td></tr><tr><td>16&#8211;24 years (<i>n</i> = 9252)</td><td>31.5 &#177; 10.5</td><td>9.7 &#177; 4.5</td><td>5.0 &#177; 3.0</td><td>3.0 &#177; 1.6</td><td>2.4 &#177; 1.4</td><td>5.6 &#177; 2.3</td><td>4.0 &#177; 2.1</td></tr><tr><td>25&#8211;34 years (<i>n</i> = 6035)</td><td>30.7 &#177; 9.3</td><td>10.4 &#177; 4.3</td><td>4.2 &#177; 2.7</td><td>3.0 &#177; 1.6</td><td>2.5 &#177; 1.3</td><td>5.3 &#177; 2.3</td><td>3.5 &#177; 2.0</td></tr><tr><td>35&#8211;44 years (<i>n</i> = 2806)</td><td>32.6 &#177; 9.4</td><td>11.4 &#177; 4.2</td><td>4.5 &#177; 2.8</td><td>3.3 &#177; 1.6</td><td>2.6 &#177; 1.3</td><td>5.4 &#177; 2.4</td><td>3.6 &#177; 1.9</td></tr><tr><td>45&#8211;54 years (<i>n</i> = 1821)</td><td>33.4 &#177; 9.0</td><td>11.9 &#177; 4.1</td><td>4.9 &#177; 2.8</td><td>3.4 &#177; 1.6</td><td>2.6 &#177; 1.3</td><td>5.4 &#177; 2.3</td><td>3.6 &#177; 2.0</td></tr><tr><td>55&#8211;64 years (<i>n</i> = 1296)</td><td>34.7 &#177; 8.7</td><td>12.6 &#177; 4.0</td><td>5.2 &#177; 2.7</td><td>3.5 &#177; 1.6</td><td>2.7 &#177; 1.2</td><td>5.4 &#177; 2.2</td><td>3.7 &#177; 1.9</td></tr><tr><td>65&#8211;74 years (<i>n</i> = 555)</td><td>35.1 &#177; 8.2</td><td>12.6 &#177; 3.6</td><td>5.7 &#177; 2.6</td><td>3.6 &#177; 1.6</td><td>2.6 &#177; 1.2</td><td>5.3 &#177; 2.1</td><td>4.0 &#177; 2.0</td></tr><tr><td>75+ years (<i>n</i> = 197)</td><td>36.8 &#177; 16.6</td><td>12.5 &#177; 6.2</td><td>6.3 &#177; 3.9</td><td>3.3 &#177; 1.8</td><td>3.0 &#177; 1.9</td><td>6.0 &#177; 3.5</td><td>4.0 &#177; 2.2</td></tr><tr><td><i>p</i>-value</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td><td rowspan="2">&lt;0.001</td></tr><tr><td>females vs. males</td></tr></table>
a297a7b78efaed8761b16bedeca252de1bc3b3b69664a6296d407bc224fb378a.png
complex
<table><tr><td></td><td colspan="3">Physician</td><td colspan="3">Chiropractor</td><td colspan="3">Physiotherapist</td><td>Total N</td></tr><tr><td><i>Gender</i></td><td><i>Prevalence (%)</i></td><td><i>S.E.</i></td><td><i>Freq.</i></td><td><i>Prevalence (%)</i></td><td><i>S.E.</i></td><td><i>Freq.</i></td><td><i>Prevalence (%)</i></td><td><i>S.E.</i></td><td><i>Freq.</i></td><td></td></tr><tr><td>Men</td><td>25.596</td><td>0.028</td><td>639613</td><td>5.86</td><td>0.02</td><td>146321</td><td>5.09</td><td>0.01</td><td>127058</td><td>2498871</td></tr><tr><td>Women</td><td>32.260</td><td>0.030</td><td>802309</td><td>6.36</td><td>0.02</td><td>158221</td><td>8.81</td><td>0.02</td><td>219067</td><td>2486999</td></tr></table>
37b666f570b93f56105635e7e396b3e858b7292b42665c2148c2aed2d7af01b8.png
simple
<table><tr><td></td><td>EAST</td><td>CENTRAL1</td><td>CENTRAL 2</td><td>WEST</td><td>SOUTH</td><td>BGD</td><td>MYA</td></tr><tr><td>CENTRAL 1</td><td>-0.009</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CENTRAL 2</td><td>0.071*</td><td>0.175**</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WEST</td><td>-0.004</td><td>0.013</td><td>0.074</td><td></td><td></td><td></td><td></td></tr><tr><td>SOUTH</td><td>-0.007</td><td>-0.010</td><td>0.065*</td><td>-0.002</td><td></td><td></td><td></td></tr><tr><td>BGD</td><td>0.032</td><td>0.146**</td><td>0.180*</td><td>0.026</td><td>0.060</td><td></td><td></td></tr><tr><td>MYA</td><td>0.024</td><td>0.063*</td><td>0.267***</td><td>0.031</td><td>0.050**</td><td>0.014</td><td></td></tr><tr><td>THAI</td><td>0.055***</td><td>0.043</td><td>0.351***</td><td>0.069***</td><td>0.078***</td><td>0.071</td><td>0.002</td></tr></table>
f51235449f3aef60422acfe01da02d2edfc2655144303520a5dd79df49061573.png
complex
<table><tr><td rowspan="2">Characteristic</td><td rowspan="2">All patients no. (%)</td><td colspan="5">Marital status</td></tr><tr><td>Married no. (%)</td><td>Widowed no. (%)</td><td>Never married no. (%)</td><td>Divorced no. (%)</td><td><i>P</i>&#8208;value</td></tr><tr><td>No. of patients</td><td>61077 (100.0)</td><td>40527 (66.4)</td><td>2768 (4.5)</td><td>12889 (21.1)</td><td>4893 (8.0)</td><td></td></tr><tr><td colspan="7">Sex</td></tr><tr><td>Male</td><td>13388 (21.9)</td><td>9798 (24.1)</td><td>256 (9.2)</td><td>2547 (19.8)</td><td>787 (16.1)</td><td rowspan="2">0.001</td></tr><tr><td>Female</td><td>47689 (78.1)</td><td>30729 (75.8)</td><td>2512 (90.8)</td><td>10342 (80.2)</td><td>4106 (83.9)</td></tr><tr><td>Age (mean &#177; SD)</td><td>47.7 &#177; 14.8</td><td>48.9 &#177; 12.9</td><td>68.3 &#177; 11.9</td><td>38.0 &#177; 15.2</td><td>51.5 &#177; 12.1</td><td></td></tr><tr><td>&lt;45</td><td>25975 (42.5)</td><td>15937 (39.3)</td><td>108 (3.9)</td><td>8523 (66.1)</td><td>1407 (28.8)</td><td rowspan="4">0.001b</td></tr><tr><td>Mean &#177; SD</td><td>33.8 &#177; 7.6</td><td>36.1 &#177; 5.7</td><td>38.0 &#177; 5.4</td><td>29.0 &#177; 8.6</td><td>37.0 &#177; 5.9</td></tr><tr><td>&#8805;45</td><td>35102 (57.5)</td><td>24590 (60.7)</td><td>2660 (96.1)</td><td>4366 (33.9)</td><td>3486 (71.2)</td></tr><tr><td>Mean &#177; SD</td><td>57.9 &#177; 9.6</td><td>57.1 &#177; 9.0</td><td>69.6 &#177; 10.4</td><td>55.5 &#177; 8.5</td><td>57.4 &#177; 8.6</td></tr><tr><td colspan="7">Race</td></tr><tr><td>Black</td><td>3869 (6.3)</td><td>1763 (4.4)</td><td>238 (8.6)</td><td>1383 (10.7)</td><td>485 (9.9)</td><td rowspan="3">0.001</td></tr><tr><td>White</td><td>56566 (92.6)</td><td>38351 (94.6)</td><td>2515 (90.9)</td><td>11329 (87.9)</td><td>4371 (89.3)</td></tr><tr><td>Othera</td><td>642 (1.0)</td><td>413 (1.0)</td><td>15 (0.5)</td><td>177 (1.4)</td><td>37 (0.8)</td></tr><tr><td colspan="7">Histology type</td></tr><tr><td>Papillary</td><td>57427 (94.0)</td><td>38273 (94.4)</td><td>2535 (91.6)</td><td>12042 (93.4)</td><td>4577 (93.5)</td><td rowspan="2">0.001</td></tr><tr><td>Follicular</td><td>3650 (6.0)</td><td>2254 (5.6)</td><td>233 (8.4)</td><td>847 (6.6)</td><td>316 (6.5)</td></tr><tr><td colspan="7">T stage</td></tr><tr><td>T1/T2</td><td>47104 (77.1)</td><td>31658 (78.1)</td><td>1969 (71.1)</td><td>9649 (74.9)</td><td>3828 (78.2)</td><td rowspan="2">0.001</td></tr><tr><td>T3/T4</td><td>13973 (22.9)</td><td>8869 (21.9)</td><td>799 (28.9)</td><td>3240 (25.1)</td><td>1065 (21.8)</td></tr><tr><td colspan="7">N stage</td></tr><tr><td>N0</td><td>46913 (76.8)</td><td>31637 (78.1)</td><td>2274 (82.2)</td><td>9021 (70.0)</td><td>3981 (81.4)</td><td rowspan="3">0.001</td></tr><tr><td>N1a</td><td>7098 (11.6)</td><td>4536 (11.2)</td><td>223 (8.1)</td><td>1905 (14.8)</td><td>434 (8.9)</td></tr><tr><td>N1b</td><td>7066 (11.6)</td><td>4354 (10.7)</td><td>271 (9.8)</td><td>1963 (15.2)</td><td>478 (9.8)</td></tr><tr><td>Distant Metastasis</td><td>1602 (2.6)</td><td>937 (2.3)</td><td>122 (4.4)</td><td>428 (3.3)</td><td>115 (2.4)</td><td>0.001</td></tr><tr><td colspan="7">TNM Stage</td></tr><tr><td>I</td><td>44537 (72.9)</td><td>29209 (72.1)</td><td>1469 (53.1)</td><td>10540 (81.8)</td><td>3319 (67.8)</td><td rowspan="4">0.001</td></tr><tr><td>II</td><td>5088 (8.3)</td><td>3380 (8.3)</td><td>337 (12.2)</td><td>880 (6.8)</td><td>491 (10.0)</td></tr><tr><td>III</td><td>6991 (11.4)</td><td>4871 (12.0)</td><td>543 (19.6)</td><td>915 (7.1)</td><td>662 (13.5)</td></tr><tr><td>IV</td><td>4461 (7.3)</td><td>3.67 (7.6)</td><td>419 (15.1)</td><td>554 (4.3)</td><td>421 (8.6)</td></tr><tr><td colspan="7">Surgery procedures</td></tr><tr><td>Lobe.&#177;Isth.</td><td>8769 (14.4)</td><td>5840 (14.4)</td><td>504 (18.2)</td><td>1698 (13.2)</td><td>727 (14.9)</td><td rowspan="3">&gt;0.05</td></tr><tr><td>Lobe.&#177;Partial Contra&#8208;lobe.</td><td>457 (0.7)</td><td>305 (0.8)</td><td>29 (1.9)</td><td>79 (0.6)</td><td>44 (0.9)</td></tr><tr><td>TT or near TT</td><td>51851 (84.9)</td><td>34382 (84.8)</td><td>2235 (80.7)</td><td>11112 (86.2)</td><td>4122 (82.4)</td></tr><tr><td colspan="7">Adjuvant therapy</td></tr><tr><td>None</td><td>28158 (46.1)</td><td>18651 (46.0)</td><td>1468 (53.0)</td><td>5717 (44.4)</td><td>2322 (47.5)</td><td rowspan="3">&gt;0.05</td></tr><tr><td>Radioisotopes</td><td>30512 (50.0)</td><td>20322 (50.1)</td><td>1167 (42.2)</td><td>6656 (51.6)</td><td>2367 (48.4)</td></tr><tr><td>Beam radiation</td><td>2407 (3.9)</td><td>1554 (3.9)</td><td>133 (2.8)</td><td>516 (2.0)</td><td>204 (2.1)</td></tr></table>
b01b62974722f51b9d609d6fc30d00f8539936284f1341f3db5a6454c3083bdf.png
simple
<table><tr><td>Possibilities causing anxiety</td><td>Frequency</td><td>Percentages</td><td>Mean state anxiety score</td></tr><tr><td>Fear of death</td><td>91</td><td>82.7</td><td>56.3 &#177; 8.2</td></tr><tr><td>Fear of unknown</td><td>58</td><td>52.7</td><td>57.8 &#177; 8.9</td></tr><tr><td>Financial loss due to hospitalization</td><td>47</td><td>42.7</td><td>54.7 &#177; 8.6</td></tr><tr><td>Results of operation</td><td>46</td><td>41.8</td><td>55.7 &#177; 7.9</td></tr><tr><td>Needing blood transfusion</td><td>43</td><td>39.1</td><td>57.4 &#177; 9.2</td></tr><tr><td>Concern about family</td><td>43</td><td>39.1</td><td>56.9 &#177; 6.9</td></tr><tr><td>Postoperative pain</td><td>43</td><td>39.1</td><td>55.7 &#177; 9.2</td></tr><tr><td>Change of environment</td><td>41</td><td>37.3</td><td>55.2 &#177; 7.7</td></tr><tr><td>Long waiting time for operation</td><td>40</td><td>36.4</td><td>54.9 &#177; 9.0</td></tr><tr><td>Unexpected events</td><td>39</td><td>35.5</td><td>55.2 &#177; 9.2</td></tr><tr><td>Being patient and coming to hospital</td><td>35</td><td>31.8</td><td>51.8 &#177; 8.9</td></tr><tr><td>Dependency</td><td>34</td><td>30.9</td><td>55.1 &#177; 8.7</td></tr><tr><td>Fear of physical disability</td><td>33</td><td>30</td><td>53.9 &#177; 8.7</td></tr><tr><td>Fear of complications</td><td>31</td><td>28.2</td><td>53.3. &#177; 7.3</td></tr><tr><td>Cancellations</td><td>31</td><td>28.2</td><td>54.6 &#177; 9.0</td></tr><tr><td>Alteration in body image</td><td>26</td><td>23.6</td><td>56.7 &#177; 7.5</td></tr><tr><td>Possible unknown diagnostic results</td><td>24</td><td>21.8</td><td>53.2 &#177; 6.6</td></tr><tr><td>Lack of information</td><td>18</td><td>16.4</td><td>51.3 &#177; 8.1</td></tr><tr><td>Nil per mouth</td><td>16</td><td>14.5</td><td>55.6 &#177; 1.0</td></tr><tr><td>Harm from doctor or nurse mistake</td><td>16</td><td>14.5</td><td>57.7 &#177; 8.8</td></tr><tr><td>Terminology and language used</td><td>16</td><td>14.5</td><td>53.8 &#177; 1.2</td></tr><tr><td>Sickness and vomiting</td><td>15</td><td>13.6</td><td>53.7 &#177; 8.3</td></tr><tr><td>Fear of not knowing what occurs while unconscious during anesthesia</td><td>14</td><td>12.7</td><td>52.8 &#177; 9.2</td></tr><tr><td>Concern about fellow patient</td><td>13</td><td>11.8</td><td>55.6 &#177; 9.2</td></tr><tr><td>Absence from work</td><td>13</td><td>11.8</td><td>55.7 &#177; 9.8</td></tr><tr><td>Inaccurate information</td><td>12</td><td>10.9</td><td>55.5 &#177; 8.9</td></tr><tr><td>Short waiting time for operation</td><td>10</td><td>9.1</td><td>56.1 &#177; 7.4</td></tr><tr><td>Getting stuck of needle</td><td>9</td><td>8.2</td><td>54.3 &#177; 1.2</td></tr><tr><td>Lack of knowledge of ward</td><td>9</td><td>8.2</td><td>51.3 &#177; 8.1</td></tr><tr><td>Not awakening from anesthesia</td><td>8</td><td>7.3</td><td>55 &#177; 1.2</td></tr><tr><td>Information from previous negative hospital experiences</td><td>8</td><td>7.3</td><td>55 &#177; 1.2</td></tr><tr><td>Familiarity with facilities</td><td>7</td><td>6.4</td><td>58 &#177; 7.1</td></tr><tr><td>Lack of recognition of staff</td><td>5</td><td>4.5</td><td>55.6 &#177; 6.7</td></tr><tr><td>Awareness during surgery</td><td>4</td><td>3.6</td><td>63.3 &#177; 2.5</td></tr></table>
e082e9ad7613b595833b67b286ce5e9244ad6addb050b3557a0245fb4a28a698.png
simple
<table><tr><td> </td><td> </td><td><i>Autism (20)</i></td><td><i>Control (20)</i></td><td> </td><td>P<i>-values</i></td></tr><tr><td>Age (years)</td><td>Mean&#177;s.d.</td><td>11.25&#177;1.58</td><td>11.26&#177;1.64</td><td><i>t</i> (38)=&#8722;0.02</td><td>0.97</td></tr><tr><td>IQ</td><td>Mean&#177;s.d.</td><td>108.25&#177;14.31</td><td>115.95&#177;10.97</td><td><i>t</i> (38)=&#8722;1.9</td><td>0.06</td></tr><tr><td>Sex</td><td>Male:female</td><td>16:4</td><td>13:7</td><td><i>&#967;</i><sup>2</sup>(1)=1.12</td><td>0.28</td></tr><tr><td>Handedness</td><td>Right:left</td><td>18:2</td><td>17:3</td><td><i>&#967;</i><sup>2</sup>(1)=0.22</td><td>0.63</td></tr></table>
223a1b47636e2be07f4a5414d96924e66ad0b2db347a0c88309387fd8f2d1be0.png
simple
<table><tr><td>Genipin concentration (% w/v)</td><td>Surface density (mg/mm<sup>3</sup>)</td><td>Degree of cross-link (%)</td><td>Contact angle (&#176;)</td></tr><tr><td>0</td><td>1.28 &#177; 0.04</td><td>&#8212;</td><td>54.91 &#177; 4.29</td></tr><tr><td>0.010</td><td>1.33 &#177; 0.06*</td><td>13.84 &#177; 2.59</td><td>54.71 &#177; 9.74</td></tr><tr><td>0.025</td><td>1.33 &#177; 0.03*</td><td>18.82 &#177; 4.00</td><td>52.06 &#177; 7.66</td></tr><tr><td>0.050</td><td>1.36 &#177; 0.09*</td><td>22.64 &#177; 1.89<sup>&#8224;</sup></td><td>53.85 &#177; 3.29</td></tr><tr><td>0.075</td><td>1.35 &#177; 0.07*</td><td>29.75 &#177; 6.46<sup>&#8224;</sup></td><td>52.63 &#177; 3.57</td></tr><tr><td>0.100</td><td>1.35 &#177; 0.10*</td><td>38.97 &#177; 4.51<sup>&#8224;</sup></td><td>54.04 &#177; 10.10</td></tr></table>
331a5775b891419edaffde27b0dd450038d7dec9452cdda7fa2ded29d9e2be97.png
simple
<table><tr><td>Histone H3 Acetyl K9 <sup>1</sup></td><td>Histone H3 Tri Methyl K4 <sup>2</sup></td></tr><tr><td>Blocking solution <sup>3</sup>: 5 min</td><td>Blocking solution <sup>3</sup>: 5 min</td></tr><tr><td>primary antibody <sup>1</sup>: 1:200 in PBS <sup>5</sup>, incubation: 16 h, 4 &#176;C</td><td>primary antibody <sup>2</sup>: 1:500 in PBS <sup>5</sup>, incubation: 16 h, 4 &#176;C</td></tr><tr><td>PostBlock <sup>3</sup>: 20 min</td><td>PostBlock <sup>3</sup>: 20 min</td></tr><tr><td>HRP Polymer <sup>3</sup>: 30 min</td><td>HRP Polymer <sup>3</sup>: 30 min</td></tr><tr><td>Chromogen: DAB <sup>4</sup> (0.5 min)</td><td>Chromogen: DAB <sup>4</sup> (1 min)</td></tr></table>
f51034271a4dff1eb5a473c36de62d31399b1d584db2a53fc8ddbeb01b8b352a.png
complex
<table><tr><td> </td><td> </td><td colspan="3">Target concentration</td><td colspan="2">Mean measured concentration</td></tr><tr><td>Net type</td><td>Chemical</td><td>Units</td><td>Mean</td><td>Range</td><td>Roof</td><td>Sides</td></tr><tr><td rowspan="3">PermaNet 3.0</td><td rowspan="2">Deltamethrin</td><td>g/kg</td><td>2.8 (sides)</td><td>2.1 - 3.5</td><td>-</td><td>3.1</td></tr><tr><td>g/kg</td><td>4 (roof)</td><td>3.0 - 5.0</td><td>3.9</td><td>-</td></tr><tr><td>Piperonyl butoxide</td><td>g/kg</td><td>25 (roof)</td><td>18.8 - 31.3</td><td>18.7</td><td>-</td></tr><tr><td>PermaNet 2.0</td><td>Deltamethrin</td><td>mg/m<sup>2</sup></td><td>55</td><td>41.3 - 68.8</td><td>69.4</td><td>65.6</td></tr><tr><td>NetProtect</td><td>Deltamethrin</td><td>g/kg</td><td>1.8</td><td>1.4 - 2.3</td><td>1.6</td><td>1.6</td></tr><tr><td>Interceptor</td><td>Alpha-cypermethrin</td><td>mg/m<sup>2</sup></td><td>200</td><td>150.0 - 250.0</td><td>171.0</td><td>251.0</td></tr><tr><td>Olyset</td><td>Permethrin</td><td>g/kg</td><td>20</td><td>17.0 - 23.0</td><td>21.0</td><td>21.6</td></tr></table>
36213d18cfd964f18daa318f2296f379017000379d9e540ac06e0e1ad04ecd29.png
complex
<table><tr><td rowspan="2">Female </td><td colspan="2">Normal weight (BMI 5th to 85th)</td><td rowspan="2"><i>P</i> value</td><td colspan="2">Overweight (BMI over 85th)</td><td rowspan="2"><i>P</i> value</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>NW</td><td>CONW</td><td>OW</td><td>COOW</td></tr><tr><td> </td><td>604 (72.7%)</td><td>83 (9.6%)</td><td>NW versus CONW</td><td>20 (2.5%)</td><td>125 (15.1%)</td><td>OW versus COOW</td><td>Among groups</td></tr><tr><td>Age (years)</td><td>15.4 &#177; 0.1</td><td>15.4 &#177; 0.2</td><td>0.879</td><td>15.6 &#177; 0.4</td><td>15.3 &#177; 0.2</td><td>0.579</td><td>0.945</td></tr><tr><td>Height (cm)</td><td>160.5 &#177; 0.3</td><td>158.7 &#177; 1</td><td>0.074</td><td>161.9 &#177; 0.8</td><td>160.8 &#177; 0.5</td><td>0.227</td><td>0.082</td></tr><tr><td>Weight (kg)</td><td>50.8 &#177; 0.2</td><td>54.9 &#177; 1.0</td><td>&lt;0.0001</td><td>65.1 &#177; 1.2</td><td>68.6 &#177; 1</td><td>&lt;0.022</td><td>&lt;0.0001</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>19.7 &#177; 0.1</td><td>21.7 &#177; 0.2</td><td>&lt;0.0001</td><td>24.8 &#177; 0.3</td><td>26.5 &#177; 0.3</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr><tr><td>WC (cm)</td><td>65.8 &#177; 0.2</td><td>75.1 &#177; 0.6</td><td>&lt;0.0001</td><td>71.3 &#177; 0.6</td><td>81 &#177; 0.7</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr><tr><td>WHR</td><td>41 &#177; 0.1</td><td>47.3 &#177; 0.2</td><td>&lt;0.0001</td><td>44.0 &#177; 3.0</td><td>50.4 &#177; 0.4</td><td>&lt;0.0001</td><td>&lt;0.0001</td></tr><tr><td>SBP (mmHg)</td><td>101.8 &#177; 0.5</td><td>102.1 &#177; 1.4</td><td>0.813</td><td>102.2 &#177; 2.8</td><td>105.7 &#177; 1</td><td>0.242</td><td>&lt;0.006</td></tr><tr><td>DBP (mmHg)</td><td>65.7 &#177; 0.4</td><td>64.7 &#177; 1.2</td><td>0.374</td><td>66.6 &#177; 2</td><td>66.7 &#177; 1</td><td>0.953</td><td>0.568</td></tr><tr><td>Glucose (mg/dL)</td><td>87.5 &#177; 0.3</td><td>88 &#177; 0.7</td><td>0.401</td><td>87.5 &#177; 1.2</td><td>89.9 &#177; 0.8</td><td>0.081</td><td>&lt;0.028</td></tr><tr><td>Insulin (<i>&#956;</i>U/mL)</td><td>11.4 (11&#8211;11.8)</td><td>12.9 (11.9&#8211;13.9)</td><td>&lt;0.006</td><td>14.3 (12.0&#8211;17.1)</td><td>16 (14.5&#8211;17.7)</td><td>0.272</td><td>&lt;0.0001</td></tr><tr><td>HOMA-IR</td><td>2.5 (2.4&#8211;2.5)</td><td>2.8 (2.6&#8211;3)</td><td>&lt;0.006</td><td>3.1 (2.6&#8211;3.7)</td><td>3.5 (3.2&#8211;3.9)</td><td>0.201</td><td>&lt;0.0001</td></tr><tr><td>TG (mg/dL)</td><td>71.6 (68.7&#8211;74.7)</td><td>77.5 (69.5&#8211;86.6)</td><td>0.186</td><td>77.3 (59.2&#8211;100.9)</td><td>89 (80.0&#8211;99.1)</td><td>0.344</td><td>&lt;0.002</td></tr><tr><td>HDL (mg/dL)</td><td>56.4 &#177; 0.5</td><td>54.6 &#177; 1.5</td><td>0.284</td><td>50.8 &#177; 2.1</td><td>49.4 &#177; 1.2</td><td>0.563</td><td>&lt;0.0001</td></tr><tr><td>TG/HDL</td><td>1.3 (1.2&#8211;1.4)</td><td>1.5 (1.3&#8211;1.7)</td><td>0.121</td><td>1.5 (1.2&#8211;2.1)</td><td>1.8 (1.6&#8211;2.1)</td><td>0.285</td><td>&lt;0.0001</td></tr><tr><td>ALT (U/L)</td><td>10 (9.7&#8211;10.3)</td><td>11.5 (10.8&#8211;12.3)</td><td>&lt;0.001</td><td>11.8 (9.9&#8211;14.1)</td><td>12.9 (11.6&#8211;14.3)</td><td>0.392</td><td>&lt;0.0001</td></tr><tr><td>AST (U/L)</td><td>16 (15.7&#8211;16.3)</td><td>15.6 (14.8&#8211;16.5)</td><td>0.458</td><td>15.6 (13.9&#8211;17.5)</td><td>15.8 (15.3&#8211;16.4)</td><td>0.839</td><td>0.861</td></tr><tr><td>WBC (10<sup>9</sup>/L)</td><td>5.9 (5.8&#8211;6)</td><td>6.1 (5.7&#8211;6.6)</td><td>0.260 </td><td>6.3 (5.7&#8211;7.0)</td><td>6.7 (6.4&#8211;7.0)</td><td>0.351</td><td>&lt;0.0001</td></tr></table>
b3d71f747833168bf6c08b794cbc7622cf9f11ca1a80f19d955d8eba52bef804.png
complex
<table><tr><td rowspan="2">EE Estimation Models</td><td colspan="3">Static Activities</td><td colspan="3">Dynamic Activities</td><td rowspan="2">Average</td></tr><tr><td>SI</td><td>ST</td><td>REST</td><td>WK</td><td>AS</td><td>RU</td></tr><tr><td>(1) Single (IMU)</td><td>1.11 (0.54)</td><td>0.94 (0.37)</td><td>1.74 (0.33)</td><td>1.48 (0.72)</td><td>2.37 (0.81)</td><td>2.63 (0.91)</td><td>1.71 (0.68)</td></tr><tr><td>(2) Single (IMU + ECG)</td><td>0.98 (0.55)</td><td>0.90 (0.52)</td><td>1.18 (0.56)</td><td>0.98 (0.39)</td><td>1.22 (0.70)</td><td>1.74 (1.22)</td><td>1.17 (0.31)</td></tr><tr><td>(3) Activity-specific (IMU)</td><td>0.62 (0.40)</td><td>0.48 (0.29)</td><td>1.75 (0.44)</td><td>1.78 (0.41)</td><td>1.92 (0.63)</td><td>2.22 (0.93)</td><td>1.46 (0.73)</td></tr><tr><td>(4) Activity-specific (IMU + ECG)</td><td>0.44 (0.18)</td><td>0.46 (0.19)</td><td>0.76 (0.26)</td><td>1.05 (0.29)</td><td>1.10 (0.54)</td><td>1.54 (1.16)</td><td>0.89 (0.42)</td></tr></table>
b8115b50baac8c838f54b5a4d0d4926343c469ef3621f0e0b7ac80944f39d3f3.png
complex
<table><tr><td>Items</td><td>Control (<i>n</i> = 11)</td><td>DOX (<i>n</i> = 6)<sup>a</sup></td><td>PDOX (<i>n</i> = 12)</td><td><i>P</i> value</td></tr><tr><td colspan="5">Peripheral blood routine</td></tr><tr><td>RBC (T/L)</td><td>9.39 (9.17&#8211;9.84)</td><td>9.60 (8.73&#8211;12.31)</td><td>9.23 (6.65&#8211;9.75)</td><td>&gt;0.05</td></tr><tr><td>WBC (&#215;10<sup>9</sup>/L)</td><td>5.8 (4.6&#8211;7.9)</td><td>5.9 (4.2&#8211;20)</td><td>6.4 (4.7&#8211;7.6)</td><td>&gt;0.05</td></tr><tr><td>HGB (g/L)</td><td>144 (140&#8211;153)</td><td>151.5 (145&#8211;189)</td><td>150.5 (121&#8211;157)</td><td>&gt;0.05</td></tr><tr><td>PLT (&#215;10<sup>9</sup>/L)</td><td>1171 (892&#8211;1666)</td><td>1291.5 (1197&#8211;1492)</td><td>1602.5 (1350&#8211;1772)<sup>b</sup></td><td>&lt;0.05</td></tr><tr><td>NEUT (&#215;10<sup>9</sup>/L)</td><td>1.8 (1.1&#8211;1.3)</td><td>1.75 (0.7&#8211;4.2)</td><td>2.7 (1.6&#8211;3.5)</td><td>&gt;0.05</td></tr><tr><td>LYM (&#215;10<sup>9</sup>/L)</td><td>1.9 (1.1&#8211;3.5)<sup>c</sup></td><td>1.55 (0.8&#8211;6.1)</td><td>1.25 (0.6&#8211;1.8)</td><td>=0.03</td></tr><tr><td colspan="5">Liver functions</td></tr><tr><td>AST (U/L)</td><td>148.1 (116.9&#8211;237.8)</td><td>136.6 (120.8&#8211;241.0)</td><td>123.4 (108.1&#8211;182.2)</td><td>&gt;0.05</td></tr><tr><td>ALT (U/L)</td><td>49.8 (40.3&#8211;159.9)</td><td>47.1 (41.0&#8211;123.0)</td><td>42.9 (30.4&#8211;115.0</td><td>&gt;0.05</td></tr><tr><td colspan="5">Renal functions</td></tr><tr><td>BUM (mmol/L)</td><td>6.0 (3.6&#8211;9.0)</td><td>6.2 (5.4&#8211;10.7)</td><td>5.6 (3.3&#8211;8.3)</td><td>&gt;0.05</td></tr><tr><td>CR (mmol/L)</td><td>36.0 (30.0&#8211;45.0)</td><td>36.0 (33.0&#8211;39.0)</td><td>37.0(31.0&#8211;39.0)</td><td>&gt;0.05</td></tr><tr><td colspan="5">Cardiac functions</td></tr><tr><td>CK (U/L)</td><td>1022.1 (592.1&#8211;2078.4)</td><td>954.05 (183.7&#8211;2485.0)</td><td>1396.9 (593.7&#8211;1804.1)</td><td>&gt;0.05</td></tr><tr><td>CK-MB (U/L)</td><td>530.4 (184.8&#8211;912.7)</td><td>579.9 (375.9&#8211;868.9)</td><td>708.7 (1475.2&#8211;1016.4)<sup>c</sup></td><td>=0.01</td></tr><tr><td>LDH (U/L)</td><td>1600 (914.6&#8211;2323.8)</td><td>1659.7 (1031.4&#8211;2027.2)</td><td>1835.3 (1448.3&#8211;2250.1)</td><td>&gt;0.05</td></tr></table>
848f7dcc9a2d52a9196e51ae445374f80474564068cf0f15e3b062f2101a604a.png
simple
<table><tr><td>Blood products within the first 24 h</td><td>Median [IQR]</td></tr><tr><td> Red Blood Cells (Unit)</td><td>14 [11&#8211;19]</td></tr><tr><td> Fresh Frozen Plasma (Unit)</td><td>12 [8&#8211;16]</td></tr><tr><td> Platelet (Unit)</td><td>2 [1&#8211;3]</td></tr><tr><td> Fibrinogen concentrate (gr)</td><td>4.5 [3&#8211;7.5]</td></tr><tr><td>Emergency procedures</td><td>N (%)</td></tr><tr><td> Surgery for bleeding</td><td>206 (64)</td></tr><tr><td> Embolization</td><td>83 (26)</td></tr></table>
012d9fd3354ad635f28a7e793f33c6fc951164dbe2d39028bb229dece257b8d3.png
simple
<table><tr><td></td><td>Assaulted</td><td>Not assaulted</td><td><i>P</i></td></tr><tr><td>STAI</td><td>101 (89-109)</td><td>77 (69-98)</td><td>&lt; 0,001</td></tr><tr><td>Anxiety trait</td><td>48 (41-55)</td><td>40 (38-43)</td><td>0,01</td></tr><tr><td>Anxiety state</td><td>51 (46-59)</td><td>39 (34-46)</td><td>&lt; 0,001</td></tr></table>
fcc90b04242fb1dd40a1cb6bdb42b78ee1d61974f839dadee313914a2e3def49.png
simple
<table><tr><td>n = 105</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>PPV (%)</td><td>NPV (%)</td></tr><tr><td>MMSE &#8804; 26</td><td>64.10</td><td>79.59</td><td>71.42</td><td>73.58</td></tr><tr><td>CVLT-LDTR &#8804; 4</td><td>72.91</td><td>70.31</td><td>64.81</td><td>77.58</td></tr><tr><td>MMSE &#8804; 26 and/or CVLT-LDTR &#8804; 4</td><td>94.80</td><td>63.26</td><td>67.27</td><td>93.93</td></tr><tr><td>MMSE &#8804; 26 and CVLT-LDTR &#8804; 4</td><td>43.58</td><td>91.83</td><td>80.95</td><td>67.16</td></tr></table>
8dbca556b1a7d429d5c5656264a4668bc658f0fb61b6979df11d92c333f371c2.png
complex
<table><tr><td rowspan="2">Parity</td><td colspan="2">Pigs</td><td colspan="2">Rabbits</td></tr><tr><td>Litter size</td><td>Average BW</td><td>Litter size</td><td>Average BW</td></tr><tr><td>1</td><td>0.21</td><td>0.29</td><td>0.09</td><td>0.23</td></tr><tr><td>2</td><td>0.25</td><td>0.33</td><td>0.19</td><td>0.26</td></tr><tr><td>3</td><td>0.24</td><td>0.35</td><td>0.27</td><td>0.32</td></tr><tr><td>4</td><td>0.22</td><td>0.33</td><td>0.29</td><td>0.37</td></tr><tr><td>5</td><td>0.19</td><td>0.30</td><td>0.24</td><td>0.39</td></tr></table>
aa693a6cb3b15f40b84810db12ec5ac703994cb86696db30c01b2a811d6d3acc.png
simple
<table><tr><td>Characteristic</td><td>Case 1</td><td>Case 2</td><td>Case 3</td><td>Case 4</td><td>Case 5</td><td>Case 6</td><td>Case 7</td><td>Case 8</td><td>Case 9</td></tr><tr><td>Sex</td><td>Male</td><td>Female</td><td>Female</td><td>Female</td><td>Female</td><td>Female</td><td>Female</td><td>Male</td><td>Female</td></tr><tr><td>Age (years)</td><td>41</td><td>44</td><td>36</td><td>45</td><td>43</td><td>51</td><td>49</td><td>31</td><td>37</td></tr><tr><td>Medical history</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Palpitations/headaches/sweating/hypertension</td><td>Yes</td><td>Yes</td><td>Yes</td><td></td><td></td><td></td><td></td><td>Yes</td><td></td></tr><tr><td> Other</td><td></td><td></td><td>Type 1 neurofibromatosis</td><td></td><td>Takotsubo</td><td></td><td></td><td></td><td></td></tr><tr><td>Blood pressure at admission (mmHg)</td><td>160/120</td><td>180/108</td><td>157/107</td><td>130/110</td><td>140/100</td><td>130/85</td><td>141/107</td><td>160/100</td><td>129/99</td></tr><tr><td>Pre-ECMO LVEF (%)</td><td>5</td><td>20</td><td>15</td><td>20</td><td>30</td><td>20</td><td>20</td><td>30</td><td>20</td></tr><tr><td>Maximum troponin I (ng/L)</td><td>2200</td><td>34,000</td><td>43,000</td><td>15,000</td><td>2000</td><td>18,000</td><td>237</td><td>4994</td><td>2083</td></tr><tr><td>NT pro-BNP at admission (ng/L)</td><td></td><td></td><td>18,363</td><td></td><td>25,282</td><td>6363</td><td>18,471</td><td></td><td>9264</td></tr><tr><td>ECMO duration (days)</td><td>4</td><td>1</td><td>6</td><td>7</td><td>3</td><td>3</td><td>2</td><td>7</td><td>4</td></tr><tr><td>Urinary metanephrine (<i>N</i> &lt; 340 &#956;g/24 h)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>1894</td><td>7192</td><td>8738</td><td>2862</td><td>2582</td></tr><tr><td>Urinary normetanephrine (<i>N</i> &lt; 440 &#956;g/24 h)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>4973</td><td>3650</td><td>11,910</td><td>11,268</td><td>9254</td></tr><tr><td>Pheochromocytoma size (mm), side</td><td>78 &#215; 75 &#215; 70, right</td><td>60 mm, left</td><td>ND, autopsy</td><td>29, left</td><td>70, left</td><td>103 &#215; 95 &#215; 75, right</td><td>57 &#215; 47, right</td><td>59 &#215; 38, left</td><td>88 &#215; 74&#215;91, left</td></tr></table>
66c5fdc2213a02450d052f56a9722f0a94b2bfc015efdc0cb11fa5b5c8664694.png
simple
<table><tr><td> </td><td>n</td><td>Days with absence from work<sup>a</sup></td><td>Days with partial absence from work<sup>b</sup></td><td>Total days affected<sup>c</sup></td><td>Percent absence from work<sup>d</sup></td><td>Excess percent absence from work</td><td>FTE*</td></tr><tr><td>Mild/No Psychological Distress</td><td>2,463</td><td>0.6 (0.05)</td><td>1.6 (0.14)</td><td>1.4 (0.11)</td><td>5.0%</td><td>Reference</td><td>--</td></tr><tr><td>Moderate Psychological Distress</td><td>414</td><td>1.1 (0.10)</td><td>2.4 (0.32)</td><td>2.2 (0.25)</td><td>7.9%</td><td>2.9%</td><td>18</td></tr><tr><td>Severe Psychological Distress</td><td>226</td><td>2.1 (0.26)</td><td>3.1 (0.43)</td><td>3.6 (0.36)</td><td>12.8%</td><td>7.8%</td><td>23</td></tr><tr><td>Total Excess Absence from Work (FTE)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>41</td></tr></table>
9a326cc67b546bc503ff1e89e55ed9a1f719bcbd7c1487e3d7c132f323894e36.png
simple
<table><tr><td>MIGS ID</td><td>Property</td><td>Term</td><td>Evidence code<sup>a</sup></td></tr><tr><td></td><td></td><td>Domain <i>Bacteria</i></td><td>TAS [5]</td></tr><tr><td></td><td></td><td>Phylum <i>Cyanobacteria</i></td><td>TAS [6-8]</td></tr><tr><td></td><td></td><td>Class <i>Cyanobacteria</i></td><td>TAS [8,9]</td></tr><tr><td></td><td>Current classification</td><td>Order Unknown</td><td></td></tr><tr><td></td><td></td><td>Family 1.1</td><td>TAS [7]</td></tr><tr><td></td><td></td><td>Genus <i>Rubidibacter</i></td><td>TAS [1]</td></tr><tr><td></td><td></td><td>Species <i>Rubidibacter lacunae</i></td><td>TAS [1]</td></tr><tr><td></td><td></td><td>Type strain KORDI 51-2</td><td>TAS [1]</td></tr><tr><td></td><td>Gram stain</td><td>Not reported</td><td></td></tr><tr><td></td><td>Cell shape</td><td>Rods</td><td>TAS [1]</td></tr><tr><td></td><td>Motility</td><td>None</td><td>TAS [1]</td></tr><tr><td></td><td>Sporulation</td><td>None</td><td>IDA</td></tr><tr><td></td><td>Temperature range</td><td>25-35<sup>o</sup>C</td><td>TAS [1]</td></tr><tr><td></td><td>Optimum temperature</td><td>30<sup>o</sup>C</td><td>TAS [1]</td></tr><tr><td>MIGS-6</td><td>Habitat</td><td>Seawater</td><td>TAS [1]</td></tr><tr><td>MIGS-6.3</td><td>Salinity</td><td>2-7% (optimum: 5)</td><td>TAS [1]</td></tr><tr><td>MIGS-22</td><td>OxygenCarbon sourceEnergy source</td><td>AerobicAutotrophPhototroph</td><td>TAS [1]TAS [1]TAS [1]</td></tr><tr><td>MIGS-15</td><td>Biotic relationship</td><td>Free living</td><td>TAS [1]</td></tr><tr><td>MIGS-14</td><td>Pathogenicity</td><td>None</td><td>NAS</td></tr><tr><td>MIGS-4</td><td>Geographic location</td><td>Chuuk state, Micronesia</td><td>TAS [1]</td></tr><tr><td>MIGS-5</td><td>Sample collection time</td><td>July, 2004</td><td>IDA</td></tr><tr><td>MIGS-4.1 </td><td>Latitude</td><td>7<sup>o</sup> 13&#8217; N</td><td>IDA</td></tr><tr><td>MIGS-4.2</td><td>Longitude</td><td>151<sup>o</sup> 58&#8217; E</td><td>IDA</td></tr><tr><td>MIGS-4.3</td><td>Depth</td><td>40 m</td><td>IDA</td></tr><tr><td>MIGS-4.4</td><td>Altitude</td><td>Not applicable</td><td>NAS</td></tr></table>
ea892325da3d3933c05c409a2fcda9fd586918309652ee3a1d0f78aa2d05eef4.png
complex
<table><tr><td></td><td>Model 1:Demographics</td><td>Model 2:ACGs &amp; Demographics</td><td>Model 3:ADGs, Sel. EDCs &amp; Demographics</td><td>Model 4:2002 Expenditures &amp; Demographics</td><td>Model 5:ADGs, Sel. EDCs, 2002 Expenditures &amp; Demographics</td></tr><tr><td colspan="6">2003 Top 0.5% Predicted User</td></tr><tr><td>Demographics</td><td>0.49%*</td><td>0.10%</td><td>0.03%</td><td>0.03%</td><td>0.02%</td></tr><tr><td>ACGs &amp; Demographics</td><td></td><td>0.50%</td><td>0.07%</td><td>0.08%</td><td>0.06%</td></tr><tr><td>ADGs, 19 EDCs &amp; Demographics</td><td></td><td></td><td>0.50%</td><td>0.19%</td><td>0.29%</td></tr><tr><td>2002 Expenditures &amp; Demographics</td><td></td><td></td><td></td><td>0.50%</td><td>0.36%</td></tr><tr><td>ADGs, 19 EDCs, 2002 Expenditures &amp; Demographics</td><td></td><td></td><td></td><td></td><td>0.50%</td></tr><tr><td colspan="6">2003 Top 1% Predicted User</td></tr><tr><td>Demographics</td><td>1.00%</td><td>0.21%</td><td>0.11%</td><td>0.15%</td><td>0.11%</td></tr><tr><td>ACGs &amp; Demographics</td><td></td><td>1.00%</td><td>0.30%</td><td>0.30%</td><td>0.32%</td></tr><tr><td>ADGs, 19 EDCs &amp; Demographics</td><td></td><td></td><td>1.00%</td><td>0.40%</td><td>0.65%</td></tr><tr><td>2002 Expenditures &amp; Demographics</td><td></td><td></td><td></td><td>1.00%</td><td>0.69%</td></tr><tr><td>ADGs, 19 EDCs, 2002 Expenditures &amp; Demographics</td><td></td><td></td><td></td><td></td><td>1.00%</td></tr><tr><td colspan="6">2003 Top 5% Predicted User</td></tr><tr><td>Demographics</td><td>4.96%*</td><td>2.43%</td><td>2.09%</td><td>2.46%</td><td>2.01%</td></tr><tr><td>ACGs &amp; Demographics</td><td></td><td>5.00%</td><td>3.43%</td><td>3.02%</td><td>3.21%</td></tr><tr><td>ADGs, 19 EDCs &amp; Demographics</td><td></td><td></td><td>5.00%</td><td>3.09%</td><td>4.06%</td></tr><tr><td>2002 Expenditures &amp; Demographics</td><td></td><td></td><td></td><td>5.00%</td><td>3.73%</td></tr><tr><td>ADGs, 19 EDCs, 2002 Expenditures &amp; Demographics</td><td></td><td></td><td></td><td></td><td>5.00%</td></tr></table>
2db12d0e8b550b49955a8047d4f031a5703a8e5558c81fe37071510aeb4e65c4.png
complex
<table><tr><td></td><td>Patient&#8217;s results</td><td>Reference range</td></tr><tr><td colspan="3">Immunoglobulin levels</td></tr><tr><td> IgM, serum (mg/dL)</td><td>30</td><td>41&#8211;164</td></tr><tr><td> IgA, serum (mg/dL)</td><td>68</td><td>14&#8211;122</td></tr><tr><td> IgE, total (IU/mL)</td><td>10</td><td>&lt; 60</td></tr><tr><td> IgG, serum (mg/dL)</td><td>868</td><td>331&#8211;1164</td></tr><tr><td colspan="3">Lymphocyte subset panel</td></tr><tr><td> CD4+ lymphocyte (%)</td><td>43.3</td><td>23&#8211;48</td></tr><tr><td> CD4+ lymphocyte count (/&#956;L)</td><td>1115.74</td><td>500&#8211;2400</td></tr><tr><td> CD8+ lymphocyte (%)</td><td>30.06</td><td>14&#8211;33</td></tr><tr><td> CD8+ lymphocyte count (/&#956;L)</td><td>788.49</td><td>300&#8211;1600</td></tr><tr><td> CD 56+ cell (%)</td><td>12</td><td>4&#8211;23</td></tr></table>
d2b6ca9c150d172e91619fc5f59e2d51d7a43366fc8bbcecbbd99f777192e896.png
complex
<table><tr><td rowspan="3">Characteristics</td><td colspan="2">Study patients</td><td rowspan="3"><i>P</i>-value</td></tr><tr><td>Case (preterm labour)</td><td>Control (term labour)</td></tr><tr><td><i>N</i> (%)</td><td><i>N</i> (%)</td></tr><tr><td>Age</td><td> </td><td> </td><td> </td></tr><tr><td> 16&#8211;20</td><td>7 (7.0)</td><td>13 (13.0)</td><td rowspan="6">0.098</td></tr><tr><td> 21&#8211;25</td><td>15 (15.0)</td><td>17 (17.0)</td></tr><tr><td> 26&#8211;30</td><td>33 (33.0)</td><td>30 (30.0)</td></tr><tr><td> 31&#8211;35</td><td>27 (27.0)</td><td>25 (25.0)</td></tr><tr><td> 36&#8211;40</td><td>18 (18.0)</td><td>15 (15.0)</td></tr><tr><td>Mean &#177; SD (years)</td><td>29.75 &#177; 5.24</td><td>28.63 &#177; 5.92</td></tr><tr><td> </td><td colspan="2">Age range = 16&#8211;39 years</td></tr><tr><td>Parity</td><td> </td><td> </td><td> </td></tr><tr><td> Primigravidae</td><td>17 (17.0)</td><td>22 (22.0)</td><td rowspan="2">0.534</td></tr><tr><td> Multigravidae</td><td>83 (83.0)</td><td>78 (78.0)</td></tr><tr><td>Marital status</td><td> </td><td> </td><td> </td></tr><tr><td> Single</td><td>20 (20.0)</td><td>19 (19.0)</td><td rowspan="2">0.064</td></tr><tr><td> Married</td><td>80 (80.0)</td><td>81 (81.0)</td></tr><tr><td>Tribe</td><td> </td><td> </td><td> </td></tr><tr><td> Hausa</td><td>13 (13.0)</td><td>10 (10.0)</td><td rowspan="4">0.830</td></tr><tr><td> Ibo</td><td>25 (25.0)</td><td>23 (23.0)</td></tr><tr><td> Yoruba</td><td>47 (47.0)</td><td>51 (51.0)</td></tr><tr><td> Others</td><td>15 (15.0)</td><td>16 (16.0)</td></tr><tr><td>Religion</td><td> </td><td> </td><td> </td></tr><tr><td> Christianity </td><td>62 (62.0)</td><td>53 (53.0)</td><td rowspan="3">0.106</td></tr><tr><td> Islam </td><td>33 (33.0)</td><td>46 (46.0)</td></tr><tr><td> Others </td><td>5 (5.0)</td><td>1 (1.0)</td></tr><tr><td>Social class</td><td> </td><td> </td><td> </td></tr><tr><td> Upper </td><td>17 (17.0)</td><td>14 (14.0)</td><td rowspan="3">0.139</td></tr><tr><td> Middle </td><td>50 (50.0)</td><td>57 (57.0)</td></tr><tr><td> Lower </td><td>33 (33.0)</td><td>29 (29.0)</td></tr><tr><td>Total </td><td>100 (100.0)</td><td>100 (100.0)</td><td> </td></tr></table>
ac021ba561559eaab066583ed7fbfc025f4b39e66a3806373bf9b9aa87feb4b7.png
simple
<table><tr><td>Times until treatment</td><td>With complications</td><td>Without complications</td><td>Total</td></tr><tr><td>&lt;24 hours</td><td>6</td><td>9</td><td>15</td></tr><tr><td>1-2 days</td><td>5</td><td>3</td><td>8</td></tr><tr><td>3&#8211;7 days</td><td>3</td><td>5</td><td>8</td></tr><tr><td>8&#8211;14 days</td><td>2</td><td>0</td><td>2</td></tr><tr><td>&gt;15 days</td><td>5</td><td>2</td><td>7</td></tr><tr><td>Total </td><td>21</td><td>19</td><td>40</td></tr></table>
ea6bcdd6069bafb0e7af13860c200d0f701f2d47cbd0ba486dcadd55cab870cc.png
simple
<table><tr><td>Technical Characteristic</td><td>Value</td></tr><tr><td>Measurement range</td><td>30 m (indoors)/15 m (outdoors)</td></tr><tr><td>Measurement speed</td><td>43,200 points/second</td></tr><tr><td>Accuracy in the 3D representation</td><td>&#177;0.1%</td></tr><tr><td>Field of view</td><td>270&#176; (H) &#215; 360&#176; (V-in rotation)</td></tr><tr><td>Weight of head scanner</td><td>1.0 kg</td></tr></table>
aa88153c0e16db64e9c9fcb4eea4b715b50d3451ff44e82e530ee2c9a039d482.png
complex
<table><tr><td></td><td></td><td colspan="6">Estimated vs actual Y</td></tr><tr><td></td><td>Missing</td><td colspan="3">15 %</td><td colspan="3">30 %</td></tr><tr><td>Framework</td><td>Method</td><td>Bias</td><td>Var</td><td>MSE</td><td>Bias</td><td>Var</td><td>MSE</td></tr><tr><td>Plain</td><td><i>1NN</i></td><td>0.16957</td><td>0.00072</td><td>0.02947</td><td>0.30959</td><td>0.00114</td><td>0.09698</td></tr><tr><td></td><td><i>kNN</i></td><td>0.10961</td><td>0.00035</td><td>0.01236</td><td>0.21987</td><td>0.00068</td><td>0.04902</td></tr><tr><td></td><td><i>wkNN</i></td><td>0.10947</td><td>0.00035</td><td>0.01233</td><td>0.21958</td><td>0.00068</td><td>0.04890</td></tr><tr><td>RReliefF10</td><td><i>1NN</i></td><td>0.15170</td><td>0.00075</td><td>0.02377</td><td>0.29608</td><td>0.00163</td><td>0.08928</td></tr><tr><td></td><td><i>kNN</i></td><td>0.10036</td><td>0.00042</td><td>0.01049</td><td>0.20963</td><td>0.00104</td><td>0.04498</td></tr><tr><td></td><td><i>wkNN</i></td><td>0.10023</td><td>0.00041</td><td>0.01046</td><td>0.20947</td><td>0.00104</td><td>0.04492</td></tr><tr><td>RReliefF20</td><td><i>1NN</i></td><td>0.15246</td><td>0.00063</td><td>0.02387</td><td>0.29331</td><td>0.00136</td><td>0.08738</td></tr><tr><td></td><td><i>kNN</i></td><td>0.09850</td><td>0.00035</td><td>0.01005</td><td>0.20607</td><td>0.00087</td><td>0.04333</td></tr><tr><td></td><td><i>wkNN</i></td><td>0.09839</td><td>0.00035</td><td>0.01002</td><td>0.20580</td><td>0.00087</td><td>0.04322</td></tr><tr><td>RReliefF30</td><td><i>1NN</i></td><td>0.15202</td><td>0.00068</td><td>0.02379</td><td>0.29081</td><td>0.00122</td><td>0.08579</td></tr><tr><td></td><td><i>kNN</i></td><td>0.09893</td><td>0.00033</td><td>0.01012</td><td>0.20508</td><td>0.00079</td><td>0.04285</td></tr><tr><td></td><td><i>wkNN</i></td><td>0.09877</td><td>0.00033</td><td>0.01008</td><td>0.20474</td><td>0.00079</td><td>0.04271</td></tr><tr><td>Bagging</td><td><i>1NN</i></td><td>0.10287</td><td>0.00030</td><td>0.01088</td><td>0.20756</td><td>0.00063</td><td>0.04370</td></tr><tr><td></td><td><i>kNN</i></td><td>0.10608</td><td>0.00030</td><td>0.01156</td><td>0.21240</td><td>0.00061</td><td>0.04572</td></tr><tr><td></td><td><i>wkNN</i></td><td>0.10544</td><td>0.00030</td><td>0.01142</td><td>0.21078</td><td>0.00061</td><td>0.04503</td></tr><tr><td>Random</td><td><i>1NN</i></td><td>0.10629</td><td>0.00030</td><td>0.01160</td><td>0.20738</td><td>0.00059</td><td>0.04359</td></tr><tr><td></td><td><i>kNN</i></td><td>0.10626</td><td>0.00030</td><td>0.01159</td><td>0.20638</td><td>0.00058</td><td>0.04317</td></tr><tr><td></td><td><i>wkNN</i></td><td>0.10622</td><td>0.00030</td><td>0.01158</td><td>0.20631</td><td>0.00058</td><td>0.04314</td></tr><tr><td>Bagging + Random</td><td><i>1NN</i></td><td>0.11010</td><td>0.00031</td><td>0.01243</td><td>0.21258</td><td>0.00060</td><td>0.04579</td></tr><tr><td></td><td><i>kNN</i></td><td>0.11101</td><td>0.00032</td><td>0.01264</td><td>0.21422</td><td>0.00060</td><td>0.04649</td></tr><tr><td></td><td><i>wkNN</i></td><td>0.11083</td><td>0.00032</td><td>0.01260</td><td>0.21386</td><td>0.00060</td><td>0.04633</td></tr><tr><td>Mean Imputation</td><td></td><td>0.11857</td><td>0.00035</td><td>0.01441</td><td>0.22512</td><td>0.00063</td><td>0.05130</td></tr></table>
49005df68983cc980156abb42fc3626ce04abf56cfab9bae8362674c0934ab23.png
complex
<table><tr><td></td><td>Experimental group</td><td>Control group</td><td>Risk Ratio</td><td>p-value</td></tr><tr><td></td><td></td><td></td><td>(95% CI)</td><td></td></tr><tr><td></td><td>n = 500</td><td>n = 502</td><td></td><td></td></tr><tr><td></td><td>n (%)</td><td>n (%)</td><td></td><td></td></tr><tr><td>Episiotomies 95/950 (10.0%)*</td><td>43 (9.0)</td><td>52 (11.0)</td><td>0.89 (0.71-1.13)</td><td>0. 301</td></tr><tr><td colspan="5">Perineal lacerations (caesarean sections excluded)</td></tr><tr><td>1 degree 643/950</td><td>347 (69.4)</td><td>339 (67.5)</td><td>1.17 (0.85-1.62)</td><td>0. 304</td></tr><tr><td>2 degree 160/950</td><td>85 (17.0)</td><td>75 (14.9)</td><td>1.23 (0.87-1.74)</td><td>0. 214</td></tr><tr><td>3 degree 53/950</td><td>23 (4.6)</td><td>30 (6.0)</td><td>1.00 (0.65-1.56)</td><td>0. 978</td></tr><tr><td>No laceration 56/950</td><td>22 (4.6)</td><td>29 (6.1)</td><td>1.0 Ref.</td><td></td></tr><tr><td colspan="5">Oedema (caesarean sections excluded)</td></tr><tr><td>VAS 0-3</td><td>300 (82.1)</td><td>303 (85.8)</td><td>1.0 Ref.</td><td></td></tr><tr><td>VAS 4-7</td><td>56 (15.4)</td><td>44 (12.5)</td><td>1.13 (0.93-1.36)</td><td>0. 247</td></tr><tr><td>VAS 8-10</td><td>9 (2.5)</td><td>6 (1.7)</td><td>1.21 (0.79-1.83)</td><td>0. 433</td></tr></table>
a84125d13945214b8d11be29e72aa01b6d0940dac21bd1b3f9afae16df286923.png
simple
<table><tr><td>mAb</td><td>Specificity/Reference</td><td>WT</td><td>vti13</td><td>prp3</td><td>prp3/vti13</td><td>csld2</td><td>csld3-2</td><td>xxt1</td><td>xxt2</td><td>xxt5</td></tr><tr><td><i>PECTINS</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>JIM7</td><td>High DE HG[31]</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td>LM19</td><td>Low DE HG[23]</td><td>++</td><td>++</td><td>+</td><td>++</td><td>-</td><td>NA</td><td>+</td><td>+</td><td>+</td></tr><tr><td>LM5</td><td>(1&#8211;4)-galactan[32]</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td>LM6</td><td>(1&#8211;5)-arabinan[33]</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td>INRA-RU1</td><td>Rhamnogalacturonan-I[34]</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>XYLOGLUCAN</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>LM15</td><td>xylosylated XyG[29]</td><td>++</td><td>-</td><td>++</td><td>++</td><td>+</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td>LM25</td><td>galactosylated XyG epitope[20]</td><td>++</td><td>-</td><td>+</td><td>++</td><td>+</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>MANNAN</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>BS-400-4</td><td>&#223;(1&#8211;4)-mannan/galacto-&#223;(1&#8211;4)-mannan[35]</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>XYLAN</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>LM10</td><td>(1&#8211;4)-xylan[36]</td><td>++</td><td>-</td><td>++</td><td>++</td><td>++</td><td>NA</td><td>-</td><td>++</td><td>++</td></tr><tr><td>LM11</td><td>&#223;(1&#8211;4)-xylan/arabinoxylan[36]</td><td>+</td><td>-</td><td>+</td><td>+</td><td>-</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>AGP</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>LM2</td><td>AGP[37]</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>NA</td><td>-</td><td>-</td><td>-</td></tr><tr><td>JIM13</td><td>AGP[38]</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>NA</td><td>+</td><td>+</td><td>+</td></tr><tr><td>JIM8</td><td>AGP[39]</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>NA</td><td>+</td><td>+</td><td>-</td></tr><tr><td><i>EXTENSIN</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>LM1</td><td>Extensin[40]</td><td>++</td><td>++</td><td>+</td><td>++</td><td>+</td><td>NA</td><td>+</td><td>+</td><td>+</td></tr><tr><td>JIM20</td><td>Extensin[41]</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>NA</td><td>+</td><td>+</td><td>+</td></tr></table>
e57b81cfe5cbc7b5ab6a5912bc72c900d878396d772a7dcaeedf2d62caf08e07.png
simple
<table><tr><td>Ratio</td><td>Pb</td><td>Cd</td><td>Cu</td><td>Fe</td><td>Mn</td><td>Cr</td><td>Ni</td><td>Zn</td><td>Hg</td></tr><tr><td>hair/vegetables</td><td>104.2</td><td>2.3</td><td>13.7</td><td>2.6</td><td>0.7</td><td>1.9</td><td>1.7</td><td>47.3</td><td>201.3</td></tr><tr><td>hair/rice</td><td>229.7</td><td>1.1</td><td>1.9</td><td>2.3</td><td>0.3</td><td>1.4</td><td>1.2</td><td>17.9</td><td>138.6</td></tr><tr><td>hair/soil</td><td>0.148</td><td>0.533</td><td>0.217</td><td>0.001</td><td>0.004</td><td>0.001</td><td>0.006</td><td>1.865</td><td>4.033</td></tr><tr><td>hair/irrigation</td><td>3636</td><td>1655</td><td>1856</td><td>114</td><td>23</td><td>66</td><td>60</td><td>5203</td><td>5717</td></tr></table>
8823580e7244234936993a065a9e54d8d8472188669ccbb9395117c5e407b98d.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Migraine</td><td colspan="2">Tension-type headache</td><td colspan="2">pMOH</td></tr><tr><td>OR</td><td><i>P</i></td><td>OR</td><td><i>P</i></td><td>OR</td><td><i>P</i></td></tr><tr><td>Habitation</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Rural</td><td>reference</td><td></td><td>reference</td><td></td><td>reference</td><td></td></tr><tr><td>Urban</td><td>1.1 [0.77-1.6]</td><td></td><td>1.1 [0.77-1.6]</td><td></td><td>8.6 [3.2-23.6]</td><td>0.0001</td></tr><tr><td>Education</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>None/primary</td><td>reference</td><td></td><td>reference</td><td></td><td>reference</td><td></td></tr><tr><td>Secondary</td><td>1.4 [0.95-2.0]</td><td></td><td>0.46 [0.34-0.64]</td><td>&lt;0.0001</td><td>0.59 [0.38-0.90]</td><td>0.0147</td></tr><tr><td>College or university</td><td>2.1 [1.4-3.2]</td><td>0.0004</td><td>0.22 [0.14-0.37]</td><td>&lt;0.0001</td><td>1.1 [0.71-1.8]</td><td></td></tr><tr><td>Employment</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>None</td><td>reference</td><td></td><td>reference</td><td></td><td>reference</td><td></td></tr><tr><td>Unskilled</td><td>1.2 [0.84-1.7]</td><td></td><td>1.5 [1.1-2.1]</td><td>0.0149</td><td>1.6 [1.1-2.6]</td><td>0.0232</td></tr><tr><td>Skilled</td><td>1.1 [0.83-1.6]</td><td></td><td>1.6 [1.2-2.2]</td><td>0.0010</td><td>1.5 [1.03-2.3]</td><td>0.0343</td></tr><tr><td>Professional</td><td>2.1 [1.4-3.2]</td><td>0.0005</td><td>0.46 [0.26-0.82]</td><td>0.0080</td><td>1.5 [0.91-2.7]</td><td></td></tr><tr><td colspan="2">Income per month (USD)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&#8804;40</td><td>reference</td><td></td><td>reference</td><td></td><td>reference</td><td></td></tr><tr><td>&gt;40</td><td>1.3 [0.88-1.8]</td><td></td><td>1.3 [0.93-1.9]</td><td></td><td>6.0 [2.8-13.1]</td><td>&lt;0.0001</td></tr></table>
590231c8cc245bbe35160d2d841fcca25770b065c080e52aeb30330844b3bfdd.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="2">Students (<i>n</i> = 22)</td><td colspan="2">Academics (<i>n</i> = 10)</td><td colspan="2">Alumni (<i>n</i> = 74)</td></tr><tr><td><i>M</i></td><td><i>SD</i></td><td><i>M</i></td><td><i>SD</i></td><td><i>M</i></td><td><i>SD</i></td></tr><tr><td>MAKSS Awareness</td><td>2.53</td><td>4.39</td><td>2.58</td><td>3.27</td><td>2.62</td><td>4.06</td></tr><tr><td>MAKSS Knowledge</td><td>2.44</td><td>5.11</td><td>2.36</td><td>6.23</td><td>2.57</td><td>5.54</td></tr><tr><td>MAKSS Skills</td><td>2.58</td><td>6.82</td><td>2.40</td><td>6.06</td><td>2.70</td><td>7.20</td></tr><tr><td>MCSDS Social Desirability</td><td>0.46</td><td>2.62</td><td>0.56</td><td>3.23</td><td>0.52</td><td>3.10</td></tr></table>
4b06f9701b2c41f65be182712562dc6b51d55cd3d486adf246f467f39e869572.png
complex
<table><tr><td> </td><td colspan="3">30-day Mortality</td><td colspan="3">30-day to 5year Mortality</td></tr><tr><td> </td><td>HR</td><td>95% CI</td><td><i>p</i> Value</td><td>HR</td><td>95% CI</td><td><i>p</i> Value</td></tr><tr><td>Model 1</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Aging</td><td>1.069</td><td>1.018&#8211;1.123</td><td>.007</td><td>1.058</td><td>1.036&#8211;1.080</td><td>&lt;.001</td></tr><tr><td> Women</td><td>1.082</td><td>0.456&#8211;2.571</td><td>.858</td><td>0.831</td><td>0.542&#8211;1.275</td><td>.396</td></tr><tr><td> LVEF &lt;40%</td><td>1.301</td><td>0.351&#8211;4.823</td><td>.694</td><td>1.007</td><td>0.509&#8211;1.994</td><td>.984</td></tr><tr><td> Stroke history</td><td>3.868</td><td>1.411&#8211;10.597</td><td>.009</td><td>1.601</td><td>1.049&#8211;2.445</td><td>.029</td></tr><tr><td> Malignant arrhythmias/cardiac syncope/cardiogenic shock attack</td><td>26.110</td><td>4.477&#8211;91.187</td><td>&lt;.001</td><td>1.548</td><td>0.533&#8211;4.498</td><td>.422</td></tr><tr><td> STEMI</td><td>1.209</td><td>0.457&#8211;3.202</td><td>.702</td><td>1.328</td><td>0.893&#8211;1.975</td><td>.162</td></tr><tr><td> Hyperuricemia</td><td>5.849</td><td>2.171&#8211;15.761</td><td>&lt;.001</td><td>1.372</td><td>0.856&#8211;2.199</td><td>.188</td></tr><tr><td> Albumin level</td><td>0.913</td><td>0.834&#8211;0.999</td><td>.048</td><td>0.923</td><td>0.877&#8211;0.973</td><td>.003</td></tr><tr><td> FBG at admission</td><td>0.983</td><td>0.894&#8211;1.081</td><td>.720</td><td>1.003</td><td>0.948&#8211;1.062</td><td>.906</td></tr><tr><td> SBP at admission</td><td>1.008</td><td>0.989&#8211;1.026</td><td>.410</td><td>1.004</td><td>0.997&#8211;1.011</td><td>.278</td></tr><tr><td> Admission eGFR &lt;60 mL/min/1.73 m<sup>2</sup></td><td>0.633</td><td>0.242&#8211;1.657</td><td>.352</td><td>1.087</td><td>0.684&#8211;1.726</td><td>.724</td></tr><tr><td> KDIGO classification</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Absence of AKI</td><td>1.000</td><td>&#8211;</td><td>&#8211;</td><td>1.000</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Stage 1</td><td>3.344</td><td>1.186&#8211;9.433</td><td>.023</td><td>1.076</td><td>0.680 &#8211;1.701</td><td>.755</td></tr><tr><td>Stage 2</td><td>6.320</td><td>2.206&#8211;23.305</td><td>&lt;.001</td><td>1.705</td><td>0.798&#8211;3.643</td><td>.168</td></tr><tr><td>Stage 3</td><td>7.922</td><td>2.321&#8211;35.252</td><td>&lt;.001</td><td>3.593</td><td>1.305&#8211;9.892</td><td>.013</td></tr><tr><td> Aspirin therapy</td><td>0.300</td><td>0.100&#8211;0.897</td><td>.031</td><td>0.472</td><td>0.185&#8211;1.203</td><td>.116</td></tr><tr><td> &#946;-Blocker therapy</td><td>0.133</td><td>0.047&#8211;0.375</td><td>&lt;.001</td><td>0.644</td><td>0.434&#8211;0.955</td><td>.028</td></tr><tr><td> ACEI/ARB therapy</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>0.855</td><td>0.525&#8211;1.392</td><td>.530</td></tr><tr><td> PCI</td><td>1.714</td><td>0.474&#8211;6.203</td><td>.412</td><td>0.282</td><td>0.144&#8211;0.555</td><td>&lt;.001</td></tr><tr><td> CABG</td><td>10.010</td><td>0.996&#8211;42.021</td><td>.052</td><td>0.773</td><td>0.182&#8211;3.290</td><td>.728</td></tr><tr><td>Model 2</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Aging</td><td>1.067</td><td>1.018&#8211;1.118</td><td>.007</td><td>1.055</td><td>1.034&#8211;1.078</td><td>&lt;.001</td></tr><tr><td> Women</td><td>1.020</td><td>0.436&#8211;2.398</td><td>.965</td><td>0.857</td><td>0.560&#8211;1.131</td><td>.477</td></tr><tr><td> LVEF &lt;40%</td><td>1.083</td><td>0.325&#8211;3.611</td><td>.897</td><td>1.029</td><td>0.527&#8211;2.011</td><td>.933</td></tr><tr><td> Stroke history</td><td>4.157</td><td>1.538&#8211;11.238</td><td>.005</td><td>1.610</td><td>1.054&#8211;2.460</td><td>.028</td></tr><tr><td> Malignant arrhythmias/cardiac syncope/cardiogenic shock attack</td><td>23.478</td><td>7.259&#8211;75.937</td><td>&lt;.001</td><td>1.527</td><td>0.523&#8211;4.456</td><td>.438</td></tr><tr><td> STEMI</td><td>1.067</td><td>0.415&#8211;2.744</td><td>.893</td><td>1.356</td><td>0.910&#8211;2.021</td><td>.135</td></tr><tr><td> Hyperuricemia</td><td>5.301</td><td>2.059&#8211;13.647</td><td>&lt;.001</td><td>1.541</td><td>0.980&#8211;2.421</td><td>.061</td></tr><tr><td> Albumin level</td><td>0.909</td><td>0.828&#8211;0.998</td><td>.045</td><td>0.929</td><td>0882 &#8211;0.978</td><td>.005</td></tr><tr><td> FBG at admission</td><td>0.974</td><td>0.888&#8211;1.068</td><td>.570</td><td>1.015</td><td>0.963&#8211;1.070</td><td>.577</td></tr><tr><td> SBP at admission</td><td>1.010</td><td>0.992&#8211;1.028</td><td>.268</td><td>1.003</td><td>0.995&#8211;1.010</td><td>.495</td></tr><tr><td> Admission eGFR &#8805;60 mL/min/1.73 m<sup>2</sup> without AKI</td><td>1.000</td><td>&#8211;</td><td>&#8211;</td><td>1.000</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Admission eGFR &lt;60 mL/min/1.73 m<sup>2</sup> without AKI</td><td>0.519</td><td>0.102&#8211;3.022</td><td>.721</td><td>1.505</td><td>0.910&#8211;2.421</td><td>.113</td></tr><tr><td> Admission eGFR &#8805;60 mL/min/1.73 m<sup>2</sup> with AKI</td><td>4.352</td><td>1.521&#8211;15.302</td><td>.035</td><td>1.682</td><td>1.123&#8211;2.657</td><td>.018</td></tr><tr><td> Admission eGFR &lt;60 mL/min/1.73 m<sup>2</sup> with AKI</td><td>6.353</td><td>1.699&#8211;26.102</td><td>.001</td><td>1.870</td><td>1.144&#8211;3.113</td><td>.040</td></tr><tr><td> Aspirin therapy</td><td>0.323</td><td>0.113&#8211;0.922</td><td>.035</td><td>0.485</td><td>0.191&#8211;1.231</td><td>.128</td></tr><tr><td> &#946;-Blocker therapy</td><td>0.137</td><td>0.048&#8211;0.387</td><td>&lt;.001</td><td>0.648</td><td>0.439&#8211;0.958</td><td>.030</td></tr><tr><td> ACEI/ARB therapy</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>0.825</td><td>0.508&#8211;1.340</td><td>.435</td></tr><tr><td> PCI</td><td>1.636</td><td>0.455&#8211;5.890</td><td>.451</td><td>0.282</td><td>0.143&#8211;0.554</td><td>&lt;.001</td></tr><tr><td> CABG</td><td>11.878</td><td>0.533&#8211;43.569</td><td>.058</td><td>0.902</td><td>0.216 &#8211;3.772</td><td>.888</td></tr></table>
dc2137e115e5735f8243f11afc89736a15f687b65bb35f09a9099009e6099030.png
complex
<table><tr><td></td><td rowspan="2">NS-TOPSAR</td><td colspan="2">Sentinel-1</td><td>Airborne</td></tr><tr><td></td><td>IW Mode</td><td>EW Mode</td><td>TOPSAR in [24]</td></tr><tr><td>Carrier frequency (GHz)</td><td>9</td><td>5.405</td><td>5.405</td><td>9.65</td></tr><tr><td>Altitude (km)</td><td>25</td><td>693</td><td>693</td><td>5</td></tr><tr><td>Resolution</td><td rowspan="2">4.5 &#215; 4.5</td><td rowspan="2">5 &#215; 20</td><td rowspan="2">20 &#215; 40</td><td rowspan="2">2 &#215; 1</td></tr><tr><td>(range &#215; azimuth, m)</td></tr><tr><td>Swathwidth (km)</td><td>100</td><td>250</td><td>400</td><td>20</td></tr><tr><td>Revisit time</td><td>several hours</td><td>6 days</td><td>6 days</td><td>within one hour</td></tr><tr><td>Endurance</td><td>up to a few years</td><td>tens of years</td><td>tens of years</td><td>up to a few days</td></tr></table>
d27fea1f9bc85b7af7b48d490f03e5d91b21b3a0b39cdc0f7782e23620759717.png
complex
<table><tr><td>Variable</td><td colspan="2">Univariate analysis</td><td colspan="2">Multivariate analysis</td></tr><tr><td></td><td>OR (95% CI)</td><td><i>P</i> value</td><td>OR (95% CI)</td><td><i>P</i> value</td></tr><tr><td>Age</td><td>&#8211;</td><td>0.0875</td><td>&#8211;</td><td>0.809</td></tr><tr><td>Gender (Female sex)</td><td>1.11 (0.33&#8211;3.74)</td><td>0.869</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Hypertension</td><td>1.34 (0.38&#8211;4.67)</td><td>0.647</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>BAV</td><td>0.84 (0.18&#8211;3.87)</td><td>0.882</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>PDA</td><td>0.93 (0.26&#8211;3.32)</td><td>0.912</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>VSD</td><td>0.36 (0.10&#8211;1.25)</td><td>0.107</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>AR</td><td>2.90 (0.32&#8211;26.33)</td><td>0.343</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>AS</td><td>&#8211;</td><td>0.990</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Collateral circulation</td><td>4.11 (1.00&#8211;16.84)</td><td>0.050</td><td>8.35 (0.85&#8211;82.11)</td><td>0.069</td></tr><tr><td>Severity of CoA(severe)</td><td>4.93 (1.33&#8211;18.31)</td><td>0.017</td><td>7.46 (1.19&#8211;46.76)</td><td>0.032</td></tr></table>
7749a73c5bf921329fbd8892c33e7e18caf54b27c7bf71a17427c382d3c5e57e.png
simple
<table><tr><td>Variable</td><td>No. of patients (%)</td></tr><tr><td>Age, years (mean &#177; SD)</td><td>64.7 &#177; 13.7</td></tr><tr><td>Gender, male</td><td>24 (77.4)</td></tr><tr><td>Current/ex-smoker</td><td>15 (48.4)</td></tr><tr><td>Underlying disease</td><td>30 (96.8)</td></tr><tr><td> DM</td><td>18 (58.1)</td></tr><tr><td> Chronic lung disease</td><td>12 (38.7)</td></tr><tr><td>COPD/asthma</td><td>8 (25.8)</td></tr><tr><td>Old TB</td><td>2 (6.5)</td></tr><tr><td>Bronchiectasis</td><td>2 (6.5)</td></tr><tr><td> Solid organ cancer</td><td>4 (12.9)</td></tr><tr><td> Hematologic disease</td><td>4 (12.9)</td></tr><tr><td> Liver cirrhosis</td><td>3 (9.7)</td></tr><tr><td>Systemic steroids before diagnosis</td><td>17 (54.8)</td></tr><tr><td> Duration of steroids before ICU admission, day, median (IQR)</td><td>49 (14&#8211;90)</td></tr><tr><td> Daily dosage of steroids, mg, median (IQR)</td><td>50 (29&#8211;71)</td></tr><tr><td>Inhaled corticosteroids before diagnosis</td><td>3 (9.7)</td></tr><tr><td>H1N1 infection before diagnosis</td><td>3 (9.7)</td></tr></table>
6919738b103aa3d0c83b6d2e1dc321b61cf5a6b1457e539f10b9c8c5deb06cda.png
complex
<table><tr><td>Male ID</td><td>Approximate time between death and necropsy (hours)</td><td colspan="6">Whole RNA concentration (ng/&#956;l)</td></tr><tr><td> </td><td> </td><td>Testis</td><td>Heart</td><td>Spleen</td><td>Intestine</td><td>Kidney</td><td>Lung</td></tr><tr><td>Agaz0820</td><td>1</td><td>900</td><td>160</td><td>1467</td><td>105</td><td>550</td><td>500</td></tr><tr><td>Agaz0821</td><td>13</td><td>1888</td><td>180</td><td>1100</td><td>650</td><td>667</td><td>160</td></tr><tr><td>Agaz1001</td><td>18</td><td>578</td><td>90</td><td>200</td><td>34</td><td>4</td><td>180</td></tr><tr><td>Agaz1006</td><td>7</td><td>432</td><td>160</td><td>200</td><td>115</td><td>175</td><td>381</td></tr><tr><td>Agaz1007</td><td>8</td><td>500</td><td>135</td><td>389</td><td>160</td><td>514</td><td>160</td></tr><tr><td>Agaz1008</td><td>8</td><td>1000</td><td>75</td><td>375</td><td>165</td><td>446</td><td>85</td></tr><tr><td>Agaz1009</td><td>20</td><td>938</td><td>115</td><td>160</td><td>200</td><td>408</td><td>338</td></tr><tr><td>Agaz1010</td><td>20</td><td>737</td><td>120</td><td>563</td><td>596</td><td>534</td><td>89</td></tr><tr><td>Agaz1011</td><td>30</td><td>&#8211;</td><td>64</td><td>737</td><td>333</td><td>175</td><td>115</td></tr></table>
b1914a3e2294228615574a5ea12cdbc3697c7b37500db0517f6e578456bba102.png
complex
<table><tr><td>Predictor</td><td>ANCS &lt;42 points</td><td>ANCS &#8805;42 points</td><td>Crude RR (95% CI)</td><td>Adjusted RR (95% CI)<sup>a</sup></td></tr><tr><td colspan="5">Group - ITT</td></tr><tr><td> Control PCHUs</td><td>75 (17.0%)</td><td>365 (83.0%)</td><td>1</td><td>1</td></tr><tr><td> Intervention PCHUs</td><td>91 (11.8%)</td><td>679 (88.2%)</td><td>1.05 (1.01&#8211;1.10)</td><td>1.05 (1.00&#8211;1.09)</td></tr><tr><td colspan="5">Socioeconomic class</td></tr><tr><td> Upper/Upper Middle</td><td>13 (11.3%)</td><td>102 (88.7%)</td><td>1</td><td>1</td></tr><tr><td> Middle</td><td>58 (10.0%)</td><td>523 (90.0%)</td><td>0.95 (0.89&#8211;1.02)</td><td>1.10 (0.97&#8211;1.25)</td></tr><tr><td> Lower</td><td>46 (16.3%)</td><td>236 (83.7%)</td><td>1.01 (0.95&#8211;1.08)</td><td>0.95 (0.88&#8211;1.01)</td></tr><tr><td colspan="5">Illicit Drug use</td></tr><tr><td> Yes</td><td>8 (25.8%)</td><td>23 (74.2%)</td><td>1</td><td>1</td></tr><tr><td> No</td><td>133 (12.4%)</td><td>935 (87.6%)</td><td>1.14 (1.01&#8211;1.29)</td><td>1.01 (0.95&#8211;1.08)</td></tr></table>
92e74eccbaffdd4f74f56993afec1f2ee2eda3db8c81c397d536c40d815d269e.png
complex
<table><tr><td>Codon position (HXB2 gp41)</td><td colspan="3">Selection analysis method</td><td>Detected elsewhere<sup><i>a</i></sup></td></tr><tr><td></td><td>SLAC</td><td>FEL</td><td>IFEL</td><td></td></tr><tr><td>24</td><td></td><td>B, D</td><td>B, D</td><td>T, C</td></tr><tr><td>54</td><td></td><td>B, F, CRF 02_AG</td><td>CRF 01_AE</td><td></td></tr><tr><td>96</td><td>C, D</td><td>C, A, D</td><td>C, B, D, CRF 01_AE</td><td>T</td></tr><tr><td>101</td><td>B, G</td><td>B, G</td><td>B, G</td><td></td></tr><tr><td>130</td><td>B</td><td>C, A, B</td><td>C, B</td><td>T</td></tr><tr><td>137</td><td>A, B</td><td>A, B, G</td><td>B</td><td>T</td></tr><tr><td>163</td><td>C, D, CRF 02_AG</td><td>C</td><td>C, D, CRF 02_AG</td><td>C</td></tr><tr><td>165</td><td>D, G</td><td></td><td>C, A, G</td><td></td></tr><tr><td>172</td><td></td><td>C, B, G, CRF 02 _AG</td><td></td><td></td></tr><tr><td>210</td><td>C, A, CRF 01_AE</td><td>C, A, B, D, F, G</td><td>C, D, CRF 01_AE</td><td></td></tr><tr><td>214<sup><i>b</i></sup></td><td>A</td><td>A, B</td><td>A, B</td><td></td></tr><tr><td>221</td><td>G, CRF 01_AE</td><td>C, A, G, CRF 01_AE, CRF 02_AG</td><td>C, D, G, CRF 01_AE</td><td></td></tr><tr><td>230</td><td></td><td>A, D</td><td>A, G, CRF 01_AE</td><td></td></tr><tr><td>271</td><td></td><td>C, CRF 01_AE</td><td>C, B, D</td><td></td></tr><tr><td>328</td><td>C, B, G</td><td>C, B, G</td><td>C, B, G</td><td></td></tr><tr><td>332</td><td>A, B, G</td><td>A, B, G</td><td>B, D, G, CRF 01_AE</td><td>C</td></tr><tr><td>349</td><td></td><td>C, F, CRF 01_AE, CRF 02_AG</td><td>CRF 02_AG</td><td>C</td></tr></table>
3515267526772e9a423c977686d6498bee80e92ba5f56bef7e87cf43af032be6.png
simple
<table><tr><td> </td><td>Study population</td><td>Time (number) of survey</td><td>Survey population</td><td>No. examined (%)</td><td>Mean age years</td><td>No. positive (%)</td><td>GMI* for all examined</td></tr><tr><td>Community surveys</td><td>Kirare</td><td>Nov-11 (8)</td><td>178</td><td>120 (67.4)</td><td>10.1</td><td>33 (27.5)</td><td>0.3384</td></tr><tr><td> </td><td>Kiomoni</td><td>Nov-11 (8)</td><td>145</td><td>107 (73.8)</td><td>9.9</td><td>24 (22.4)</td><td>0.2776</td></tr><tr><td> </td><td>Kisimatui</td><td>Nov-11 (8)</td><td>180</td><td>129 (71.7)</td><td>9.4</td><td>25 (19.4)</td><td>0.2468</td></tr><tr><td> </td><td>All 3 communities combined</td><td>Nov-11 (8)</td><td>503</td><td>356 (70.8)</td><td>9.8</td><td>82 (23.0)</td><td>0.2865</td></tr><tr><td>School surveys</td><td>All 4 schools combined</td><td>Nov-10 (7)</td><td>453</td><td>362 (79.9)</td><td>7.4</td><td>61 (16.9)<sup>#</sup></td><td>0.2776<sup>&#167;</sup></td></tr><tr><td> </td><td> </td><td>Dec-11 (8)</td><td>382</td><td>334 (87.3)</td><td>7.2</td><td>38 (11.4)<sup>#</sup></td><td>0.2153<sup>&#167;</sup></td></tr></table>
8602202ac1289104c91aee3449f4a70aaf1e8d2530cf818d4b02a9d4e59df243.png
simple
<table><tr><td>Strain</td><td>Selected on:</td><td>Resistant to:</td></tr><tr><td>KWAG-base</td><td>No selection</td><td>-</td></tr><tr><td>KWAG-perm</td><td>Permethrin (0.75%)</td><td>Permethrin</td></tr><tr><td>MBN-base</td><td>No selection</td><td>DDT (low-level)</td></tr><tr><td>MBN-DDT</td><td>DDT (4%)</td><td>DDT, deltamethrin and permethrin (cross-resistance)</td></tr></table>
a8111ab05a7356da3c5cd72ba9d05cd06928358f2fe4e0d62164e3587b03c028.png
simple
<table><tr><td> </td><td>Adult patients</td><td>Elderly patients</td><td><i>P</i>-value</td></tr><tr><td>Healthy donors, number</td><td>14</td><td>16</td><td> </td></tr><tr><td>Age, y, mean &#177; SD</td><td>24.0 &#177; 8.1</td><td>78.4 &#177; 8.2</td><td>&lt;0.001</td></tr><tr><td>Male, n (%)</td><td>11 (79)</td><td>11 (69)</td><td>0.45</td></tr><tr><td>Comorbidity, n (%)</td><td>0 (0)</td><td>5 (31)</td><td>0.30</td></tr><tr><td>Severe sepsis, number of patients</td><td>15</td><td>40</td><td> </td></tr><tr><td>Age, y, mean &#177; SD</td><td>34.8 &#177; 11.9</td><td>77.6 &#177; 7.1</td><td>&lt;0.001</td></tr><tr><td>Male, n (%)</td><td>12 (80)</td><td>28 (70)</td><td>0.45</td></tr><tr><td>Septic shock, n (%)</td><td>5 (33)</td><td>18 (45)</td><td>0.43</td></tr><tr><td>Ventilator rate, n (%)</td><td>11 (73)</td><td>31 (78)</td><td>0.75</td></tr><tr><td>APACHE II score, mean &#177; SD</td><td>19.2 &#177; 6.9</td><td>22.5 &#177; 6.9</td><td>0.14</td></tr><tr><td> APACHE II-age score, mean &#177; SD</td><td>19.0 &#177; 5.0</td><td>15.8 &#177; 7.6</td><td>0.08</td></tr><tr><td>SAPS II score, mean &#177; SD</td><td>46.6 &#177; 17.5</td><td>58.6 &#177; 16.1</td><td>0.10</td></tr><tr><td> SAPS II-age score, mean &#177; SD</td><td>43.3 &#177; 9.6</td><td>42.7 &#177; 11.6</td><td>0.17</td></tr><tr><td>SOFA score, mean &#177; SD</td><td>7.4 &#177; 4.6</td><td>7.3 &#177; 4.1</td><td>0.87</td></tr><tr><td>Comorbidity, n (%)</td><td>4 (27)</td><td>31 (78)</td><td>0.01</td></tr><tr><td>Types of bacteria detected in first 72 h, n (%)</td><td> </td><td> </td><td> </td></tr><tr><td> Gram-positive bacteria</td><td>8 (53)</td><td>22 (55)</td><td>0.91</td></tr><tr><td> Gram-negative bacteria</td><td>15 (100)</td><td>40 (100)</td><td>1.00</td></tr><tr><td> Fungi</td><td>6 (40)</td><td>17 (43)</td><td>0.87</td></tr><tr><td>Treatment, n (%)</td><td> </td><td> </td><td> </td></tr><tr><td>Adjunctive hydrocortisone, n (%)</td><td>1 (7)</td><td>2 (5)</td><td>0.81</td></tr><tr><td>Organ support types</td><td> </td><td> </td><td> </td></tr><tr><td>Ventilator, n (%)</td><td>12 (80)</td><td>35 (86)</td><td>0.48</td></tr><tr><td>Hemofiltration, n (%)</td><td>3 (20)</td><td>10 (25)</td><td>0.70</td></tr><tr><td>Organ support duration</td><td> </td><td> </td><td> </td></tr><tr><td>Ventilator, d, mean &#177; SD</td><td>11.6 &#177; 12.3</td><td>9.3 &#177; 16.1</td><td>0.68</td></tr><tr><td>Hemofiltration, d, mean &#177; SD</td><td>7.3 &#177; 6.6</td><td>9.9 &#177; 12.8</td><td>0.26</td></tr><tr><td>ICU stay, d, mean &#177; SD</td><td>21.9 &#177; 22.6</td><td>16.6 &#177; 16.1</td><td>0.57</td></tr><tr><td>ICU-free days in 28 days, d, mean &#177; SD</td><td>11.6 &#177; 9.6</td><td>10.9 &#177; 11.6</td><td>0.64</td></tr><tr><td>Hospital stay, d, mean &#177; SD</td><td>36.3 &#177; 35.9</td><td>39.6 &#177; 41.9</td><td>0.41</td></tr></table>
ee8804c65e580d9cc2811cdac2d73dda69aa8412a19fb8e0352468c8f3767bca.png
simple
<table><tr><td>Haematological parameter</td><td>Control (n=10)</td><td>Buffaloes suffering from FUO (n=30)</td></tr><tr><td>Hb (g/dL)</td><td>12.64&#177;0.40</td><td>10.25&#177;0.64*</td></tr><tr><td>TLC (10<sup>3</sup>/&#956;L)</td><td>8.33&#177;0.34</td><td>10.57&#177;0.94</td></tr><tr><td>Neutrophils (%)</td><td>39.50&#177;1.31</td><td>54.63&#177;5.48*</td></tr><tr><td>Lymphocytes (%)</td><td>57.00&#177;0.95</td><td>40.33&#177;5.60*</td></tr><tr><td>Monocytes (%)</td><td>2.30&#177;0.45</td><td>3.53&#177;0.93</td></tr><tr><td>Eosinophils (%)</td><td>1.20&#177;0.35</td><td>1.5&#177;0.61</td></tr><tr><td>Basophils (%)</td><td>-</td><td>-</td></tr><tr><td>PCV (%)</td><td>36.90&#177;1.21</td><td>30.08&#177;1.31*</td></tr><tr><td>TEC (10<sup>6</sup>/&#956;L)</td><td>5.84&#177;0.13</td><td>5.15&#177;0.26</td></tr><tr><td>MCV (fL)</td><td>63.18&#177;1.44</td><td>58.83&#177;2.83</td></tr><tr><td>MCH (pg)</td><td>21.64&#177;0.37</td><td>20.11&#177;1.22</td></tr><tr><td>MCHC (%)</td><td>34.25&#177;0.78</td><td>34.09&#177;2.11</td></tr></table>
22ebd71415351b58dd46868ce6bc0185f3ef5679de13bc2c215ac283284503d3.png
simple
<table><tr><td><i>In vitro</i>response to:</td><td></td><td>ControlsN (%)</td><td>TST<sup>+</sup>, suspected LTBIN (%)</td><td>Cured TBN (%)</td></tr><tr><td></td><td></td><td>13 (100)</td><td>106 (100)</td><td>29 (100)</td></tr><tr><td>QFT-IT</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Positive N.(%)</td><td>0</td><td>70 (66.03)</td><td>19 (63.3)</td></tr><tr><td></td><td>IFN-&#947; (IU/ml) median (IQR)Among all</td><td>0 (0-0.1)</td><td>2.3 (0-15.1)</td><td>1.1 (0.1-4.2)</td></tr><tr><td></td><td>IFN-&#947; (IU/ml) median (IQR)Among the positive responders</td><td>NA</td><td>8.1 (2.4-22.6)</td><td>3.8 (1.5-5.0)</td></tr><tr><td>RD1 proteins</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Positive N.(%)</td><td>0</td><td>64 (60.3)</td><td>19 (65.5)</td></tr><tr><td></td><td>IFN-&#947; (IU/ml) median (IQR)Among all</td><td>0 (0-0.2)</td><td>1.4 (0.2-8.9)</td><td>1.6 (0.4-2.9)</td></tr><tr><td></td><td>IFN-&#947; (IU/ml) median (IQR)Among the positive responders</td><td>NA</td><td>7.6 (2.3-20.3)</td><td>2.6 (1.6-6.2)</td></tr></table>
aa28d4dbba89fa056e5321bd60d633d7bddf0548c579109f4f04b39095d4a970.png
simple
<table><tr><td>Unit*</td><td>Color<sup>&#182;</sup></td><td>Day<sup>&#8224;</sup></td><td>Positive culture<sup>&#8225;</sup></td><td>Leakage<sup>&#167;</sup></td></tr><tr><td>1</td><td>Red</td><td>None</td><td>No</td><td>No</td></tr><tr><td>2</td><td>Yellow/orange</td><td>30</td><td>Yes</td><td>Yes<sup>&#167;</sup></td></tr><tr><td>3</td><td>Yellow</td><td>9</td><td>Yes</td><td>Yes<sup>&#167;</sup></td></tr><tr><td>4</td><td>Red</td><td>None</td><td>No</td><td>No</td></tr><tr><td>5</td><td>Yellow/orange</td><td>19</td><td>Yes</td><td>Yes<sup>&#167;</sup></td></tr><tr><td>6</td><td>Orange</td><td>15</td><td>Yes</td><td>Yes<sup>&#167;</sup></td></tr><tr><td>7</td><td>Red</td><td>None</td><td>No</td><td>No</td></tr><tr><td>8</td><td>Orange</td><td>25</td><td>No</td><td>No</td></tr><tr><td>9</td><td>Red</td><td>None</td><td>No</td><td>No</td></tr><tr><td>10</td><td>Yellow</td><td>4</td><td>Yes</td><td>Yes<sup>&#167;</sup></td></tr><tr><td>11</td><td>Red</td><td>None</td><td>No</td><td>No</td></tr><tr><td>12</td><td>Red</td><td>None</td><td>No</td><td>No</td></tr><tr><td>13</td><td>Yellow</td><td>4</td><td>Yes</td><td>Yes<sup>&#167;</sup></td></tr><tr><td>14</td><td>Red</td><td>None</td><td>No</td><td>No</td></tr><tr><td>15</td><td>Yellow</td><td>13</td><td>No</td><td>Yes<sup>&#167;</sup></td></tr><tr><td>16</td><td>Orange</td><td>26</td><td>No</td><td>No</td></tr><tr><td>17</td><td>Orange</td><td>15</td><td>No</td><td>No</td></tr><tr><td>18</td><td>Red</td><td>None</td><td>No</td><td>No</td></tr><tr><td>19</td><td>Orange</td><td>30</td><td>No</td><td>No</td></tr><tr><td>20</td><td>Yellow</td><td>18</td><td>No</td><td>Yes<sup>&#167;</sup></td></tr></table>
e5f150c92e486a5643743dd8442913835455dfa08e6341cf1f6582050a45e742.png
simple
<table><tr><td>Study population characteristics</td><td>mean (SD)</td></tr><tr><td>Gestational age (weeks)</td><td>32.5 (2.1)</td></tr><tr><td>Weight (g)</td><td>1700 (401)</td></tr><tr><td>Length (cm)</td><td>41.1 (3.3)</td></tr><tr><td>Head circumference (cm)</td><td>29.9 (1.6)</td></tr><tr><td>Apgar score at 1 minute</td><td>8 (1)</td></tr><tr><td>Apgar score at 5 minutes</td><td>9 (1)</td></tr></table>
2a9d35013702880cc536f9c94222de7e8f1e719758d9d898ee80ee66337a457b.png
simple
<table><tr><td>Structure identifier</td><td>Description</td><td>No. of models</td><td>Reference(s)</td></tr><tr><td>U_1D3Z</td><td>Solution NMR ensemble</td><td>10</td><td>[35]</td></tr><tr><td>U_COCO</td><td>Solution NMR ensemble (1D3Z.pdb) plus COCO-derived conformers</td><td>20</td><td>this study</td></tr><tr><td>U_1XQQ</td><td>DER ensemble</td><td>128</td><td>[14]</td></tr><tr><td>U_2NR2</td><td>MUMO ensemble</td><td>144</td><td>[15]</td></tr><tr><td>U_2K39</td><td>EROS ensemble</td><td>116</td><td>[10]</td></tr><tr><td>U_ISD</td><td>ISD ensemble(ensemble provided as an example with the ISD 1.1 package)</td><td>25</td><td>[26]</td></tr><tr><td>U_NNR</td><td>NOE(2)+S<sup>2</sup>(8)+RDC(8) restrained ensemble</td><td>32</td><td>this study</td></tr><tr><td>U_CNS</td><td>RECOORD ensemble calculated with CNS</td><td>25</td><td>[34]</td></tr><tr><td>U_CNW</td><td>RECOORD ensemble calculated with CNS in water</td><td>25</td><td>[34]</td></tr><tr><td>U_CYA</td><td>RECOORD ensemble calculated with CYANA</td><td>25</td><td>[34]</td></tr><tr><td>U_CYW</td><td>RECOORD ensemble calculated with CYANA in water</td><td>25</td><td>[34]</td></tr><tr><td>U_1UBQMD</td><td>5ns MD simulation started from the X-ray structure 1UBQ</td><td>32</td><td>this study</td></tr><tr><td>U_1G6J</td><td>Ubiquitin in reverse micelles</td><td>32</td><td>[36]</td></tr><tr><td>U_1V80</td><td>Ubiquitin at 30 bar</td><td>10</td><td>[37]</td></tr><tr><td>U_1V81</td><td>Ubiquitin at 3000 bar</td><td>10</td><td>[37]</td></tr><tr><td>U_2JZZ</td><td>Solid-state NMR structure</td><td>20</td><td>[38]</td></tr></table>
0ccc2932bf2b98d82837aa3c1e37f62da9644f0fb469419df57caa5293413ae3.png
simple
<table><tr><td>Variables</td><td>Fragmented QRS(n = 79)</td><td>Non-fragmented QRS(n = 257)</td><td>p value</td></tr><tr><td>Age,years</td><td>51.4 &#177; 4.6</td><td>50.8 &#177; 3.1</td><td>0.408</td></tr><tr><td>Gender, Male,%</td><td>59.5</td><td>62.6</td><td>0.614</td></tr><tr><td>Hypertension,%</td><td>30.4</td><td>25.3</td><td>0.970</td></tr><tr><td>Smoking,%</td><td>38</td><td>27.6</td><td>0.079</td></tr><tr><td>CAD,%</td><td>41.8</td><td>30.4</td><td>0.059</td></tr><tr><td>MVD,%</td><td>25.3</td><td>5.1</td><td>&lt; 0.001</td></tr><tr><td>Stenotic CAD,%</td><td>40.5</td><td>10.5</td><td>&lt; 0.001</td></tr><tr><td>LDL,mg/dl</td><td>125 &#177; 34</td><td>118 &#177; 26</td><td>0.089</td></tr><tr><td>TG,mg/dl</td><td>161 &#177; 43</td><td>156 &#177; 46</td><td>0.124</td></tr><tr><td>HDL,mg/dl</td><td>39.1 &#177; 8.2</td><td>39.2 &#177; 8</td><td>0.979</td></tr><tr><td>Glucose</td><td>91 &#177; 14</td><td>89 &#177; 11</td><td>0.195</td></tr><tr><td>Creatinin</td><td>0.95 &#177; 0.25</td><td>0.9 &#177; 0.18</td><td>0.127</td></tr><tr><td>WBC</td><td>6.9 &#177; 2.3</td><td>6.7 &#177; 2.2</td><td>0.474</td></tr><tr><td>Hemoglobin</td><td>13 &#177; 2.3</td><td>13.1 &#177; 2.4</td><td>0.635</td></tr><tr><td>LVEF</td><td>59.3 &#177; 6</td><td>60.7 &#177; 5.1</td><td>0.070</td></tr></table>
295e1cdc0a969b392ac81da21e7187e1a6c2ef4c42ad510b87ddfa011f01e1e4.png
simple
<table><tr><td>Patient no.</td><td>Underlying disease</td><td>CSF WBC (cells/mm<sup>3</sup>)</td><td>Imaging pattern (MRI)</td><td>CSF HSV viral load (copies/ml)</td><td>Outcome</td></tr><tr><td>1</td><td>Normal</td><td>230</td><td>Fronto-temporal lesions</td><td>16,975</td><td>Complete recovery</td></tr><tr><td>2</td><td>Normal</td><td>350</td><td>Fronto-temporal lesions</td><td>2214</td><td>Complete recovery</td></tr><tr><td>3</td><td>Normal</td><td>70</td><td>Fronto-temporal lesions</td><td>Qualitative PCR</td><td>Complete recovery</td></tr><tr><td>4</td><td>Normal</td><td>730</td><td>Temporal lobe lesions</td><td>11,755,813</td><td>Partial recovery</td></tr><tr><td>5</td><td>Normal</td><td>22</td><td>Fronto-temporal and thalamic lesions</td><td>500,000</td><td>Partial recovery</td></tr><tr><td>6</td><td>Normal</td><td>90</td><td>Temporal lobe lesions</td><td>71,875</td><td>Complete recovery</td></tr><tr><td>7</td><td>Hematologic malignancy</td><td>147</td><td>Temporal lobe lesions</td><td>30,750</td><td>Complete recovery</td></tr><tr><td>8</td><td>Normal</td><td>75</td><td>Fronto-temporal and thalamic lesions</td><td>12,200</td><td>Partial recovery</td></tr><tr><td>9</td><td>DM</td><td>510</td><td>Other cortical and subcortical lesions</td><td>3325</td><td>Dead</td></tr><tr><td>10</td><td>Normal</td><td>40</td><td>Normal CT</td><td>1491</td><td>Partial recovery</td></tr><tr><td>11</td><td>Hematologic Malignancy</td><td>40</td><td>Other cortical and subcortical lesions</td><td>740</td><td>Dead</td></tr><tr><td>12</td><td>Normal</td><td>60</td><td>Fronto-temporal and thalamic lesions</td><td>39</td><td>Partial recovery</td></tr><tr><td>13</td><td>DM</td><td>15</td><td>N/A</td><td>Qualitative PCR</td><td>Partial recovery</td></tr><tr><td>14</td><td>Normal</td><td>600</td><td>Temporal lobe lesions</td><td>Qualitative PCR</td><td>Partial recovery</td></tr><tr><td>15</td><td>Old ischemic stroke</td><td>22</td><td>Fronto-temporal lesions</td><td>Qualitative PCR</td><td>Partial recovery</td></tr><tr><td>16</td><td>Normal</td><td>30</td><td>Temporal lobe lesions</td><td>Qualitative PCR</td><td>Partial recovery</td></tr><tr><td>17</td><td>Normal</td><td>20</td><td>Other cortical and subcortical lesions</td><td>Qualitative PCR</td><td>Partial recovery</td></tr></table>
03864f26e0b6511e0ced4a7e123306335dd90bfeb00ef8351483ced03fe209d5.png
complex
<table><tr><td>Variable</td><td colspan="2">Range (Q4&#8211;Q1)</td><td colspan="3">Slope of index inequality (95 % CI)</td><td colspan="3">Relative index of inequality (95 % CI)</td><td colspan="2">Concentration Index</td></tr><tr><td></td><td>2008</td><td>2012</td><td>2008</td><td>2012</td><td>Change in equity (<i>P</i>-value)</td><td>2008</td><td>2012</td><td>Change in equity (<i>P</i>-value)</td><td>2008</td><td>2012</td></tr><tr><td>Received any ANC</td><td>&#8211;4.3</td><td>2.6</td><td>&#8722;0.047**(&#8722;0.094 - -0.001)</td><td>0.051(&#8722;0.027 - 0.130)</td><td>0.030</td><td>0.951**(0.904 - 1.000)</td><td>1.056(0.971 - 1.149)</td><td>0.037</td><td>&#8722;0.005</td><td>0.015</td></tr><tr><td>Attended &#8805;4 ANC visits</td><td>5.7</td><td>16.0</td><td>0.024(&#8722;0.084 - 0.132)</td><td>0.209***(0.129 - 0.288)</td><td>0.005</td><td>1.027(0.909 - 1.160)</td><td>1.271***(1.139 - 1.417)</td><td>0.008</td><td>0.011</td><td>0.033</td></tr><tr><td>ANC visit &lt;20 weeks gestation</td><td>23.5</td><td>30.1</td><td>0.274***(0.106 - 0.442)</td><td>0.312***(0.165 - 0.460)</td><td>0.741</td><td>1.831***(1.268 - 2.644)</td><td>1.593***(1.278 - 1.984)</td><td>0.525</td><td>0.116</td><td>0.077</td></tr><tr><td>Skilled birth attendant</td><td>8.5</td><td>8.4</td><td>0.121***(0.066 - 0.176)</td><td>0.113**(0.020 - 0.207)</td><td>0.888</td><td>1.135***(1.071 - 1.202)</td><td>1.124**(1.021 - 1.238)</td><td>0.869</td><td>0.017</td><td>0.018</td></tr><tr><td>Doctor attended childbirth</td><td>44</td><td>53.7</td><td>0.401***(0.270 - 0.531)</td><td>0.587***(0.449 - 0.724)</td><td>0.063</td><td>5.285***(2.971 - 9.398)</td><td>5.802***(3.856 - 8.728)</td><td>0.797</td><td>0.300</td><td>0.268</td></tr><tr><td>Offered HIV testing in pregnancy</td><td>&#8722;8.4</td><td>&#8722;7.0</td><td>&#8722;0.042(&#8722;0.106 - 0.021)</td><td>&#8722;0.042(&#8722;0.093 - 0.009)</td><td>0.999</td><td>0.951(0.880 - 1.028)</td><td>0.940(0.862 - 1.024)</td><td>0.833</td><td>&#8722;0.007</td><td>&#8722;0.004</td></tr><tr><td>HIV test in past 2 years</td><td>&#8211;2.8</td><td>1.3</td><td>&#8722;0.050(&#8722;0.152 - 0.051)</td><td>&#8722;0.004(&#8722;0.049 - 0.041)</td><td>0.419</td><td>0.943(0.838 - 1.061)</td><td>0.996(0.951 - 1.042)</td><td>0.405</td><td>0.000</td><td>&#8722;0.006</td></tr><tr><td>Never had HIV Test</td><td>&#8211;1.4</td><td>5.0</td><td>&#8722;0.028(&#8722;0.120 - 0.065)</td><td>0.030(&#8722;0.031 - 0.091)</td><td>0.297</td><td>0.739(0.264 - 2.068)</td><td>2.631(0.395 - 17.518)</td><td>0.236</td><td>&#8722;0.001</td><td>0.450</td></tr><tr><td>Planned pregnancy</td><td>22.5</td><td>30.6</td><td>0.134(&#8722;0.032 - 0.301)</td><td>0.391***(0.258 - 0.524)</td><td>0.009</td><td>1.391(0.929 - 2.084)</td><td>2.999***(2.096 - 4.292)</td><td>0.004</td><td>0.078</td><td>0.161</td></tr><tr><td>Five or more children</td><td>&#8211;8.2</td><td>&#8722;11.5</td><td>&#8722;0.099***(&#8722;0.139 - -0.060)</td><td>&#8722;0.117***(&#8722;0.162 - -0.073)</td><td>0.548</td><td>0.129***(0.033 - 0.497)</td><td>0.045***(0.014 - 0.144)</td><td>0.255</td><td>&#8722;0.326</td><td>&#8722;0.324</td></tr><tr><td>Poor-fair health status</td><td>&#8211;10.5</td><td>&#8722;1.0</td><td>&#8722;0.150***(&#8722;0.234 - -0.066)</td><td>0.022(&#8722;0.068 - 0.112)</td><td>0.004</td><td>0.331***(0.167 - 0.654)</td><td>1.165(0.631 - 2.151)</td><td>0.004</td><td>&#8722;0.043</td><td>&#8722;0.040</td></tr><tr><td>HIV infection</td><td>&#8211;20.6</td><td>&#8722;21.7</td><td>&#8722;0.281***(&#8722;0.427 - -0.136)</td><td>&#8722;0.251***(&#8722;0.372 - -0.129)</td><td>0.38</td><td>0.340***(0.178 - 0.649)</td><td>0.372***(0.224 - 0.620)</td><td>0.821</td><td>&#8722;0.193</td><td>&#8722;0.213</td></tr></table>
d2e407e6d6675ae6f47754835ad26503fe256d60ee2129938538975f7c421ce6.png
complex
<table><tr><td rowspan="2"> </td><td>CR &amp; TT at T0</td><td>CR at T1</td><td>TT at T1</td><td>CR at T2</td><td>TT at T2</td><td>CR at T3</td><td>TT at T3</td><td>CR at T4</td><td>TT at T4</td><td>CR at T5</td><td>TT at T5</td></tr><tr><td>n=121</td><td>n=62</td><td>n=59</td><td>n=62</td><td>n=59</td><td>n=50</td><td>n=51</td><td>n=30</td><td>n=36</td><td>n=16</td><td>n=18</td></tr><tr><td>arm symptoms</td><td>24,33</td><td>21,00 (2,50)</td><td>18,07 (2,32)</td><td>21,24 (2,82)</td><td>18,01 (2,08)</td><td>22,02 (3,73)</td><td>26,33 (4,27)</td><td>19,89 (5,10)</td><td>19,96 (4,40)</td><td>11,14 (5,76)</td><td>18,78 (6,49)</td></tr><tr><td>breast symptoms</td><td>20,94</td><td>33,30 <sup>a</sup> (2,78)</td><td>29,57 (2,74)</td><td>23,67 (2,58)</td><td>24,10 (2,35)</td><td>17,99 (3,17)</td><td>15,94 (2,52)</td><td>14,55 (4,24)</td><td>12,60 (3,30)</td><td>6,87 (5,63)</td><td>16,77 (4,99)</td></tr><tr><td>body image</td><td>73,35</td><td>69,60 (2,14)</td><td>70,62 (2,49)</td><td>73,21 (2,48)</td><td>77,80 (2,55)</td><td>74,74 (3,67)</td><td>77,51 (2,87)</td><td>73,62 (5,76)</td><td>78,40 (4,93)</td><td>74,91 (7,02)</td><td>79,08 (7,36)</td></tr><tr><td>future perspective</td><td>53,44</td><td>57,33 (3,64)</td><td>51,02 (3,44)</td><td>58,36 (3,38)</td><td>58,62 (3,26)</td><td>61,78 (4,03)</td><td>65,44 (3,53)</td><td>64,55 (5,84)</td><td>64,55 (6,27)</td><td>59,69 (7,59)</td><td>68,03 (10,08)</td></tr><tr><td>systemic treatment side effects</td><td>14,64</td><td>22,50 (1,87)</td><td>25,81<sup>a</sup> (2,83)</td><td>22,52 (2,06)</td><td>21,21 (2,88)</td><td>18,01 (2,20)</td><td>17,88 (2,57)</td><td>19,40 (3,19)</td><td>13,20 (2,95)</td><td>17,62 (4,80)</td><td>15,24 (4,28)</td></tr><tr><td> </td><td>n=21</td><td>n=22</td><td>n=26</td><td>n=16</td><td>n=20</td><td>n=8</td><td>n=10</td><td>n=8</td><td>n=6</td><td>n=3</td><td>n=3</td></tr><tr><td>upset by hair loss</td><td>34,92</td><td>48,25 <sup>a</sup> (8,16)</td><td>27,51 (9,26)</td><td>23,81 <sup>a</sup> (11,11)</td><td>40,48 <sup>a</sup> (5,56)</td><td>46,02 <sup>a</sup> (11,10)</td><td>28,25 <sup>a</sup> (16,33)</td><td>1,62 <sup>a</sup> (0,00)</td><td>23,81 (29,40)</td><td>34,92 <sup>a</sup> (0,00)</td><td>34,92 <sup>a</sup> (0,00)</td></tr><tr><td> </td><td>n=104</td><td>n=53</td><td>n=50</td><td>n=53</td><td>n=53</td><td>n=42</td><td>n=45</td><td>n=26</td><td>n=30</td><td>n=13</td><td>n=15</td></tr><tr><td>sexual functioning</td><td>23,85</td><td>21,02 (2,68)</td><td>23,52 (3,45)</td><td>24,48 (3,04)</td><td>22,60 (3,36)</td><td>24,65 (3,50)</td><td>24,59 (2,90)</td><td>21,85 (4,44)</td><td>27,19 (3,61)</td><td>25,14 (6,92)</td><td>21,63 (5,36)</td></tr><tr><td> </td><td>n=61</td><td>n=23</td><td>n=23</td><td>n=29</td><td>n=32</td><td>n=24</td><td>n=29</td><td>n=15</td><td>n=19</td><td>n=8</td><td>n=9</td></tr><tr><td>sexual enjoyment</td><td>55,74</td><td>53,98 (5,39)</td><td>47,40 (3,31)</td><td>48,16 (5,77)</td><td>50,61 (5,45)</td><td>61,29 <sup>a</sup> (4,86)</td><td>49,94 (4,98)</td><td>64,07 (5,98)</td><td>48,59 (5,16)</td><td>62,40 <sup>a</sup> (6,67)</td><td>46,21 (9,52)</td></tr></table>
d5f1ab894b6d5b9e9c96498e741a2b0269ef1175089003d06466df6210bb6c17.png
complex
<table><tr><td>Variable</td><td colspan="2">Non-smoker (n = 22)</td><td colspan="2">Smoker (n = 22)</td><td colspan="2"><i>t</i>-test</td></tr><tr><td> </td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td><i>t</i>-value</td><td><i>P</i>-value</td></tr><tr><td>Age (years)</td><td>41.5</td><td>15.8</td><td>46.0</td><td>11.4</td><td>1.1</td><td>.290</td></tr><tr><td>Duration of smoking (years)</td><td>NA</td><td>NA</td><td>24.3</td><td>9.7</td><td>NA</td><td>NA</td></tr><tr><td>Number of cigarettes smoked daily</td><td>NA</td><td>NA</td><td>17.4</td><td>7.0</td><td>NA</td><td>NA</td></tr><tr><td>Brinkman index</td><td>NA</td><td>NA</td><td>430</td><td>246.7</td><td>NA</td><td>NA</td></tr></table>
5eec062dcd8075c8549336db52f30e730b28098d9517701ef59717a31342ebf0.png
simple
<table><tr><td>Pathogenic step</td><td>Candidate biomarkers</td><td>Potential approaches and targets of disease-specific therapy</td></tr><tr><td>Elevated production of Gd-IgA1</td><td>Serum level of Gd-IgA1 (lectin or antibody ELISA)IgA1 hinge-region <i>O</i>-glycopeptide profiles (mass spectrometric analysis)</td><td>Reduce production of Gd-IgA1Manipulate enzyme expression in IgA1-producing cellsReduce number of cells secreting Gd-IgA1</td></tr><tr><td>Production of autoantibodies specific for Gd-IgA1</td><td>Serum levels of autoantibodies (IgG and IgA) specific for Gd-IgA1</td><td>Reduce production of autoantibodies specific for Gd-IgA1Deplete cells producing the autoantibodyManipulate affinity maturation of autoantibodies to reduce affinity for the autoantigenRemove the autoantibodies from circulation</td></tr><tr><td>Formation of pathogenic IgA1-containing immune complexes</td><td>Circulating IgA-containing immune complexesSpecific components of circulating immune complexes</td><td>Block immune complex formation and enhance their removal from circulation and catabolismBlock epitopes of autoantigen (Gd-IgA1) by non-crosslinking antibodiesBlock autoantibodies by an epitope-containing glycopeptide or glycomimeticBlock activation of complement</td></tr><tr><td>Glomerular deposition and injury</td><td>Complement components and their degradation productsNovel markers of glomerular injuryUrinary immune complexesUrinary peptidomic profiles</td><td>Block activation of mesangial cellsReduce complement activation <i>in situ</i>Block binding of IgA1-containing immune complexes to mesangial cellsBlock mesangial-cell signaling induced by IgA1-containing immune complexes</td></tr></table>
4fbda3c12fb64c82d35c1e0f1464597a9b2f8665932a8cdeaed4d30c18a5233a.png
complex
<table><tr><td>Brain region intensity</td><td colspan="3">MNI peak coordinates (X, Y, Z)</td><td>Volume</td><td>Peak activity</td></tr><tr><td>Precuneus</td><td>3</td><td>&#8722;69</td><td>57</td><td>120</td><td>9.2972</td></tr><tr><td>Posterior cingulate gyrus</td><td>0</td><td>&#8722;66</td><td>12</td><td>63</td><td>6.3883</td></tr><tr><td>Right medial superior frontal gyrus</td><td>3</td><td>63</td><td>9</td><td>67</td><td>6.6306</td></tr><tr><td>Left middle frontal gyrus</td><td>&#8722;12</td><td>33</td><td>51</td><td>30</td><td>6.0696</td></tr><tr><td>Left medial superior frontal gyrus</td><td>&#8722;3</td><td>30</td><td>57</td><td>74</td><td>6.6797</td></tr><tr><td>Left supplementary motor area</td><td>&#8722;3</td><td>15</td><td>69</td><td>52</td><td>5.598</td></tr></table>
1bf0c2527d147cbaeecb1e8a41771cef8337697a3387eaf7e0bee0c012405ef2.png
simple
<table><tr><td>Variable</td><td>HR (95% CI)</td><td><i>P</i> value</td></tr><tr><td>MACE</td><td> </td><td> </td></tr><tr><td> CTO-PCI successful</td><td>0.58 (0.32&#8211;0.94)</td><td>&lt;0.01</td></tr><tr><td> Prior MI</td><td>3.89 (1.95&#8211;7.84)</td><td>&lt;0.05</td></tr><tr><td> CKD</td><td>3.51 (1.52&#8211;7.87)</td><td>&lt;0.01</td></tr><tr><td> LVEF (per-10% increment)</td><td>0.94 (0.88&#8211;0.99)</td><td>&lt;0.05</td></tr><tr><td>Mortality</td><td> </td><td> </td></tr><tr><td> CTO-PCI successful</td><td>0.35 (0.19&#8211;0.68)</td><td>&lt;0.01</td></tr><tr><td> Age</td><td>1.08 (1.02&#8211;1.11)</td><td>&lt;0.01</td></tr><tr><td> Prior MI</td><td>2.31 (0.73&#8211;7.35)</td><td>0.16</td></tr><tr><td> CKD</td><td>7.18 (2.95&#8211;17.40)</td><td>&lt;0.01</td></tr><tr><td> LVEF (per-10% increment)</td><td>0.87 (0.77&#8211;0.93)</td><td>&lt;0.01</td></tr></table>
108fdbded1f676acdaa11c68bad46320d99850f5b06ed6b852df574a1063b89b.png
complex
<table><tr><td></td><td colspan="3">Serum (ng/ml)</td><td colspan="3">Urine (&#956;g/mmol creatinine)</td></tr><tr><td></td><td>Odds ratio</td><td>95% confidence interval</td><td><i>P </i>value</td><td>Odds ratio</td><td>95% confidence interval</td><td><i>P </i>value</td></tr><tr><td>Full study</td><td colspan="3">(219 cases/891 controls)</td><td colspan="3">(198 cases/797 controls)</td></tr><tr><td> Total isoflavones</td><td>1.03</td><td>0.95 to 1.11</td><td>0.479</td><td>1.08</td><td>1.00 to 1.16</td><td>0.055</td></tr><tr><td> Total lignans</td><td>0.99</td><td>0.90 to 1.08</td><td>0.728</td><td>1.01</td><td>0.94 to 1.09</td><td>0.758</td></tr><tr><td> Daidzein</td><td>1.04</td><td>0.98 to 1.10</td><td>0.225</td><td>1.05</td><td>0.99 to 1.10</td><td>0.096</td></tr><tr><td> Equol</td><td>1.04</td><td>0.98 to 1.10</td><td>0.167</td><td>1.03</td><td>0.99 to 1.06</td><td>0.131</td></tr><tr><td> <i>o</i>-Desmethylangolensin</td><td>1.03</td><td>0.97 to 1.09</td><td>0.390</td><td>1.02</td><td>0.98 to 1.06</td><td>0.250</td></tr><tr><td> Genistein</td><td>1.00</td><td>0.94 to 1.05</td><td>0.911</td><td>1.01</td><td>0.97 to 1.05</td><td>0.706</td></tr><tr><td> Glycitein</td><td>1.03</td><td>0.97 to 1.10</td><td>0.345</td><td>1.03</td><td>0.98 to 1.07</td><td>0.248</td></tr><tr><td> Enterodiol</td><td>1.02</td><td>0.96 to 1.09</td><td>0.461</td><td>1.01</td><td>0.96 to 1.05</td><td>0.772</td></tr><tr><td> Enterolactone</td><td>0.98</td><td>0.91 to 1.05</td><td>0.564</td><td>0.99</td><td>0.94 to 1.04</td><td>0.718</td></tr><tr><td>Oestrogen receptor-positive subgroup</td><td colspan="3">(105 cases/365 controls)</td><td colspan="3">(95 cases/329 controls)</td></tr><tr><td> Total isoflavones</td><td>1.01</td><td>0.91 to 1.12</td><td>0.818</td><td>1.09</td><td>0.97 to 1.22</td><td>0.154</td></tr><tr><td> Total lignans</td><td>1.02</td><td>0.89 to 1.17</td><td>0.774</td><td>1.12</td><td>0.99 to 1.28</td><td>0.083</td></tr><tr><td> Daidzein</td><td>1.05</td><td>0.97 to 1.13</td><td>0.260</td><td>1.03</td><td>0.96 to 1.10</td><td>0.468</td></tr><tr><td> Equol</td><td>1.01</td><td>0.93 to 1.09</td><td>0.887</td><td>1.07</td><td>1.01 to 1.12</td><td>0.013</td></tr><tr><td> <i>o</i>-Desmethylangolensin</td><td>1.05</td><td>0.96 to 1.14</td><td>0.314</td><td>1.04</td><td>0.98 to 1.10</td><td>0.192</td></tr><tr><td> Genistein</td><td>0.99</td><td>0.92 to 1.06</td><td>0.775</td><td>1.00</td><td>0.94 to 1.05</td><td>0.882</td></tr><tr><td> Glycitein</td><td>1.03</td><td>0.93 to 1.13</td><td>0.614</td><td>1.04</td><td>0.98 to 1.10</td><td>0.186</td></tr><tr><td> Enterodiol</td><td>1.00</td><td>0.92 to 1.09</td><td>0.990</td><td>1.04</td><td>0.98 to 1.11</td><td>0.235</td></tr><tr><td> Enterolactone</td><td>1.01</td><td>0.91 to 1.14</td><td>0.806</td><td>1.08</td><td>0.98 to 1.19</td><td>0.115</td></tr></table>
a63fdcc2ee6ec910ae84378cdb022bef6ae3903761759a083a37b23483595b1c.png
complex
<table><tr><td>Demographic data</td><td colspan="2">Households</td></tr><tr><td>Number of household members</td><td>N</td><td>%</td></tr><tr><td>1&#8211;4 members</td><td>29</td><td>26.9%</td></tr><tr><td>5&#8211;8 members</td><td>32</td><td>29.6%</td></tr><tr><td>9&#8211;12 members</td><td>34</td><td>31.5%</td></tr><tr><td>&gt;13 members</td><td>13</td><td>12.0%</td></tr><tr><td>Total</td><td>108</td><td>100.0%</td></tr><tr><td>Mean household size (members)</td><td>8.6</td><td></td></tr><tr><td>Median household size (members)</td><td>8</td><td></td></tr><tr><td>Number of children &lt;5 in households</td><td>N</td><td>%</td></tr><tr><td>0 children</td><td>9</td><td>8.3%</td></tr><tr><td>1 children</td><td>16</td><td>14.8%</td></tr><tr><td>2 children</td><td>34</td><td>31.5%</td></tr><tr><td>3 children</td><td>29</td><td>26.9%</td></tr><tr><td>4 children</td><td>10</td><td>9.3%</td></tr><tr><td>5 children</td><td>3</td><td>2.8%</td></tr><tr><td>6 children</td><td>5</td><td>4.6%</td></tr><tr><td>&#8805;10 children</td><td>2</td><td>1.8</td></tr><tr><td>Total</td><td>97</td><td>100.0</td></tr><tr><td>Mean number of children &lt;5 per household</td><td>2.6</td><td></td></tr><tr><td>Median number of children &lt;5 per household</td><td>2</td><td></td></tr><tr><td>Profession of head of household</td><td>N</td><td>%</td></tr><tr><td>Subsistence farmer</td><td>46</td><td>42.6%</td></tr><tr><td>Subsistence farmer + Daily worker</td><td>8</td><td>7.4%</td></tr><tr><td>Subsistence farmer + Other profession*</td><td>6</td><td>5.6%</td></tr><tr><td>Subsistence farmer + Farmer for trading</td><td>5</td><td>4.6%</td></tr><tr><td>Health worker</td><td>5</td><td>4.6%</td></tr><tr><td>No work</td><td>5</td><td>4.6%</td></tr><tr><td>Workman</td><td>4</td><td>3.7%</td></tr><tr><td>Subsistence farmer + Hunter</td><td>4</td><td>3.7%</td></tr><tr><td>Subsistence farmer + Teacher</td><td>3</td><td>2.8%</td></tr><tr><td>Subsistence farmers + Other professions&#8224;</td><td>14</td><td>13.0%</td></tr><tr><td>Other professions&#8225;</td><td>7</td><td>6.5%</td></tr><tr><td>Missing</td><td>1</td><td>0.9%</td></tr><tr><td>Total</td><td>108</td><td>100.0%</td></tr></table>
345703c6f6ade022a50a69408e79fb81874de69217db0aee92ec03184a697d4f.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">HIV-infected</td><td>Healthy controls</td></tr><tr><td><i>LTNP</i></td><td><i>Normal progressors</i></td><td></td></tr><tr><td>Number</td><td>5</td><td>13</td><td>7</td></tr><tr><td>Median age, years</td><td>49</td><td>39</td><td>41</td></tr><tr><td>Median CD4 cells, cells/&#956;l</td><td>1240</td><td>565</td><td>n.a.</td></tr><tr><td>Median Log (viral load)</td><td>1.7</td><td>4.3</td><td>n.a.</td></tr></table>
417230c2b868d9a993722c558549a7da1fa89c1cc21c48729f2fd78837b22139.png
simple
<table><tr><td>Year of birth</td><td>Number of ONS Birth records</td><td>Number of ONS birth records linked to HES birth records</td><td>Percentage linked</td></tr><tr><td>2005</td><td>617 613</td><td>609 778</td><td>98.73</td></tr><tr><td>2006</td><td>640 271</td><td>633 183</td><td>98.89</td></tr><tr><td>2007</td><td>659 061</td><td>651 551</td><td>98.86</td></tr><tr><td>2008</td><td>676 999</td><td>668 967</td><td>98.81</td></tr><tr><td>2009</td><td>675 330</td><td>669 926</td><td>99.20</td></tr><tr><td>2010</td><td>687 100</td><td>682 261</td><td>99.30</td></tr><tr><td>2011</td><td>688 681</td><td>683 768</td><td>99.29</td></tr><tr><td>2012</td><td>698 457</td><td>693 221</td><td>99.25</td></tr><tr><td>2013</td><td>668 433</td><td>662 963</td><td>99.18</td></tr><tr><td>2014</td><td>664 967</td><td>659 192</td><td>99.13</td></tr></table>
597396e932ab90eaed59e8eff2c9e70095e52555ee77029956eb9e99301c51a5.png
complex
<table><tr><td>Model</td><td>Covariates included</td><td>OR (95% CI)<sup>*</sup></td><td><i>P</i>value</td></tr><tr><td rowspan="4">1</td><td>Long PPI exposure (2 or more days)</td><td>2.19 (1.27 &#8211; 3.78)</td><td>.005</td></tr><tr><td>H2RA use</td><td>1.12 (0.70 &#8211; 1.79)</td><td>.628</td></tr><tr><td>Antibiotic use</td><td>2.53 (1.23 &#8211; 5.23)</td><td>.012</td></tr><tr><td>Immunosuppression</td><td>0.79 (0.51 &#8211; 1.23)</td><td>.297</td></tr><tr><td rowspan="3">2</td><td>Long PPI exposure (2 or more days)</td><td>2.08 (1.26 &#8211; 3.43)</td><td>.004</td></tr><tr><td>Antibiotic use</td><td>2.53 (1.25 &#8211; 5.29)</td><td>.010</td></tr><tr><td>Immunosuppression</td><td>0.79 (0.51 &#8211; 1.22)</td><td>.282</td></tr><tr><td rowspan="2">3</td><td>Long PPI exposure (2 or more days)</td><td>2.03 (1.23 &#8211; 3.36)</td><td>.006</td></tr><tr><td>Antibiotic use</td><td>2.52 (1.23 &#8211; 5.18)</td><td>.012</td></tr></table>
3e0ea6f0cf34ba3075e63708e46f97622b6ad0dfa79cb070e05800a9d53ea0d9.png
simple
<table><tr><td></td><td>MBA failures</td><td>MBA controls</td><td><i>p</i>-Value</td></tr><tr><td>Transportal ACLR (<i>n</i> = 26)</td><td>25.0</td><td>20.7</td><td>&lt;0.001</td></tr><tr><td>Transtibial ACLR (<i>n</i> = 28)</td><td>24.0</td><td>20.3</td><td>0.003</td></tr></table>
aaf1401e12d310a1c282cefc5fd1d0196fda237152c1681e899ddd93486af6f7.png
simple
<table><tr><td>Variable</td><td>SHAM</td><td>STZ</td></tr><tr><td>Aortic flow rate (mL g<sup>-1</sup> min<sup>-1</sup>)</td><td>24.4 &#177; 1.5</td><td>14.2 &#177; 2.9*</td></tr><tr><td>Coronary flow rate (mL g<sup>-1</sup> min<sup>-1</sup>)</td><td>6.05 &#177; 0.39</td><td>7.16 &#177; 0.65</td></tr><tr><td>Work (J kg<sup>-1</sup>)</td><td>1.48 &#177; 0.09</td><td>1.06 &#177; 0.11*</td></tr><tr><td>Total Vo<sub>2</sub> (J kg<sup>-1</sup>)</td><td>10.4 &#177; 0.51</td><td>10.0 &#177; 0.66</td></tr><tr><td>Total efficiency (%)</td><td>14.5 &#177; 0.49</td><td>10.4 &#177; 0.88*</td></tr></table>
50d4c7a1bf9e17ffde7dc5ae5ee7f850f5321430879b597d801fe98a8e76c140.png
simple
<table><tr><td>Factor</td><td>Respondents(<i>n</i> = 56)</td></tr><tr><td>Comorbidities of parturient</td><td>31 (55)</td></tr><tr><td>BMI</td><td>39 (70)</td></tr><tr><td>Quality of SAD seal</td><td>42 (75)</td></tr><tr><td>Fasting status </td><td>24 (43)</td></tr><tr><td>Other</td><td> </td></tr><tr><td> Team skill</td><td>2 (4)</td></tr><tr><td> Clinical situation</td><td>2 (4)</td></tr><tr><td> Speed of surgeon</td><td>2 (4)</td></tr></table>
83ec2f42d3e2726c759898074e2ee7321d2dfe0e7e2d7cc04816763ae5fb67ed.png
complex
<table><tr><td>Health behaviour</td><td>Amount or frequency</td><td colspan="3">Girls</td><td colspan="3">Boys</td></tr><tr><td> </td><td> </td><td>Latent class I n = 1256</td><td>Latent class II n = 1071</td><td>Latent class III n = 1098</td><td>Latent class I n = 862</td><td>Latent class II n = 628</td><td>Latent class III n = 1583</td></tr><tr><td>Stress-related eating</td><td>At least to some extent</td><td>732 (58.3%)</td><td>527 (49.2%)</td><td>218 (19.9%)</td><td>188 (21.8%)</td><td>142 (22.6%)</td><td>136 (8.6%)</td></tr><tr><td>Physical activity</td><td>&lt;2 hours a week</td><td>310 (24.7%)</td><td>694 (64.8%)</td><td>384 (35.0%)</td><td>126 (14.6%)</td><td>361 (57.5%)</td><td>471 (29.8%)</td></tr><tr><td> </td><td>2&#8211;3 hours a week</td><td>407 (32.4%)</td><td>252 (23.5%)</td><td>369 (33.6%)</td><td>229 (26.6%)</td><td>124 (19.7%)</td><td>361 (22.8%)</td></tr><tr><td> </td><td>&gt;3 hours a week</td><td>539 (42.9%)</td><td>125 (11.7%)</td><td>345 (31.4%)</td><td>507 (58.8%)</td><td>143 (22.8%)</td><td>751 (47.4%)</td></tr><tr><td>Tobacco use</td><td>Never smoked or taken snuff</td><td>304 (24.2%)</td><td>97 (9.1%)</td><td>735 (66.9%)</td><td>291 (33.8%)</td><td>70 (11.1%)</td><td>765 (48.3%)</td></tr><tr><td> </td><td>Experimental or occasional use of cigarettes or snuff</td><td>557 (44.3%)</td><td>455 (42.5%)</td><td>363 (33.1%)</td><td>351 (40.7%)</td><td>146 (23.2%)</td><td>704 (44.5%)</td></tr><tr><td> </td><td>Smoking or taking snuff regularly</td><td>395 (31.4%)</td><td>519 (48.5%)</td><td>0 (0%)</td><td>220 (25.5%)</td><td>412 (65.6%)</td><td>114 (7.2%)</td></tr><tr><td>Sleeping</td><td>&lt;8 hours per night</td><td>388 (30.9%)</td><td>378 (35.3%)</td><td>72 (6.6%)</td><td>167 (19.4%)</td><td>252 (40.1%)</td><td>100 (6.3%)</td></tr><tr><td> </td><td>8&#8211;9 hours per night</td><td>735 (58.5%)</td><td>549 (51.3%)</td><td>951 (86.6%)</td><td>564 (65.4%)</td><td>253 (40.3%)</td><td>1224 (77.3%)</td></tr><tr><td> </td><td>&#8805;9 hours per night</td><td>133 (10.6%)</td><td>144 (13.4%)</td><td>75 (6.8%)</td><td>131 (15.2%)</td><td>123 (19.6%)</td><td>259 (16.4%)</td></tr><tr><td>Binge eating</td><td>Once a month - daily</td><td>167 (13.3%)</td><td>139 (13.0%)</td><td>2 (0.2%)</td><td>111 (12.9%)</td><td>145 (23.1%)</td><td>64 (4.0%)</td></tr><tr><td>Strict diet to control weight</td><td>Occasionally or often</td><td>792 (63.1%)</td><td>213 (19.9%)</td><td>17 (1.5%)</td><td>241 (28.0%)</td><td>35 (5.6%)</td><td>27 (1.7%)</td></tr><tr><td>Heavy exercise to control weight</td><td>Occasionally or often</td><td>1256 (100.0%)</td><td>0 (0%)</td><td>207 (18.9%)</td><td>862 (100.0%)</td><td>0 (0%)</td><td>46 (2.9%)</td></tr><tr><td>Eating meals with one&#8217;s family</td><td>A few times a week or less often</td><td>574 (45.7%)</td><td>572 (53.4%)</td><td>103 (9.4%)</td><td>250 (29.0%)</td><td>300 (47.8%)</td><td>220 (13.9%)</td></tr></table>
624b2d134e880f7babb69674efcc1aa4d40b0bda70b0de744187933755dc0aa8.png
simple
<table><tr><td>Genes</td><td>Forward primer(5&#8242;&#8208; 3&#8242;)</td><td>Reverse primer(5&#8242;&#8208; 3&#8242;)</td></tr><tr><td>GAPDH</td><td>CGCTAACATCAAATGGGGTG</td><td>TTGCTGACAATCTTGAGGGAG</td></tr><tr><td>HIF&#8208;1&#945;</td><td>AAGCCCAGAGTCACTGGGACT</td><td>GTACTCACTGGGACTGTTAGGCTC</td></tr><tr><td>BMP&#8208;2</td><td>GAAGCCATCGAGGAACTTTCAG</td><td>GGAAATTTTGAGCTGGCTGTG</td></tr><tr><td>Runx2</td><td>ACTCTGCCGAGCTACGAAATG</td><td>GGGACCGTCCACTGTCACT</td></tr><tr><td>COL&#8208;I</td><td>CCGTGACCTCAAGATGTGCC</td><td>GAACCTTCGCTTCCATACTCG</td></tr><tr><td>OST</td><td>GATGCGGTCCCTAGTTCTACC</td><td>CCTCCAGTGAGTGGGATGTTT</td></tr><tr><td>OPN</td><td>AGCACACAAGCAGACGTTTTG</td><td>GCAACTGGGATGACCTTGATAG</td></tr><tr><td>ERK1</td><td>CTGGCTTTCTGACCGAGTATGT</td><td>AATTTAGGTCCTCTTGGGATGG</td></tr><tr><td>ERK2</td><td>GCACCAACCATTGAGCAGAT</td><td>TCACGGTGCAGAACATTAGCT</td></tr><tr><td>p38</td><td>AGATGCCGAAGATGAACTTCG</td><td>GGTCAGGCTCTTCCATTCGT</td></tr><tr><td>JNK</td><td>TCCAGCACCCGTACATCAAC</td><td>TCTTAGTTCGCTCCTCCAAATC</td></tr></table>
db7de62b6cf1abbee45022f2ab7175533963451be77f10657b2cea42415114e4.png
simple
<table><tr><td>Participant (diagnosis)</td><td>Trauma type</td><td>Psychotic symptoms</td><td>Target hotspot and associated memory</td><td>Key tf-CBTp; phase 4 intervention</td></tr><tr><td>P1<i>Primary</i>: unspecified non-organic psychosis<i>Secondary</i>: PTSD</td><td>Childhood; multipleSought asylum in the UK</td><td>Auditory command hallucinationsVisual hallucinationsParanoia</td><td>Witnessing murder of childhood friend; childhood physical abuse; held captive and tortured</td><td>Cognitive restructuringReliving with CRImagery rescripting (for nightmares and visions)</td></tr><tr><td>P2<i>Primary</i>: schizophrenia<i>Secondary</i>: severe depressive episode with psychotic symptoms</td><td>Adult; single event</td><td>Auditory command hallucinationsPersecutory beliefs</td><td>Living in conflict zone and held at gunpoint by terrorists</td><td>Cognitive restructuringReliving with CR</td></tr><tr><td>P3<i>Primary</i>: other non-organic psychotic disorder<i>Secondary</i>: PTSD</td><td>Childhood; multipleSought asylum in the UK</td><td>Auditory hallucinationsVisual, tactile, and olfactory hallucinationsPersecutory beliefs</td><td>Living in conflict zone (civil war/genocide); parents killed. Held captive and gang raped; witnessed murder of grandfather</td><td>Cognitive restructuringImagery rescripting</td></tr><tr><td>P4<i>Primary</i>: unspecified non-organic psychosis<i>Secondary</i>: none</td><td>Childhood; single event</td><td>Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs</td><td>Rape in childhood</td><td>Cognitive restructuringImagery rescripting for trauma event and visual hallucinationsSchema work</td></tr><tr><td>P5<i>Primary</i>: PTSD<i>Secondary</i>: emotionally unstable personality disorder</td><td>Adult; multiple</td><td>Auditory command hallucinationsVisual, olfactory, and tactile hallucinationsPersecutory beliefs</td><td>Several rapes and extreme physical assaults (long-term domestic violence); stillbirth of child</td><td>Cognitive restructuringReliving with CR for trauma eventsImagery rescripting for visual, olfactory tactile, and hallucinations</td></tr><tr><td>P6<i>Primary</i>: severe depressive episode with psychotic symptoms<i>Secondary</i>: none</td><td>Childhood; single event</td><td>Auditory hallucinationsPersecutory beliefs</td><td>Physical and emotional abuse</td><td>Imagery rescriptingSchema work</td></tr><tr><td>P7<i>Primary</i>: schizophrenia<i>Secondary</i>: severe depressive episode with psychotic symptoms</td><td>Adult; single event</td><td>Auditory hallucinationsVisual, tactile, and olfactory hallucinationsPersecutory beliefs</td><td>Being threatened with a knife</td><td>Cognitive restructuring reliving with CR</td></tr><tr><td>P8<i>Primary</i>:PTSD<i>Secondary</i>: severe depressive episode with psychotic symptoms</td><td>Adult; multipleSought asylum in the UK</td><td>Commanding voicesVisual and tactile hallucinationsPersecutory beliefs</td><td>Long-term imprisonment with physical and sexual torture. Witnessing murder in prison</td><td>Cognitive restructuring reliving with CRImagery rescripting</td></tr><tr><td>P9<i>Primary</i>: severe depressive episode with psychotic symptoms<i>Secondary</i>: none</td><td>Childhood; multiple</td><td>Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs</td><td>Repeated childhood physical abuse</td><td>Cognitive restructuringImagery rescripting for trauma events, visual and tactile hallucinations, and nightmares</td></tr></table>
a2f126fa85a80d5c65f2303630557e51bcb74ab709ea30650dc18525ae155745.png
complex
<table><tr><td>Complain</td><td>n of cases</td><td>n of positive cases</td></tr><tr><td>Discharge</td><td>750</td><td>20 (2.7%)</td></tr><tr><td>Discharge and itching</td><td>120</td><td>10 (8.3%)</td></tr><tr><td>Discharge, itching and burning sensation</td><td>130</td><td>20 (15.4%)</td></tr><tr><td>Total</td><td>1000</td><td>50</td></tr><tr><td>P value</td><td colspan="2">0.129</td></tr></table>
ead741bb97914b8a529923cb90ba1f6021286b1339debd1275fd317acb20cc01.png
complex
<table><tr><td colspan="2">Pancreatitis</td><td colspan="2">Neoplastic conditions</td><td colspan="2">Other</td></tr><tr><td>Acute</td><td>34.4 %</td><td>pancreatic ACC</td><td>19.8 %</td><td>fistula</td><td>2.3 %</td></tr><tr><td>Chronic</td><td>15.3 %</td><td>n. r.</td><td>9.9 %</td><td>transplant rejection</td><td rowspan="2">1.5 %</td></tr><tr><td></td><td></td><td>NEC</td><td>4.6 %</td><td></td></tr><tr><td></td><td></td><td>adeno-carcinoma</td><td>3.8 %</td><td>anastomotic leakage</td><td>0.8 %</td></tr><tr><td></td><td></td><td>IPMN</td><td>3.1 %</td><td></td><td></td></tr><tr><td></td><td></td><td>other</td><td>4.6 %</td><td></td><td></td></tr><tr><td>Total</td><td>49.6 %</td><td>total</td><td>45.8 %</td><td>total</td><td>4.6 %</td></tr></table>
db41151f189813e3ca128d243fc806bef740dfb99648cdb46c050fee375e5115.png
complex
<table><tr><td>Test variable</td><td colspan="2">Schizophrenia patients (24)</td><td colspan="2">Healthy adults (24)</td></tr><tr><td></td><td>M</td><td>SD</td><td>M</td><td>SD</td></tr><tr><td>Age</td><td>42.43</td><td>6.85</td><td>40.63</td><td>6.66</td></tr><tr><td>Education (in years)</td><td>10.5</td><td>3.41</td><td>11.08</td><td>2.78</td></tr><tr><td>Digit span forward</td><td>4.58</td><td>1.31</td><td>5.00</td><td>1.59</td></tr><tr><td>Digit span backward</td><td>4.08</td><td>1.38</td><td>4.88</td><td>1.73</td></tr><tr><td>PANAS pos</td><td>29.05</td><td>4.90</td><td>31.25</td><td>3.23</td></tr><tr><td>PANAS neg</td><td>18.95</td><td>4.25</td><td>22.29</td><td>6.67</td></tr><tr><td colspan="5">BPRS</td></tr><tr><td>Total</td><td>22.56</td><td>3.14</td><td></td><td></td></tr><tr><td>Positive symptoms</td><td>7.31</td><td>1.67</td><td></td><td></td></tr><tr><td>Negative symptoms</td><td>3.56</td><td>1.80</td><td></td><td></td></tr></table>
fbb84054c37a5d0dfb274af221eb2253d6ce45010442942f6318fefd6c1dbe5c.png
simple
<table><tr><td>Gene</td><td>Forward</td><td>Reverse</td></tr><tr><td>18s rRNA</td><td>CCCAGTGAGAATGCCCTCTA</td><td>TGGCTGAGCAAGGTGTTATG</td></tr><tr><td>Scleraxis</td><td>CCCAAACAGATCTGCACCTT</td><td>ATCCGCCTCTAACTCCGAAT</td></tr><tr><td>Tenascin-C</td><td>AACCCGTCCAAAGAGACCTT</td><td>GCGTGGGATGGAAGTATCAT</td></tr><tr><td>Tenomodulin</td><td>GTCCCTCAAGTGAAGGTGGA</td><td>CCTCGACGGCAGTAAATACAA</td></tr><tr><td>Collagen type-1 alpha 1</td><td>TGCGAAGACACCAAGAACTG</td><td>GACTCCTGTGGTTTGGTCGT</td></tr><tr><td>Cartilage oligomeric matrix protein</td><td>AGAACATCATCTGGGCCAAC</td><td>CGCTGGATCTCGTAGTCCTC</td></tr><tr><td>Thrombos pondin-4</td><td>GGGAAATGGGGTTACCTGTT</td><td>CGGGTAGCAGGGATGATATT</td></tr></table>